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PRELUDE
“I am among those who think that science has great beauty. A scientist in his 
laboratory is not only a technician: he is also a child placed before natural 
phenomena which impress him like a fairy tale.”
Marie Curie, 1933
CONTENTS
CONTENTS
Section 1 Scope and General Introduction  13
Section 2 Strategies to optimize antibody-based radionuclide imaging of 
cancer
 39
Chapter 2.1
Prospects in radionuclide imaging of prostate cancer
The Prostate 2012; 72(11):1262-1272
41
Chapter 2.2
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab’)2 
and Fab fragments in nude mice with PSMA-expressing xenografts
Contrast Media and Molecular Imaging 2014 (in press)
63
Chapter 2.3
Pretargeted immuno-PET and radioimmunotherapy of prostate 
cancer with an anti-TROP-2 x anti-HSG bispecific antibody
Eur J Nucl Med Mol Imaging 2013; 40(9):1377-1383
81
Chapter 2.4
Anti-CEA antibody fragments labeled with [18F]AlF for PET imaging 
of CEA-expressing tumors
Bioconjugate Chemistry 2014; 25(2):335-341
97
Section 3 Dual-modality imaging of prostate cancer 113
Chapter 3.1
Targeted dual-modality NIRF and radionuclide imaging of cancer: 
preclinical status and clinical applications
Molecular Imaging and Biology 2014 (in press)
115
Chapter 3.2 
Dual-modality image-guided surgery of prostate cancer with a 
radiolabeled fluorescent anti-PSMA monoclonal antibody
Journal of Nuclear Medicine 2014; 55(6):995-1001
135
Chapter 3.3 
Pretargeted dual-modality immuno-SPECT and near-infrared 
fluorescence imaging for image-guided surgery of prostate cancer
(Submitted for publication)
153
Section 4 Epilogue 169
General Discussion
Summary
Samenvatting
Zusammenfassung
List of Publications
Curriculum Vitae
Dankwoord
171
179
185
191
197
199
201

1
Scope and General Introduction
CHAPTER 1
16
SCOPE OF THIS THESIS
   1SCOPE
17
SCOPE OF THIS THESIS
In oncology, the search for tumor lesions in the body of a patient can be compared 
to the proverbial looking for the needle in a haystack. For various malignancies, 
the outcome of treatment mainly depends on early detection of the disease and 
complete removal of all tumor lesions. To achieve this, accurate and highly sensitive 
imaging modalities are pivotal to improve early detection of cancer and provide 
guidance for surgical removal of tumor lesions. 
As prostate cancer is one of the most frequent cancers in men worldwide and is only 
curable when detected in early stages, this thesis focuses on the development and 
evaluation of strategies to optimize antibody-based imaging of prostate cancer to 
improve the detection of tumor lesions. 
In the first section of this thesis, a general introduction to prostate cancer is provided 
and the basic principles of radionuclide and fluorescence imaging are described.
The second section focuses on strategies to optimize antibody-based radionuclide 
imaging of cancer, such as the use of antibody fragments (chapter 2.2 and 2.4) or the 
application of pretargeting strategies (chapter 2.3) to increase tumor-to-background 
ratios and potentially enhance the sensitivity to detect tumor lesions.
The third section of this thesis is devoted to preclinical advances and the current 
clinical status of diagnostic and therapeutic dual-modality approaches based on 
radionuclide and near-infrared fluorescence imaging. A dual-modality imaging 
strategy based on an anti-PSMA monoclonal antibody was developed and 
characterized in a subcutaneous as well as in a metastatic tumor model (chapter 
3.2). Additionally, one of the optimization strategies described in the second section, 
a pretargeting approach, using a bispecific antibody in combination with a hapten-
peptide, was applied and characterized for dual-modality imaging of prostate cancer 
(chapter 3.3). Finally, the feasibility of both dual-modality strategies for image-
guided surgery was investigated. 
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PROSTATE CANCER
Malignancies of the prostate gland are one of the most significant health problems 
for the male population worldwide. In Europe, prostate cancer outnumbers lung and 
colorectal cancer, being the most common solid neoplasm with an incidence of 214 
cases per 1000 men [1] and the second most common cause of death in men [2]. 
Several factors are known to drastically increase the risk for the development 
of prostate cancer, such as increasing age or heredity. Another risk factor for the 
development of adenocarcinoma of the prostate is ethnicity [3]. Other factors 
such as diet/nutrition, alcohol consumption, pattern of sexual behavior, chronic 
inflammation, and exposure to ultraviolet irradiation are being discussed to play a 
role in the development of prostate cancer and in the progression of latent prostate 
cancer to a clinical variant [4, 5]. At present, adenocarcinoma of the prostate are 
classified by the 2005 ISUP Modified Gleason scoring system.
First line diagnostic tools for prostate cancer include digital rectal 
examination (DRE), measurement of serum concentration of the prostate-specific 
antigen (PSA), and transrectal ultrasonography (TRUS) [3]. Most adenocarcinomas 
of the prostate are located in the peripheral zone of the gland. This fact allows the 
detection of lesions of a volume of 0.2 ml or larger. A suspect DRE represents a 
strong indication for (ultrasound-guided) biopsy of the prostate. In addition to DRE, 
serum levels of PSA can be measured for diagnostic purposes of prostate cancer. The 
kallikrein-like serine protease PSA is an organ-specific marker of the prostate gland 
and elevated levels of PSA are a strong indicator for disease processes in the prostate 
such as prostate carcinoma. However, since PSA is not cancer-specific, elevated levels 
of PSA are not only found in case of malignant disease, but can also be caused by 
benign diseases of the prostate, for instance benign prostatic hypertrophy (BPH) 
or prostatitis. So far, several modifications have been described to increase the 
specificity of PSA and to facilitate the discrimination between prostate cancer and 
BPH, such as the free/total PSA (f/t PSA) ratio. While the greatest amount of PSA in 
the blood is bound to serum proteins, a small amount circulates freely. In men with 
prostate cancer, the ratio between the amount of free and total PSA is decreased. 
However, several aspects limit the use of the f/t PSA ratio as an independent 
marker for prostate cancer, such as instability of free PSA especially at 4°C and 
room temperature, or variable assay characteristics [3]. In addition to more specific 
discrimination between malignant and benign diseases of the prostate, the f/t PSA 
ratio was found to decrease the number of unnecessary biopsies significantly [6]. 
Mainly based on PSA level and suspect DRE, but also taking into account the 
age of the patient, comorbidity and therapeutic consequences, a biopsy of the 
prostate can be performed. Currently, the standard method to obtain material for 
histopathologic examination is TRUS-guided biopsy. In case of negative biopsies, 
but persisting clinical suspicion for malignant involvement of the prostate, magnetic 
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resonance imaging (MRI) may provide information on the anterior lobe of the prostate. 
For the detection of metastases, pelvic CT/MRI or bone scans are recommended [11].
At present, the therapeutic management of prostate cancer is stage-specific. 
In low-risk prostate cancer, one approach is active surveillance. Initially, patients 
eligible for active surveillance are not treated, however in case of progressive 
disease, patients will receive curative treatment. Currently, radical prostatectomy 
involving removal of the entire prostate gland and resection of both seminal vesicles 
along with sufficient surrounding tissue to obtain a negative resection margin, is the 
surgical treatment option of choice for localized prostate cancer [11]. The intent 
of radical prostatectomy is curative in men with localized prostate cancer with a 
life expectancy of more than 10 years. Radical prostatectomy can be performed 
in open procedures, which include radical retropubic prostatectomy (RRP) and 
perineal prostatectomy. Currently however, robot-assisted laparoscopic radical 
prostatectomy (RALP) represents the gold standard surgical approach for clinically 
localized prostate cancer in the United States and is increasingly used in Europe. 
Compared to the non-laparoscopic approach, the percentage of RALP yielding 
negative-surgical margins seems to be equivalent. In intermediate-risk localized 
prostate cancer, radical prostatectomy should be accompanied by extended lymph 
node dissection if the estimated risk for positive lymph nodes exceeds 5%. In addition, 
this procedure should be performed in high-risk cases, where the estimated risk for 
positive lymph nodes is 15-40% [7, 11]. Among others, postoperative complications 
include persistent urinary incontinence, urinary fistulas, impotence, and bladder 
neck obstruction [11]. In case of adverse tumor characteristics such as extraprostatic 
involvement of the disease, presence of tumor cell containing resection margins, 
or seminal vesicle invasion, adjuvant radiotherapy may be used after recuperation 
from surgery [11]. In addition, neoadjuvant hormonal therapy can be considered 
prior to surgical interventions to decrease the size of hormone dependent prostate 
cancer lesions. While this attempt does not improve overall survival or disease-free 
survival, the rate of positive resection margins and lymph node invasion could be 
decreased significantly [8]. Another treatment option for prostate cancer is radiation 
therapy. Currently, intensity modulated radiotherapy (IMRT) with or without image 
guidance (IGRT) can be considered as the gold standard [11]. The addition of short-
term androgen deprivation treatment (ADT) to external irradiation has been shown 
to improve overall survival in certain patient groups [11]. Another treatment option 
is transperitoneal brachyherapy, for which patients with low-risk prostate cancer are 
the most suitable candidates [11]. Alternative treatment options for patients with 
clinically localized prostate cancer are cryosurgical ablation of the prostate (CSAP) 
[9] and high-intensity ultrasound (HIFU) [10], with the latter still being considered an 
experimental treatment. 
Treatment for advanced prostate cancer usually consists of a combination of 
several therapeutic options such as hormone, chemo-, or radiation therapy.
GENERAL INTRODUCTION
21
   1
Initial treatment of men with metastatic prostate cancer is ADT with luteinizing 
hormone-releasing hormone (LHRH) agonists, anti-androgens, or a combined 
androgen blockade [11]. While the cancer lesions of most patients respond well to 
ADT initially, recurrence/progression of the disease after several years is common. 
When this occurs, the disease is considered to be castration resistant. In this case, 
secondary hormone therapy represents a treatment option since a portion of the 
cancer cells might still respond to androgen deprivation. Secondary hormone therapy 
includes addition or substitution of an anti-androgen by another type of androgen or 
prescription of another androgen blocking agent such as estrogen, steroids [11] or 
the antifungal medication ketoconazole [12, 13]. 
Other options to treat advanced disseminated prostate cancer are sipuleucel T, 
a dendritic cell vaccine, abiraterone, a drug blocking the production of androgens, 
and radium-223, a alpha-emitting radionuclide that localizes in bone and can be 
effective for the treatment of bone metastases. In addition, taxane chemotherapy 
for instance with docetaxel can be considered [11]. 
In follow-up after treatment with curative intent, serum PSA measurements and 
DRE should be performed 3, 6, and 12 months after treatment, then every 6 months 
until 3 years. After this, follow-up should be performed annually. For hormone therapy, 
patients should be evaluated at 3 and 6 months after initiation of the treatment. 
During the last decades, extensive research has been focused on the development 
of molecular imaging techniques that might improve prostate cancer detection. For 
diagnostic as well as therapeutic imaging purposes, specific targeting of the tumor is 
a prerequisite. Tumor targeting can be achieved with various strategies of which the 
binding of antibodies that target tumor-associated antigens is particularly promising. 
TUMOR TARGETING
The term antibody (Antikörper) was first mentioned by the German scientist and 
Nobel Price laureate Paul Ehrlich in 1891 [14]. In the following years, he proposed his 
theory for antibody and antigen interactions, hypothesizing that receptors on the cell 
surface could bind specifically to toxins in a lock-and-key interaction. 
Several years later, tumor-associated antigens were identified and the idea 
emerged, that antibodies could be used to target these tumor specific cell surface 
molecules for diagnostic as well as therapeutic purposes. During the last decades, 
various tumor-associated antigens have been identified which are specific to 
either one single tumor entity or to multiple malignancies. Within this thesis, the 
targetability of several tumor-associated antigens such as PSMA (chapter 2.2 and 3.2), 
TROP-2 (chapter 2.3 and 3.3), or CEA (chapter 2.4) was evaluated.
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Prostate-specific membrane antigen 
The prostate-specific membrane antigen (PSMA) is a type II transmembrane protein 
(figure 1) [15]. PSMA is expressed in high levels in 95% of all prostate cancers [16]. 
In particular poorly differentiated, metastatic, and hormone refractory carcinomas 
express significantly higher levels of PSMA compared to benign prostate tissues 
[17]. Due to the selective overexpression of PSMA on the surface of prostate cancer 
cells, PSMA provides an excellent target for prostate cancer imaging [18]. Initial 
validation of PSMA as an in vivo target resulted from imaging with the monoclonal 
antibody capromab pendetide (7E11/CYT-356, ProstaScint), which was labeled to 
the radionuclide 111In [19]. Capromab pendetide was FDA approved for imaging soft 
tissue metastatic lesions of prostate cancer for presurgical staging. Additionally, it 
was approved for evaluation of PSA relapse after local therapy. However, capromab 
binds to an intracellular domain of PSMA, which is considered a suboptimal target 
for imaging purposes. To overcome limitations due to intracellular localization of the 
target of capromab, anti-PSMA antibodies, such as J591, J415, and J533 have been 
developed [20], which bind to the extracellular domain of PSMA. These antibodies 
are considered to be more suitable for imaging approaches, since the binding site is 
more accessible for the targeting agent. PSMA-targeting with another monoclonal 
antibody (D2B) directed against the extracellular domain of PSMA is described in 
chapter 2.2 and 3.2 of this thesis.
 Figure 1: Schematic representation of PSMA
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Epithelial glycoprotein-1
Another well described antigen is the epithelial glycoprotein-1, also known as EGP-1, 
TROP-2, GA733-1, gp50/T16, TACSTD2 (tumor-associated calcium signal transducer 
2), which is a 46 kDa transmembrane glycoprotein expressed in carcinomas of the 
lung, bladder, breast, cervix, ovary, stomach and prostate [21]. While most normal 
human tissues do not express TROP-2, including lymph nodes, heart, connective 
tissues, blood vessels, stomach, jejunum and duodenum, TROP-2 is found at low 
levels in several normal glandular cells, including glands in the bronchus, breast, 
prostate and skin, and ducts and acini of the pancreas [22]. 
TROP-2 can be targeted by several antibodies, such as the humanized IgG1 
monoclonal antibody hRS7, which was originally developed for human non-small cell 
carcinoma of the lung [22]. In addition, this antibody is reactive with bladder, breast, 
cervix, ovary, stomach and prostate carcinomas [23]. It has been shown previously, 
that hRS7 labeled with 111In or 89Zr is an excellent targeting agent to visualize TROP-2 
expressing prostate cancer with SPECT or PET [23].
Carcinoembryonic antigen
The carcinoembryonic antigen (CEA) is a glycoprotein with a molecular mass of 180-
200 kDa, which is attached to the cellular membrane by a glycosyl phosphatidylinositol 
anchor [24]. It consists for 60% of carbohydrates and has a molecular mass of 180-
200 kDa. CEA is a tumor-associated antigen, that is overexpressed in 95% of colorectal 
cancers. CEA expression in tumors is approximately 60-fold higher compared to 
nonmalignant tissues [25]. 
So far, various antibodies have been developed which target CEA, such as the 
monoclonal antibodies hMN-14 [26] (labetuzumab) or T84.66 [27].
While achieving specific tumor targeting is one of the challenges for molecular 
imaging of cancer, another challenge is the visualization of the targeting agent, which 
is bound to its target. At present, multiple imaging modalities are available for these 
purposes, such as radionuclide imaging or fluorescence based-imaging approaches.
RADIONUCLIDE IMAGING
Radioactive decay refers to a process in which the nucleus of an unstable atom 
loses energy by spontaneous emission of ionizing radiation in form of photons 
and/or alpha/beta particles. Radionuclide imaging techniques such as positron 
emission tomography (PET) or single-photon emission tomography (SPECT) are 
based on detection of these emissions produced during radioactive decay. The use 
of radionuclide imaging in clinical practice is promoted by several advantages such 
as high sensitivity and the option to label targeting molecules with radionuclides
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that allow accumulation of radionuclides in tissues of interest. Major limitations of 
nuclear imaging for clinical purposes are the use of ionizing radiation, the relatively 
low spatial resolution, and the lack of anatomical references.
PET and SPECT
In PET, image information is provided by two photons with an energy of 511 keV 
each, which are emitted in opposite directions, when a positron interacts with 
an electron in a process called annihilation. These photons are detected by a PET 
camera and localized by a series of opposing detectors that correspond to several 
rings of scintillation crystals. The acquisition of an image is based on simultaneous 
(coincidental) detection of the pairs of photons. Photons that are not detected pair 
wise, are ignored in this technique. After collection of sufficient events, a three-
dimensional image can be reconstructed. An important advantage of PET is that fact 
that this technique is quantitative, which allows correlation between contrast agent 
and image intensity.
In SPECT imaging, as opposed to PET imaging, gamma emissions are measured 
directly using a (set of) rotating detectors, which acquire a series of two-dimensional 
projection images from multiple angles around the longitudinal axis of the patient/
animal. Different techniques are available to reconstruct these tomographic images 
such as back-projection or Fourier transform reconstruction.
Radionuclides
Several factors should be considered when determining which radionuclide is most 
suitable for a particular medical application. First, the half-life of a radionuclide 
should be taken into account. For imaging with intact antibodies, radionuclides 
with longer half-life of days to weeks are suitable, since accumulation of intact 
antibodies in tumors takes several days. In addition, radionuclides with a longer 
half-life are useful in settings when imaging is required several times after injection. 
Radionuclides with a shorter physical half-life such as 18F (110 min) or 68Ga (68 min) 
are more suitable for imaging with antibody fragments or peptides owing to their 
fast pharmacokinetics and tumor accumulation. Due to the intermediate half-life of 
111In (2.8 days), this radionuclide is suitable for imaging with intact antibodies as well 
as antibody fragments or even peptides. 111In was used as a radiotracer in several 
chapters of this thesis (2.2, 2.3, 3.2, and 3.3) in approaches using intact antibodies, 
antibody fragments, or pretargeting systems. 
Another important consideration is the emission profile of the radionuclide. 
Depending on their emission profile, radionuclides can be used for SPECT or PET 
imaging purposes. For PET, one of the most widely used radionuclides is 18F. The 
positron-emitter 18F has ideal properties for PET due to the low energy of the 
positrons emitted (635 keV) that reveals optimal spatial resolution of PET images 
[28]. In addition, the lack of other emissions favors PET imaging. 68Ga in contrast
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has a higher positron energy (1899 keV), which limits the resolution of PET images. 
Advantage of 68Ga over 18F is that labeling procedures for 68Ga are relatively 
straightforward, because 68Ga can be chelated with macrocyclic chelates such as 
DOTA or NOTA. In contrast, the labeling of 18F in general is cumbersome requiring 
labeling of a prosthetic group, deprotection and subsequent conjugation to a protein 
[29]. To benefit from the advantageous emission profile of 18F, more efficient and 
straightforward labeling methods are desirable. In chapter 2.4 of this thesis, a newly 
developed radiofluorination method is applied which allows 18F-labeling to heat-
sensitive molecules in a effective 2-step procedure.
For SPECT imaging, radionuclides which emit gamma rays with energies of 100 
to 200 keV would be ideal [30]. For this imaging modality, radionuclides such as 111In 
or 99mTc can be used.
Another important issue to be addressed is the availability of the radionuclide. 
68Ga for instance is generated by a 68Ge/68Ga generator, allowing 68Ga generation on-
demand. However, 68Ge/68Ga generators are not widely available. Radionuclides such 
as 18F are produced in a cyclotron. 
Radiolabeled targeting agents in prostate cancer
Recently, substantial progress has been made in the development of radionuclide 
imaging techniques for prostate cancer. The value of numerous radiolabeled tracers 
such as metabolite tracers, androgen receptor binding ligands, bombesin- and 
gastrin-releasing peptide receptor binding ligands, or antibodies, for the detection 
of prostate cancer has been evaluated. The recent advances and new developments 
in radionuclide imaging of prostate cancer are discussed in more detail in chapter 2.1 
of this thesis.
RADIOIMMUNOTHERAPY FOR PROSTATE CANCER
In radioimmunotherapy, radiolabeled antibodies or antibody fragments are used 
to target a certain cancer-specific antigen and deliver a therapeutic radiation dose. 
This approach allows delivery of radiation to tumor tissue but spares normal organs. 
Radioimmunotherapy can be administered either in a single dose or in multiple doses 
within a fractionated regimen. The effectiveness of this treatment modality depends 
on several factors, such as the cumulative radiation dose to the tumor, the dose-
rate, and the tumor radiosensitivity [31]. Radioimmunotherapy has been studied 
extensively for several malignancies, mainly non-Hodgkin’s lymphoma exploiting 
CD20-expression [31], but also solid tumors such as colorectal cancer and prostate 
cancer. So far, several clinical phase I trials have evaluated the role of the anti-PSMA 
antibody J591 for radioimmunotherapy of prostate cancer [32, 33]. In these studies, 
this antibody was labeled with 90Y or 177Lu and delivered to patients with metastatic 
castration-resistant prostate cancer.
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These studies revealed a maximum tolerated dose (MTD) for a single administration 
regimen of 17.5 mCi/m2 for 90Y-J591 and 70 mCi/m2 for 177Lu-J591. In addition, 
dosimetry and pharmacokinetics were determined and preliminary evidence was 
provided for anti-tumor activity. 
For radioimmunotherapy, it is crucial to carefully select the radionuclide to obtain 
an optimal balance between the therapeutic effect and unwanted side effects [24]. 
For therapeutic purposes, β-emitting radionuclides such as 177Lu or 90Y are suitable. 
Compared to 90Y (half-life 2.7 days), the half-life of 177Lu is relatively long (6.7 days). In 
addition, the penetration range of the beta-particles emitted by 177Lu in tissue is 2.5 
mm due to their low-energy (betamax 498 keV). As 90Y emits higher energy (betamax 
2.28 meV), the penetration range in tissue is higher, resulting in a maximum of 12 
mm [24]. Due to these properties, 177Lu is more suitable for the treatment of small 
tumors and micro-metastases. In chapter 2.3 of this thesis, the role of a pretargeting 
approach with the bispecific antibody TF12 and the 177Lu-labeled peptide IMP288 for 
radioimmunotherapy of prostate cancer is evaluated. 
FLUORESCENCE IMAGING
In certain settings, fluorescence imaging might be more suitable to visulaize tumor-
associated antigens than radionuclide imaging. In fluorescence imaging, a source of 
light with a specific wavelength is required to excite the fluorophore. Upon excitation, 
the electrons of the fluorophore remain in the excited state for approximately 10-8 
seconds [34], called the lifetime of the fluorophore. This phase is followed by return 
of the fluorophore to its ground state, which may be accompanied by emission 
of a photon. The quantum yield is defined as the ratio of the number of photons 
emitted to the number of photons absorbed. Photons propagating to tissue, either 
generated by excitation light entering tissue from the outside, or generated after 
excitation of the fluorophore, are subject to three main parameters: light absorption, 
light scattering, and light reflection and refraction (figure 2). After excitation of the 
fluorophore, Stokes shift occurs, a phenomenon describing the shift from shorter 
wavelength (higher energetic state) to higher wavelength (lower energetic state). 
Absorption of photons can be caused by microscopic elements such as fatty acids, 
amino acids, ions, proteins, phospholipids, and water as well as larger structures 
such as organelles and cellular membranes. Due to limited tissue penetration depth 
caused by tissue absorption and scattering of light, applications for fluorescence 
imaging remained rather limited. This limitation can partially be overcome by 
adapting light to the near-infrared (NIR) regions (650 – 900 nm), as photons in the 
NIR range of light travel much deeper through tissue than photons in the visible light 
range (400 – 600 nm) [35], resulting in a tissue penetration depth in the millimeter 
to centimeter range [36]. In the NIR spectral region, the main absorbing elements
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are deoxyhemoglobin, oxyhemoglobin, water, and lipids, which consequences in less 
absorption compared to light in the visible range, allowing deeper penetration of 
photons into the tissue [34]. 
The second phenomenon, scattering, is much more prominent than absorption 
of photons. The term scattering refers to a change in direction of the photons when 
traveling through tissue. Directional changes of the photons occur multiple times 
and result in a gradual randomization of the tissue penetration direction which 
consequences in a reduction of signal strength and accuracy. In general, after having 
propagated around 1 mm of tissue, photons have an equal probability of traveling 
in any direction. This, together with the fact that scattering occurs much more 
frequently than absorption, the transport of light through tissue can be regarded as 
an diffusive process [34]. 
However, scattering of photons on their way through tissue can be advantageous 
for near-infrared fluorescence (NIRF) imaging purposes as the path of the contorted 
light of photons that excite the fluorophore is similar to that of the emitted photons 
[34]. Consequently, highly scattering tissues cause retention of photons in that area 
and enhance the likelihood of induction of fluorescence [37].
The third parameter that influences photons on their way through tissue is 
reflection/refraction. Due to a mismatch between the refraction indices of tissue and 
air, photons emitted by the fluorophore will change their direction upon penetrating 
from tissue to air. Depending on the angle on which the photon reaches the tissue-
to-air border, reflection of the fluorescent signal can occur. While the internal diffuse 
reflection coefficient remains negligibly small for perpendicular angles, the reflection 
coefficient can reach up to 50% at larger angles [34], resulting in backwards reflection 
of the fluorescent signal into the tissue and thereby causing an overall loss of signal 
intensity and an increase in diffusivity of the signal. In chapter 3.1 of this thesis, the 
preclinical developments and the current clinical status of targeted fluorescence 
imaging combined with radionuclide imaging are reviewed.
Figure 2: Schematic representation of how photons propagate through tissue
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Fluorescence imaging systems
The typical fluorescence imaging system consists of a spectrally-resolved light 
source which excites the fluorophores. Subsequently, the light which is emitted from 
the fluorophores is detected by a charge-coupled device (CCD) camera, whereas 
excitation light is filtered out. So far, several dedicated NIRF camera systems have 
been used for intra-operative optical imaging and image-guided surgery, including 
the Photodynamic Eye (PDE, Hamamatsu Photonics, Hamamatsu City, Japan) [38], 
and the Fluorescence-assisted Resection and Exploration (FLARETM) system, a self-
build system from the Fragioni laboratory (Brookline, MA, USA) [39]. More recently, 
a smaller variant of the FLARETM system, the Mini-FLARETM, has been developed by 
the same group. Another recently developed system is the Artemis imaging system 
(O2view, Marken, The Netherlands), a real-time imaging system combining visible 
light with NIRF light images. 
In the studies described in this thesis (chapter 3.2 and 3.3), the IVIS Lumina II 
imaging system (Xenogen VivoVision IVIS Lumina II, Caliper Life Sciences, Lincolnshire, 
United Kingdom) was used. A schematic representation of this imaging system is 
displayed in figure 3.
Fluorophores
For fluorescence imaging, various different fluorophores can be used, depending on 
the imaging purpose. For in vivo imaging purposes, fluorophores which emit light 
in the near-infrared fluorescent range are usually used since they have relatively 
deep tissue penetration. At present, NIR fluorophores can be categorized into 
two main classes, inorganic and organic NIR dyes [40]. Inorganic NIRF dyes mainly 
Figure 3: Schematic representation of the IVIS imaging system used in chapter
3.2 and 3.3
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associate with quantum dots and other nanoparticles. The use of inorganic NIRF dyes 
is mainly restricted by the potential cytotoxicity of nanoparticles due to heavy metal 
ingredients such as cadmium and selenium or surface-coatings. Major advantage of 
organic NIRF dyes is their feasibility for covalent conjugation with various molecules 
such as amino acids, nucleotides, DNA, or antibodies [40]. At present, various organic 
NIR fluorophores are being evaluated for biological imaging applications, such as 
cyanine dyes which are small organic molecules with two aromatic nitrogen-containing 
heterocycles linked by a polymethine bridge [40]. Another important organic 
fluorophore is IRDye800CW. This fluorophore possesses optimal characteristics for 
clinical uses. The toxicity of IRDye800CW carboxylate has been evaluated preclinically, 
showing no toxicity in doses up to 20mg/kg intravenously or intradermally [41]. In 
chapter 3.2 and 3.3 of this thesis, targeting agents conjugated to both IRDye800CW 
and 111In are evaluated regarding their tumor binding characteristics. 
Ideal properties of NIR fluorophores are a large stokes shift, high molar absorption 
coefficient, and high quantum yield [40]. In addition, water solubility is a prerequisite 
to avoid dye aggregation in aqueous solutions. Moreover, the fluorophore should 
be chemically and photo-stable in solutions and biological conditions and suitable 
functional groups need to be present to allow bioconjugation to targeting molecules 
[40]. 
Fluorescence imaging in prostate cancer
So far, several preclinical studies have been focused on fluorescence imaging of 
prostate cancer. Humbet et al. developed a small molecule specific for PSMA and 
conjugated it to the fluorophore indocyanine green (ICG) [42]. It has been shown that 
this conjugate specifically binds to PSMA-expressing prostate cancer xenografts and 
can be visualized with NIRF imaging. Another group synthesized a PSMA NIRF imaging 
agent by conjugation of the PSMA inhibitor CTT-54.2 with the fluorophore Cy5.5 [43]. 
This probe was successfully applied for labeling of PSMA-expressing LNCaP cells in 
two- and three-dimensional cell cultures. Recently, Kelderhouse et al. conjugated a 
PSMA-targeting ligand to three different fluorophores (DyLight680, Alexa Fluor 647, 
and IRDye800CW) [44]. They demonstrated that this fluorescently labeled tumor-
targeting probe can be used to visualize PSMA-expressing prostate tumor tissue 
in vivo and to perform image-guided resection of tumors. Jin et al. conjugated the 
monoclonal antibody H6-11, which recognizes a β-N-acetylglucoside group on PC3 
cells, to IRDye800CW and performed optical imaging in mice with PC-3 tumors [45]. 
In this study, good tumor-to-muscle contrast was reported with clear visualization of 
the tumors on fluorescence images. Zhu et al. labeled the monoclonal anti-EpCAM 
antibody 7.4 to IRDye800CW and performed NIRF imaging in mice with prostate 
cancer lymph node metastases [46]. In this study, tumor lesions could be visualized 
specifically with NIRF imaging. 
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In addition to these preclinical studies, fluorescence imaging of prostate cancer has 
been evaluated clinically. Van der Poel et al. showed the applicability of sentinel 
lymph node imaging using multimodal ICG-99mTc-NanoColloid in prostate cancer 
patients [47]. They showed that this imaging agent can be used to facilitate the 
dissection of sentinel lymph nodes during RALP.
DUAL-MODALITY IMAGING
As described above, both radionuclide and fluorescence imaging can be used to 
image cancer lesions in vivo. While radionuclide imaging has high sensitivity and is 
suitable for the detection of even deeply seeded tumors, intra-operative application 
of this technique is limited and based on gamma probe detection. NIRF imaging in 
contrast, is suitable for intra-operative purposes and can provide real-time images 
of tumor lesions. However, fluorescence imaging is limited by a penetration depth in 
the millimeter range. By combination of radionuclide and fluorescence imaging, both 
techniques might complement each other and contribute to improvements in the 
detection and surgical removal of prostate cancer lesions. In section 3 of this thesis, 
two dual-modality radionuclide and fluorescence imaging approaches are evaluated, 
one using a dual-labeled monoclonal antibody and one using pretargeting with a 
fluorescent 111In-labeled peptide. 
OPTIMIZATION OF ANTIBODY-BASED IMAGING
During the last decades, several strategies have been introduced to optimize tumor 
targeting. The main strategies for these purposes are the use of antibody fragments 
or pretargeting strategies. 
Antibody fragments
In particular settings, visualization of tumor lesions might be required relatively early 
after injection of the radiolabeled antibody. For instance, when the patient’s status 
needs to be evaluated several times within a short time interval or when imaging 
is required directly before and after treatment. Intact antibodies (157 kDa) clear 
relatively slowly from the circulation. Therefore, the optimal time for imaging with 
good tumor-to-background ratios is only reached several days after injection of the 
radiolabeled antibody. 
In general, lower molecular weight agents provide higher target-to-nontarget 
ratios. Antibody fragments (F(ab’)2, Fab, scFv, diabodies, a.o.) represent promising 
candidates for radioimmunotargeting of cancer lesions (figure 4).
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Thus, one strategy to optimize the targeting and clearance characteristics of antibodies 
against tumor-associated antigens is the development of antibody fragments. While 
it has been shown that the tumor uptake of antibody fragments is usually lower 
compared to the tumor uptake that is reached with intact antibody molecules [48, 
49], antibody fragments are especially useful in settings when imaging is required 
early after injection. Due to the rapid clearance of antibody fragments, high tumor-
to-background ratios can be reached as early as several hours after injection of the 
radiolabeled antibody fragment. 
Most important limitation of imaging of cancer with antibody fragments is 
the fact that smaller sized imaging agents also tend to show high accumulation in 
the kidneys. In chapter 2.2 of this thesis, antibody fragments are used to evaluate 
whether tumor targeting can be improved in vivo by the use of fragments compared 
to intact IgG molecules.
Pretargeting strategies
Visualization of tumors with antibodies might be hampered by slow clearance from 
the blood due to recycling via receptors. This results in low tumor-to-background 
ratios especially early after injection. In addition, it takes several days before 
sufficient accumulation of the antibody within the tumor is reached. As described 
earlier, these limitations can partially be overcome by the use of antibody fragments. 
Another promising approach to overcome these limitations and to improve tumor 
targeting and increase tumor-to-background ratios is the pretargeting approach. In 
pretargeting, tumor tissue is pretargeted with an unlabeled antibody construct (that 
is injected i.v. in the first phase). Subsequently, the construct will accumulate in the 
tumor via its specific binding sites. As soon as the antibody construct has been cleared 
from the blood, a radiolabeled peptide with affinity for the antibody construct is 
injected intravenously. The radioactive peptide will then distribute within the body
Figure 4: Schematic representation of an intact IgG antibody molecule and several 
antibody fragments
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and bind to the antibody construct in the tumor. Unbound radioactive peptides will 
be cleared via the renal clearance route from the blood rapidly, due to their small 
size. 
The concept of pretargeting has been proposed for the first time in 1984 [50]. 
Goodwin and colleagues proposed that tumors could be pretargeted with agents 
which possess specificity for both the tumor and a radiolabeled ligand. Since then, 
extensive research has been focused on the development of pretargeting strategies, 
resulting in two main approaches for pretargeting based on antibody constructs 
can be distinguished. First, the interaction between (strept)avidin and biotin can be 
exploited and secondly, bispecific antibodies (bsAb) can be used that possess both, 
affinity for tumor tissue as well as for the radiolabeled peptide (figure 5) [51]. 
Figure 5: Schematic representation of a pretargeting strategy using bispecific 
antibodies. a) Endothelium and tumor cell, b) bsAb circulate in the bloodstream and c) 
accumulate to the tumor cell. Subsequently, intravenously administered radiolabeled 
peptide circulates through the blood (d)) and binds to the bsAb which is bound to the 
tumor cell (e)).
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The first pretargeting strategy is based on the avid binding of avidin to biotin. The 
protein avidin is a constituent of the egg white of amphibians and birds that can bind 
to biotin (vitamin H) [52] with high affinity (Ka = 1015 M-1) [53, 54]. Alternatively, 
the bacterial analog streptavidin can be used for pretargeting purposes, since it has 
comparable biotin-binding characteristics. However, the retention of streptavidin in 
healthy tissues is lower compared to avidin [55]. 
These (strept)avidin – biotin pretargeting approaches have several limitations 
compared to pretargeting approaches using bsAb. First, due to the high affinity 
of (strept)avidin to biotin, both agents also complex in the circulatory system. 
Consequently, tumor uptake will be lower. To overcome this limitation, clearing 
agents could be used that remove the excess of the antibody conjugate from the 
circulation prior to administration of the radioactive small molecule. However, 
another disadvantage restricting the use of (strept)avidin – biotin pretargeting 
approaches is the fact that (strept)avidin is immunogenic in humans and can only be 
applied once to a patient. 
Pretargeting with bispecific antibodies
Major advantage of the pretargeting approach using bsAb however is the fact that 
bsAb can be humanized which reduces the immunogenicity. In general, bsAb can be 
produced in three different ways: 1. Biologically by fusion of two hybridoma cell lines 
which produce two parental monoclonal antibodies, 2. chemically by conjugation of 
antibody fragments, and 3. by recombinant DNA methods producing fusion proteins of 
single chain antibodies of antibody fragments. Bispecific antibodies can be produced 
with different valencies: It has been shown that malignant tissues can be pretargeted 
in a more efficient ways when the bsAb is trivalent and consists of a F(ab’)2 and a Fab 
fragment compared to bivalent bsAb, consisting of two Fab fragments [56]. Trivalent 
bsAb have dual specificity of the tumor antigen, while they are monospecific for 
the radioactive peptide. Consequently, the bsAb is more effectively trapped in the 
tumor. To produce humanized trivalent bsAb constructs efficiently, the dock-and-lock 
methodology was introduced by Rossi et al. in 2006. This technology is based on the 
dimerization and docking domain of cAMP-dependent protein kinase A. Both anti-
tumor Fab fragments form dimers. The dimer sequence of this construct has high 
affinity for the anti-hapten Fab (docking). Subsequently, cysteine residues are placed 
to form disulfide bridges which stabilize the trivalent bsAb (locking) [24].  So far, 
dock-and-lock conjugates have been synthesized for several malignancies, including 
colorectal cancer (anti-CEA x anti-HSG bsAb TF2 [57]) or prostate cancer (anti-TROP-2 
x anti-HSG bsAb TF12).
Practical considerations in pretargeting
In pretargeting, the administration of both the bispecific antibody as well as the 
peptide need to be tuned carefully to obtain maximum tumor-to-background ratios.
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Two main factors determine the tumor targeting capacity gained by this approach: (i) 
the interval between administration of the bispecific antibody and the peptide, and 
(ii) the dose of both agents. Both aspects have been evaluated in previous studies. 
The interval between administration of bispecific antibody and peptide is mainly 
determined by the blood clearance and tumor accretion of the bispecific antibody 
over time. However, the interval should not be too long either, as the retention 
time of the antibody at the binding site at the tumor can be limited. Therefore, 
the best compromise between low tracer amounts in the blood and highest tracer 
accumulation in the tumor should be used. For TF-based antibodies, the interval 
between administration of antibody and peptide is approximately 16-18 hours. The 
same concept applies for the interval between administration of the peptide and 
image acquisition. Optimal images will be acquired when tracer accumulation within 
the circulation is low and accumulation to the tumor is high. Usually, this interval is 
approximately 1-2 hours.
The second aspect to be considered is the dosing of both bispecific antibody 
and peptide. While increasing the dose of the bispecific antibody can improve tumor 
targeting, the dose should not be too high to prevent saturation of the antigens 
expressed in the tumor. In addition, the dose of the peptide needs to be taken into 
account. For imaging purposes, this dose is mainly determined by the radiolabeling 
procedure and the minimum amount of peptide that is required to label the desirable 
amount of radioactivity [24]. In general, a low dose of the peptide leads to a higher 
ratio between bispecific antibody and peptide in the circulation. As a consequence, 
a relatively higher amount of circulating peptide could be captured by the remaining 
bsAb in the circulation. This would increase the circulatory half-life of the peptide. In 
addition, less peptide would be available to accumulate to the tumor. 
Pretargeting agents for prostate cancer
The monoclonal antibody hRS7 is a humanized IgG1 monoclonal antibody, which 
is directed against TROP-2. Previous studies in nude mice with prostate cancer 
xenografts have shown excellent in vivo targeting of the TROP-2 expressing tumors 
[23]. 
However, as hRS7, like all intact monoclonal antibodies, clears slowly from the 
circulatory system, tumor-to-background ratios, especially at early time points after 
injection, were poor. To improve this, the bsAb TF12 (molecular weight 157 kDa) 
was developed for pretargeting of TROP-2 expressing tumors. TF12 is a trivalent 
bispecific antibody consisting of two anti-TROP-2 Fab fragments and one anti-HSG 
(histamine-succinyl-glycine) Fab fragment. Via the latter Fab fragment, TF12 has a 
high affinity for the DOTA (7,10-tetra-azacyclododecane-N,N’,N’’,N’’’)-tetraacetic 
acid conjugated D-Tyr-D-Lys-D-Glu-D-Lys tetrapeptide IMP288 (molecular weight 
1456 Da), in which both NH2 groups of the lysine residues are substituted with a 
HSG-moiety, forming DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2. In chapter 2.3
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of this thesis, the feasibility of TF12 and IMP288 for pretargeting prostate cancer is 
evaluated. In addition, in chapter 3.3 of this thesis, the fluorescent peptide RDC018 
which is derived from IMP288 and contains a IRDye800CW moiety, is used for dual-
modality imaging in TF12-pretargeted prostate cancer. A schematic representation of 
TF12, IMP288 and RDC018 is provided in figure 6.
Figure 6: Pretargeting agents for prostate cancer. a) Schematic representation of the 
bispecific antibody TF12. The dimerized anti-TROP-2 construct is linked to the anti-
HSG Fab, resulting in a tri-Fab bispecific antibody construct. Chemical structures of b) 
IMP288 and c) RDC018 are presented.
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ABSTRACT
Prostate cancer is the most common malignancy in men in the Western world 
and represents a major health problem with substantial morbidity and mortality. 
Sensitivity and specificity of digital rectal examination (DRE) and evaluation of the 
prostate-specific antigen (PSA) are suitable for diagnosis of prostate cancer, but 
have limited value for staging. Imaging of prostate cancer has become increasingly 
important to improve staging and management of prostate cancer patients. 
Conventional imaging modalities, such as transrectal ultrasound and computed 
tomography show limited accuracy for a reliable assessment of prostate cancer. The 
diagnostic value of magnetic resonance imaging has improved by dynamic contrast 
enhancement (DCI-MRI) and diffusion-weighted magnetic resonance imaging (DWI). 
Recently, substantial progress has been made in the development of functional 
and molecular imaging modalities, such as positron emission tomography using 
radiolabeled metabolic tracers, receptor-binding ligands, amino acids, peptides, or 
antibodies. Here, we review the value of these novel radionuclide imaging techniques 
in the assessment of prostate cancer.
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INTRODUCTION
Prostate cancer remains the most common malignancy in men in Europe, with an 
incidence of 382,000 cases and a mortality rate of 89,000 in 2008 [1]. In early stages 
of the disease, neoplastically transformed prostate cells are confined to the prostate 
gland. In later stages, malignant cells metastasize to other parts of the body, typically 
including bones and lymph nodes. Currently, metastatic prostate cancer is essentially 
incurable. Therefore, early diagnosis represents the most effective strategy with a 
change for curative treatment options and consequently minimizes prostate cancer-
related mortality [2]. 
At present, in the US, screening for prostate cancer is advisable for men above 
40 years of age by evaluation of the prostate-specific antigen levels (PSA) and by 
digital rectal examination (DRE). When abnormalities are suspected or have been 
found, further evaluation is commenced, typically by taking transrectal ultrasound 
(TRUS)-guided biopsy [3]. The most commonly used histopathological grading system 
for prostate cancer is the Gleason score. Together with other patient parameters 
like age, health state, PSA levels, and biopsy pathology, the Gleason grading system 
predicts prognosis and helps to guide therapeutic management. Patients with a low 
Gleason score have well to moderately differentiated prostate cancer histology and 
usually have localized disease. These early-stage patients can have a very indolent 
course of the disease with low mortality rates and can be monitored by watchful 
waiting to prevent overtreatment and treatment-related morbidity.
Curative treatment of confined prostate cancer includes radical prostatectomy 
performed either as an open conventional procedure or by (robot-assisted) 
laparoscopic surgery and may be combined with various forms of radiation therapy 
(RT), including 3-dimensional conformal RT, intensity-modulated RT, or proton beam 
RT [4]. Other curative treatment options include brachytherapy combined with 
external-beam RT, high-intensity focused ultrasound, and cryosurgery. However, in a 
substantial proportion of prostate cancer patients, primary curative treatment fails, 
as becomes evident by frequent recurrences of the disease. In general, the first sign 
indicating treatment failure is a shorter doubling time of PSA serum levels that may 
occur months or even years before development of clinical symptoms or radiographic 
indications for recurrent disease. However, the diagnostic use of PSA levels has 
several important drawbacks. Due to low sensitivity and specificity, the diagnostic 
value of PSA levels is limited and may yield both false-negative and false-positive 
results, leading to under- and overtreatment, respectively. Most notably, evaluation 
of PSA levels fails to differentiate between local and metastatic disease, which is 
in fact a prerequisite for appropriate management of the disease [5]. Therefore, 
new highly sensitive and specific imaging modalities for accurate visualization of 
prostate cancer and reliable monitoring of therapy response are urgently needed. 
Radionuclide imaging techniques such as PET and SPECT are very sensitive imaging
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modalities as picomolar amounts of tracers can be detected. Depending on the 
radiotracer used, these techniques can visualize specific molecular processes. 
Here, we review conventional and novel imaging modalities in prostate cancer 
and discuss the new developments in radionuclide imaging of prostate cancer in 
more detail.
CONVENTIONAL IMAGING METHODS
Transrectal Ultrasound
Today, transrectal ultrasound (TRUS) is the most commonly used technique for 
further clinical evaluation of size and anatomy of the prostate gland. TRUS has 
several advantages including high level of safety, favorable portability, relatively low 
costs, ease of use, and the possibility to perform real-time imaging. However, several 
disadvantages like low resolution, sensitivity, and specificity limit the reliability of 
TRUS. In particular, TRUS has a limited ability to delineate small cancer foci which 
usually are isoechoic and therefore cannot be detected. Moreover, the majority of 
hypoechoic foci detected by TRUS are not malignant, but rather represent conditions 
such as benign prostatic hyperplasia (BPH), atrophy, or inflammatory processes in 
the prostate gland [6]. 
Currently, several modulations of TRUS are clinically available, including Doppler 
TRUS and contrast-enhanced TRUS with microbubbles. Using Doppler TRUS, regions 
of tumors with hypervascularity can be detected. However, since many small tumors 
are not angiogenic, the sensitivity of Doppler TRUS is not significantly increased 
compared to TRUS [7]. In contrast-enhanced TRUS with microbubbles, the sensitivity 
to detect tumor foci is higher than in conventional TRUS, still, imaging does not 
reliably discriminate between inflammatory and malignant processes in the prostate 
[8].
Computed Tomography
Due to its soft-tissue type tissue architecture, the prostate gland can only poorly be 
visualized by computed tomography (CT). An accurate distinction between neoplastic 
and healthy tissue by CT is currently not feasible. Therefore, the use of CT in prostate 
cancer is limited to providing an anatomic reference for functional imaging modalities 
and for the detection of metastatic bone involvement.
Magnetic Resonance Imaging
The soft-tissue resolution of Magnetic Resonance Imaging (MRI) is superior to CT. 
MRI accurately visualizes the anatomy of the prostate, which allows a more reliable 
detection of prostate cancer. Moreover, with innovative techniques such as diffusion-
weighted MRI (DWI), MR spectroscopy (MRS), and dynamic contrast-enhanced MRI
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(DCI-MRI), functional assessment of the disease is also possible, resulting in a more 
precise staging and follow-up of prostate cancer.
In malignant tumors with high cellular density, diffusion of water molecules is 
restricted, a process that can be visualized by DWI [9]. Typically, prostate cancers 
have relatively tight glandular elements with increased cellular density and decreased 
extracellular space, producing high-signal-intensity foci on DWI [8]. Unfortunately, 
the specificity of this modality is relatively low since benign hyperplastic changes can 
also show low water diffusion [8]. 
MRS is a technique that provides information on aberrant levels of cellular 
metabolites. Prostate cancer is associated with locally elevated levels of choline and 
polyamine and decreased levels of citrate that can be evaluated by MRS. Recent 
reports indicate that MRS appears to be a promising functional imaging modality for 
the detection of prostate cancer [10–12]. Unfortunately, to obtain increased tumor 
detection rate MRS needs to be combined with MRI, which is technically challenging 
and therefore currently not widely available [13]. 
With DCE-MRI, tumor vascularization can be visualized by quantitative kinetic 
parameters that reflect blood flow and the vascular permeability [8]. DCE-MRI has 
higher specificity than MRI alone [14]. However, small low-grade tumors might 
be missed due to lack of angiogenesis. Furthermore, there is a concern regarding 
gadolinium-based contrast agents due to the risk for induction of nephrogenic 
systemic fibrosis in patients with renal failure [8].
More advanced imaging techniques include high-resolution MRI combined 
with lymphotropic superparamagnetic (ultra) small particles of iron oxide, (U)
SPIO. Administered intravenously, (U)SPIO penetrate the vascular endothelium and 
enter the interstitial space and lymph vessels, finally reaching the lymph nodes. In 
the lymph nodes, the particles are phagocytised by macrophages which produces 
signal variations. In case of malignant involvement of the lymph node, absence of 
macrophage activity leads to signal modification. Consequently, affected lymph 
nodes will appear hyperintense on T2-weighted MRIs [15]. It has been found 
that USPIO-MRI has a significantly higher sensitivity than conventional MRI [16]. 
However, several disadvantages may limit the clinical use of USPIO-MRI, such as 
the requirement for particular expertise, its timeconsuming nature, and the limited 
sensitivity of USPIO-MRI in small lymph nodes (<5 mm). Recently, the uptake of 
bombesin-functionalized iron oxide nanoparticles in PC3 prostate cancer cells has 
been evaluated and preclinical data indicate that this approach may yield a prostate 
cancer-selective imaging probe [17].
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Positron Emission Tomography
Radiolabeled metabolite tracers. 
Today, positron emission tomography (PET) is emerging as an important functional 
imaging modality in various malignancies. Using PET, specific cellular and molecular 
processes, such as glucose metabolism and cell proliferation can be functionally 
visualized. The most commonly used tracer for PET imaging is 18F-fluorodeoxyglucose 
(18F-FDG). Tumor cells can be depicted by this technique by exploiting their enhanced 
glucose demand that is mainly due to increased aerobic glycolysis in malignant cells, 
allowing them to be distinguished from normal cells [18]. 18F-FDG is taken up via 
glucose transporters. Intracellularly, 18F-FDG is rapidly phosphorylated after which 
it cannot be metabolized any further. Consequently, 18F-FDG is trapped inside 
metabolically active cells and can be visualized with PET. For anatomic reference for 
the functional PET images, integrated PET/CT has become the standard technology. 
Unfortunately, in primary prostate cancer 18F-FDG-PET with or without integration 
of CT has limited sensitivity. A large fraction of prostate cancers expresses only low 
numbers of glucose transporters such as Glut-1, which limits 18F-FDG uptake [19]. In 
addition, sensitivity of 18F-FDG-PET is also limited since 18F-FDG is excreted mainly via 
the urinary tract, obscuring the prostate gland, and restricting the identification of 
pelvic lymph node metastases [20]. 
3-Deoxy-3-fluorothymidine (FLT) radiolabeled with 18F is another potential tracer 
for monitoring early effects of treatment of hormone-refractory prostate cancer. FLT 
has been introduced as a radiopharmaceutical for assessing tumor proliferation with 
PET imaging. Oyama et al. [21] demonstrated a significant decrease of FLT uptake 
in tumors after administration of docetaxel, while the changes of FDG uptake were 
minimal. Immunohistochemical analysis revealed that the changes of FLT uptake 
were correlated with those of proliferation activity. 
Currently, choline radiolabeled with 11C (figure 1) or 18F (figure 2) is routinely 
used as PET tracer to image prostate cancer [22]. The use of choline is based on the 
fact that it is a key precursor in the biosynthesis of phosphatidylcholine, a major 
component of the cell membrane. An explanation for increased choline uptake in 
prostate cancer might be the increased proliferation rate in tumors [23]. Another 
possible explanation is upregulation of choline kinase in cancer cells [24]. 
The major advantage of 11C-choline PET is the limited excretion rate via the 
urinary system, which minimizes obscuring of the prostate and therefore enables 
imaging of the pelvis without confounding bladder activity [25]. Rinnab and 
coworkers [26] evaluated 11C-choline PET/CT in 50 patients with biochemical 
recurrence and reported a sensitivity of 91% at PSA concentrations below 2.5 ng/
ml and a specificity of 50%. Besides low specificity, the use of the tracer 11C-choline 
is limited by the short half-life of 11C (t ½ = 20 min), which requires the availability of 
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an on-site cyclotron [22]. With a half-life of 110 min, 18F-labeled choline (18F-FCH) 
overcomes this limitation. However, urinary excretion of 18F-FCH is higher than that of 
11C-choline and might confound image interpretation. Eschmann et al. [27] compared 
11C-choline PET/CT with conventional whole-body MRI and reported a better overall 
diagnostic performance with 11C-choline PET/CT due to higher detection rate of lymph 
node metastases and other local disease related alterations. However, for detection 
of bone metastases, the authors recommend a combination of both techniques to 
improve diagnostic accuracy.
Acetate is another commonly used tracer for PET imaging of prostate cancer. 
Intracellularly, acetate is converted into acetyl-CoA and incorporated into cholesterol 
and fatty acids, which finally form the cellular membrane. Recently, fatty acid 
synthesis was shown to be increased in prostate cancer with fatty-acid synthase 
being overexpressed [28]. Since acetate is excreted mainly via the pancreas [8], 
confounding bias through bladder activity is prevented which enables accurate 
imaging of the pelvis. Therefore, 11C-acetate PET has been clinically evaluated for 
detection and follow-up of prostate cancer. A clinical trial by Albrecht et al. [29] 
suggested that 11C-acetate PET might be useful for the detection of recurrent prostate 
cancer, especially in very early work-up of postoperative patients presenting with 
very low PSA values. Those data confirmed previous PET studies by Oyama et al. [30], 
who showed that 11C-acetate uptake in the prostate bed as well as in lymph nodes 
was superior to that of 18F-FDG. 
Figure 1: PET/CT image acquired after injection of 11C-choline in a patient with prostate 
cancer. This image shows metastatic involvement of a lymph node (white arrow) and 
vertebrae (green and red arrow).
50
CHAPTER 2.1
18F-fluoroacetate, an 18F-labeled analogue of acetate, has also been developed 
for PET. Similar to acetate, 18F-fluoroacetate is substrate for acetyl coenzyme A 
synthase, but with lower specificity. 18F-fluoroacetate represents a new alternative 
for 11C-acetate in PET imaging of prostate cancer with the benefit of using a positron 
emitter with a longer half-life [31]. Small-animal PET series with 18F-fluoroacetate 
in CWR22 tumor-bearing mice showed clear delineation of tumor tissue compared 
to reference organs, suggesting that it might be a useful PET tracer for imaging of 
Figure 2: Transaxial slices of 18F-choline PET/CT images of a patient with metastasized 
prostate cancer. Panel A shows local recurrence of prostate cancer in the left 
retrovesical area. Panels (B-H) show metastatic involvement of lymph nodes.
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malignancies [31]. Matthies et al. [32] provided preliminary clinical data of a prostate 
cancer patient with rising PSA and progressive bone metastases. They showed that, 
compared to 11C-acetate, 18F-fluoroacetate PET offers the possibility of delayed 
imaging with the potential to further increase tumor to-background ratios. 
For detection of malignant bone metastases, 18F-sodium fluoride PET (figure 
3) has shown high sensitivity and specificity [33]. The uptake in malignant lesions 
represents the increase in local blood flow and osteoblast activity. 18F-fluoride PET 
has been found to be more sensitive than 99mTc-methylene diphosphonate (99mTc-
MDP) planar bone scintigraphy, especially in the early detection of metastases [33]. 
18F-fluoride PET is characterized by a two-fold higher bone uptake than 99mTc-MDP, 
faster clearance from the blood pool and a higher target-to-background ratio [33]. 
Unfortunately, like 99mTc-MDP, 18F-fluoride PET is not tumor-selective and false-positive 
rates may be high [34]. However, this limitation can be overcome by integration of 
18F-fluoride PET with CT, which provides higher specificity and sensitivity [35]. More 
recent data indicate 18F-FCH PET/CT to be more specific than 18F-fluoride PET/CT in 
the early detection of bone metastases [36]. 
Figure 3: Coronal and sagittal slices of a Na-F-18 PET scan of a patient with bone 
metastases in clavicula (black arrow), lumbal spine (white arrow), and left femur (gray 
arrow).
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Another potential tracer for PET imaging of prostate cancer is 18F-fluoropropionic 
acid (18F-FPA). It is hypothesized that, as discussed above for fluoroacetate, 18F-FPA 
mimics acetate and therefore accumulates in tumor tissue [37]. Compared to 18F-FDG, 
18F-FPA showed more accurate delineation of CWR22 prostate cancer xenografts in 
mice. However, further research is necessary to evaluate if 18F-FPA offers further 
advantages over existing tracers for prostate cancer. 
Radiolabeled androgen receptor binding ligands. 
Recently, the imaging agent 18F-fluoro-5-alpha-dihydrotestosterone (18F-FDHT) that 
binds to androgen receptors, has been developed. Functional androgen receptor 
expression is a key factor in anti-androgen-based treatment of prostate cancer. 
Consequently 18F-FDHT PET/CT may be exploited to monitor viable and androgen-
sensitive tumor tissue and for the evaluation of anti-androgen therapy response 
[38]. The major advantage of this modality is that androgen-sensitive tumors can 
be detected whereas androgen-resistant tumors cannot, predicting if anti-androgen-
based approaches represent a therapeutic option for individual patients. 18F-FDHT 
PET/CT seems to be more likely to be of use in advanced disease with metastatic 
bone involvement rather than in localized prostate cancer, since background uptake 
can be high [39]. However, so far, experience with 18F-FDHT PET/CT is limited and 
more studies evaluating its role in prostate cancer are needed. 
Radiolabeled bombesin and gastrin-releasing peptide receptor binding ligands.
Since bombesin and gastrin-releasing peptide receptors (GRPR) are overexpressed 
in prostate cancer, they represent a potential target for molecular imaging. The first 
radiolabeled bombesin analog (Cu-64-DOTA-8-amino-octanoicacid-bombesin) was 
introduced by Rogers et al. [39]. In this study, specific tumor localization of 64Cu-
DOTA-Aoc-bombesin in mice with PC3 xenografts was demonstrated by microPET 
imaging and was confirmed by biodistribution studies. However, the high uptake of 
64Cu-labeled bombesin in normal tissues prevented its clinical implementation. 
In a very recent study, the values of the 111In-labeled bombesin agonists PESIN, 
AMBA, MP2346, and MP2653 and the 99mTc-labeled antagonist Demobesin-1 for 
SPECT/CT imaging of prostate cancer were evaluated in SCID mice xenografted 
with human GRPR-overexpressing PC3 tumors [40]. Schroeder et al. showed that 
Demobesin-1 was superior to the other agents with respect to in vivo stability, tumor 
uptake, and retention. Typically, renal and pancreatic clearance for Demobesin-1 
was fast. The best GRPR agonists in this study were PESIN and AMBA with sufficient 
in vivo stabilities and relatively high tumor uptake and retention. However, further 
studies are needed to evaluate the clinical use of these agents in patients with 
prostate cancer. 
In another study, novel series of [64Cu-NO2A-(X)-BBN(7–14)NH2] agonists 
for the specific targeting of GRPR on human PC3 cells and tumor tissue have been
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evaluated [41]. The [64Cu-NO2A-(AMBA)-BBN(7–14)NH2] conjugate exhibited the 
highest accumulation in tumor tissue and the most efficient whole-body clearance 
via the renal–urinary excretion pathway. 
One of the first clinical studies for imaging androgen-dependent prostate cancer 
using 99mTc-[Leu13]BN has been performed by Scopinaro and colleagues in eight 
patients with primary prostate cancer. They were able to visualize eight cancers in 
the prostate fossa with SPECT. Moreover, they reported uptake in obturator nodes 
which were proven to be cancer-specific by histopathology in three patients that 
were negative on MRI and CT [42]. In another study, Vincentis et al. [43] reported 
detection of prostate cancer by 99mTc-BN SPECT in 12 out of 12 patients with 
androgen-dependent prostate cancer and visualization of loco-regional lymph nodes 
in 4 out of 12 patients. These preliminary data suggest that 99mTc BN SPECT could be 
useful to detect primary prostate cancer and to evaluate locoregional lymph node 
involvement. 
Other strategies focus on imaging of the heterodimeric transmembrane 
glycoprotein αvβ3 integrin that plays an important role in angiogenesis, metastasis, 
and the development of bone metastases in prostate cancer [44]. To image 
expression of αvβ3, the PET tracer 
18F-galacto-RGD was developed. Compared to 
conventional bone scans, the detection rate of bone metastases was higher using 
tracer 18F-galacto-RGD PET. However, uptake of 18F-galacto-RGD was heterogeneous, 
which suggests a variation in αvβ3 expression in prostate cancer metastases [45]. 
During invasion, angiogenesis, and metastasis of GRPR-positive tumors, the 
endothelial cells around the tumor tissue are activated and express high levels of 
integrin αvβ3. Thus, many GRPR-positive tumors are also positive for integrin αvβ3 
[45]. Due to this, dual-receptor targeting of αvβ3 and GRPR represents another 
potential approach for detection of prostate cancer. Therefore, a BBN-RGD peptide 
heterodimer has been developed, that recognizes GRPR through the BBN motif and 
integrin through the RGD motif. In prostate cancer xenograft models, the BBNRGD 
heterodimer labeled with 18F exhibited excellent tumor uptake and favorable in vivo 
kinetics superior to the BBN and RGD analogues [46]. 
In a subsequent study, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) has 
been used as a chelator and the potential advantages of 64Cu-labeled NOTA-RGD 
bombesin heterodimer above the monomeric analogues NOTA-RGD and NOTA-
bombesin for imaging GRPR-positive tumors were demonstrated [47]. 
Radiolabeled antibody imaging. 
Currently, extensive research is focused on both imaging and therapy of several types 
of malignancies using radiolabeled monoclonal antibodies (mAbs) directed towards 
relevant tumor-associated cell surface antigens. 
Recently, several anti-PSMA antibodies have been developed that target the 
prostate-specific membrane antigen (PSMA). The first antibody used to target 
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PSMA in prostate cancer is capromab pendetide (7E11-C5). Capromab pendetide 
(Prostascint®) is a monoclonal antibody labeled with 111Indium that specifically targets 
an intracellular epitope of PSMA. Capromab pendetide was approved by the FDA for 
imaging of soft tissue sites in metastatic prostate cancer for presurgical staging. In 
addition, it was approved for the evaluation of PSA relapse after local therapy. In 
a low number of presurgical patients with high-risk disease that show no lesions 
on CT or MRI scans, capromab pendetide detected positive nodes, thereby sparing 
these patients unnecessary surgical procedures [48]. However, as indicated above, 
capromab pendetide binds to the intracellular domain of PSMA. Therefore, binding 
to viable tumor cells requires internalization. Alternatively, capromab pendetide may 
only bind to dead cells with disrupted cellular membranes. In addition, localization of 
capromab uptake is limited by nonspecific binding and relatively high activity in the 
blood [8]. However, due to the relatively long half-life of 111Indium (2.8 days), SPECT 
images can be obtained several days after injection, allowing washout of background 
activity from blood and bowel. Using capromab pendetide, detection of recurrence 
of disease, lymph node metastases, and other metastatic involvement is possible 
and combination with CT to improve anatomical resolution increases its specificity. 
One of the major limitations of imaging with radiolabeled capromab is the poor 
penetration in bone, limiting the detection of metastatic bone involvement [49]. 
To overcome limitations due to intracellular binding of capromab, antibodies 
binding to the epitopes on the extracellular domain of PSMA, such as J591, J415, and 
J533, have been developed that show high affinity binding to viable PSMA-expressing 
LNCaP cells [50]. In a preclinical study, mice were treated with J591 radiolabeled with 
131Iodine, 177Lutetium, and 90Yttrium. 177Lu and 90Y provide better dosimetry due to 
their longer biological half-lives [51]. However, due to development of human-anti-
mouse antibody (HAMA) responses, repetitive dosing was restricted. Meanwhile, a 
humanized form of J591 has been developed, which was well-tolerated and showed 
high tumor targeting capacity [52]. The first clinical studies with 111In-, 90Y, and 177Lu-
radiolabeled humanized mAb J591 have been performed by Bander et al. [53]. Tumor 
targeting results of 53 patients that received radiolabeled humanized J591 in phase 
1 trials have been analyzed. In 43 evaluable patients, J591 accurately targeted bone 
lesions in 94% and soft tissue lesions in 72% of the patients, respectively. They also 
showed that the humanized antibody is less immunogenic and can be administered 
several times to the same patient with persistently accurate tumor targeting activity. 
More recently, a phase-II clinical trial with 177Lu-J591 for metastatic castration-
resistant prostate cancer has been completed with excellent targeting of CT or MRI 
proven sites of prostate cancer metastases in 94% of the patients [54]. During this 
study, thrombocytopenia was the most commonly seen hematologic toxicity and 
limited the dose of 177Lu-J591. Also, 90Y-J591 is known for its hematologic toxicity 
causing significant myelosuppression.
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Recently, three other antibodies were identified that are directed against alternative 
epitopes on PSMA that appear to have diagnostic potential for prostate cancer [55]. 
Wolf et al. characterized the monoclonal antibodies 3/A12, 3/E7, and 3/F11 in vitro 
and demonstrated a high affinity binding to PSMA-positive C4-2 cells for all three 
antibodies. A subsequent study focused on in vivo behavior, biodistribution, and 
tumor uptake of the 64Cu-DOTA labeled antibodies 3/F11 and 3/E7 and fragments of 
3/A12 [52]. PET imaging demonstrated specific tumor uptake of these monoclonal 
antibodies in PSMA-positive C4-2 tumors in SCID mouse xenografts models, which 
further confirmed possible use of those antibodies in imaging of prostate cancer. 
Very recently, the potential targeting ability of the humanized IgG1 mAb hRS7 which 
is also directed against the epithelial glycoprotein-1 (EGP-1) was evaluated [67]. They 
evaluated the biodistribution of 111In-, 125I-, and 89Zr-labeled hRS7 and performed 
immuno-PET and immuno-SPECT with 111In-hRS7 and 89Zr-hRS7 in mice with s.c. and 
intraprostatic PC3 xenografts. They showed that specific tumor uptake of hRS7 is 
high with high tumor-to-blood ratios, which allowed excellent immuno-PET/CT and 
immuno-SPECT imaging of the PC3 xenografts [67]. 
In another recent study performed by the same group, a pretargeting 
approach for localizing advanced prostate cancer based on an anti-EGP-1 antibody 
in subcutaneous and orthotopic PC3 mouse models was developed [57]. EGP-1 
is a pancarcinoma marker that is expressed at high levels on virtually all-prostate 
carcinomas. The pretargeting approach resulted in high uptake in the tumor, rapid 
blood clearance, and excellent tumor-to-blood ratios for 111In-IMP-288 in the PC-3 
tumors. As early as 1 h after injection of the radiolabeled peptide, pretargeted 
immuno-PET images clearly visualized the subcutaneous and orthotopic tumors 
with minimal activity in the kidneys. Van Rij et al. showed that pretargeting with the 
bispecific antibody TF12 in combination with radiolabeled IMP-288 is an excellent 
approach for specific, fast, high-contrast imaging of prostate cancer. 
Another important cell surface target for molecular imaging of prostate cancer 
is the prostate stem cell antigen (PSCA), which is overexpressed in a majority of 
prostate cancers and has low levels of expression in a very limited number of normal 
tissues. PSCA has been detected in approximately 60% of lymph node and liver 
metastases [58] and strong PSCA staining has been observed in 87–100% of bone 
metastases [56]. Elevated PSCA expression has also been shown to correlate with 
increased tumor stage, grade, and progression to androgen independence. Olafsen 
et al. studied a humanized anti-PSCA monoclonal antibody 1G8 (hu1G8) in preclinical 
models [59] and showed that PET evaluation in LAPC-9-xenografted mice following 
radioiodination with the positron emitter 124I provided high contrast PET images. 
Due to the slow clearance kinetics of the antibody, enhanced target-to-background 
images were not obtained until 1 week after administration of 124I-hu1G8. To 
facilitate and accelerate clearance from blood, antibody fragments of various sizes 
were used in subsequent studies. Leyton et al. evaluated the role of the from hu1G8
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antibody derived minibody 2B3 labeled with 131I or 124I for imaging prostate cancer 
xenograft-bearing mice. The 2B3 minibody showed fast blood clearance in comparison 
to the intact hu1G8 monoclonal antibody, which resulted in the ability to image 
prostate cancer xenografts within 21 h in contrast to 168 h with the intact antibody 
[60]. Remarkably, the 2B3 minibody mimicked the tumor uptake of the intact hu1G8 
monoclonal antibody in the LAPC-9 model despite its rapid elimination from the 
circulation. Due to the ability of the 2B3 antibody to image androgen-independent 
as well as androgen-dependent xenografts, 2B3 has promising potential as a rapid 
imaging agent for high-risk prostate cancer patients [60]. 
Another recent study evaluated the tumor targeting activity of an internalizing 
human single-chain antibody fragment (scFv) UA20 that is directed against a still 
unknown antigen. UA20 was labeled with 99mTc to target human prostate carcinoma 
in DU145 xenograft mouse models [61]. In this study, UA20 scFv showed rapid and 
specific internalization in prostate tumor cells in vitro and accumulation in prostate 
tumor xenografts in vivo. SPECT/CT showed significant tumor uptake as early as 1 h 
after injection and at 3 h after injection, tumor uptake was 4.4% ID/g. In contrast, the 
control antibody N3M2 showed a tumor uptake of only 0.26% ID/g that was similar 
to nonspecific uptake in muscle and fat. These data indicated the potential of UA20 
scFv for future development for prostate cancer imaging.
Radiolabeled amino acid imaging. 
Radiolabeled amino acids may be alternative tracers for imaging of prostate cancer, 
since their uptake is frequently increased in rapidly proliferating cells [28]. 
A potential tracer for PET imaging of prostate cancer is the radiolabeled amino 
acid methionine. Since accumulation of 11C-methionine in tumor cells reflects 
transport of amino acids and protein synthesis, enhanced metabolism of tumors 
can be visualized with 11C-methionine. Methionine is mainly metabolized in liver and 
pancreas, without excretion via the urinary tract [3]. 
The few studies available that investigated the role of 11C-methionine PET in 
prostate cancer indicate superiority of 11C-methionine PET over 18F-FDG PET in the 
detection of metastatic bone and soft tissue lesions [62]. Nunez et al. obtained a 
relatively high sensitivity (72.1%) of 11C-methionine PET for the detection of bone 
and soft-tissue metastases, which compared favorably with the sensitivity of 48% 
for 18F-FDG PET. A possible explanation for this difference in sensitivity of detection 
of metastatic lesions might be the relatively high activity of 18F-FDG in the bladder, 
interfering with the evaluation of the prostate and nearby tissues. In contrast, only a 
minimal amount of 11C-methionine is excreted via the urinary system allowing more 
reliable evaluation of pelvic structures. As a consequence 18F-FDG may have limited 
ability to detect abdominal retroperitoneal metastases [37]. 
In a pilot study, the L-leucine analogue anti-1-amino-3-18F-fluorocyclobutyl-1-
carboxylic acid (anti-18F-FACBC) showed uptake in primary and metastatic prostate
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cancer. Bladder excretion of anti-18F-FACBC was found to be low and data indicate a 
potential role for anti-18F-FACBC in the differentiation between BPH and malignant 
transformation of the prostate gland [63]. However, anti-18F-FACBC needs to be 
further evaluated in clinical studies. 
Since tumors express specific antigens, radiolabeled antibodies can target 
the antigens and can be of diagnostic value. However, due to the long circulatory 
half-life of radiolabeled antibodies, high target to background ratios are obtained 
several days after injection. Therefore, peptides that target those antigens represent 
alternatives for imaging of prostate cancer [64]. PET imaging of xenografted tumors 
overexpressing PSMA was achieved with a PSMA inhibitor labeled with 11C. This 
11C-DCMC compound specifically binds with high affinity to the extracellular domain 
of PSMA [65]. 11C-DCMC showed clear delineation of the tumor at 30 min after 
injection. This PSMA inhibitor was also labeled with 18F. High uptake of 18F-DCFBC was 
observed in the PSMA-positive tumors whereas uptake in PSMA-negative tumors 
remained low [66].
CONCLUSION AND FUTURE PERSPECTIVES
Since conventional approaches have limited value in the early detection, staging, 
and follow-up of prostate cancer, extensive research currently focuses on the 
development of highly sensitive and specific imaging modalities for accurate 
visualization of prostate cancer. 
Improvements on conventional MR imaging have yielded promising new 
approaches such as DWI, MRS, or DCI-MRI, which allow for more accurate disease 
staging and follow-up of prostate cancer. 
Substantial progress has been made in the development of radionuclide 
imaging techniques and the value of numerous radioactive tracers for the detection 
of prostate cancer has been evaluated. Since sensitivity of 18F-FDG-PET for imaging 
of prostate cancer is limited, tracers like 11C-choline, 18F-FCH, 11C-acetate, and 
11C-methionine represent more appropriate alternatives for prostate cancer imaging. 
11C-methionine PET is superior to 18F-FDG-PET in both the detection of soft tissue 
lesions and the early detection of bone metastases. For evaluation of tumor bed and 
lymph nodes, 11C-acetate PET was superior to 18F-FDG-PET. However, in progressive 
disease and detection of bone metastases, 18F-fluoroacetate might be superior 
to 11C-acetate. For this purpose, 18F-fluoride PET represents another appropriate 
tracer for detection of bone involvement with high sensitivity and specificity. The 
relatively novel tracer 18F-FPA appears to be superior to 18F-FDG in the detection of 
prostate cancer; however, more preclinical and clinical data are needed for further 
evaluation. Receptor binding ligands like 18F-FDHT may have a value in the detection 
of androgen-sensitivity of the tumor, which would direct therapeutic strategies
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towards anti-androgen-based approaches. During the last decade, a wide range 
of antibodies and antibody fragments, such as capromab pendetide, 3/A12, 3/E7, 
3/F11, 2B3, and UA20 have been developed which show promising potential for 
targeted imaging of prostate cancer. 
More studies are necessary to accurately compare novel imaging modalities 
and their tracers for optimal suitability in the early detection of (recurrent) prostate 
cancer, metastatic manifestations, and response to therapy. 
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ABSTRACT
Background
D2B is a new monoclonal antibody directed against an extracellular domain of 
prostate-specific membrane antigen (PSMA), which is overexpressed in prostate 
cancer. The potential of D2B IgG, and F(ab’)2 and Fab fragments of this antibody for 
targeting prostate cancer was determined in mice bearing subcutaneous prostate 
cancer xenografts.
Methods
The optimal time point for imaging was determined in biodistribution and microSPECT 
imaging studies with 111In-D2B IgG, 111In-capromab pendetide, 111In-D2B F(ab’)2 and 
111In-D2B Fab fragments in mice with PSMA-expressing LNCaP and PSMA-negative 
PC3 tumors at several time points after injection.
Results
All 111In-labeled antibody formats specifically accumulated in the LNCaP tumors, with 
highest uptake of 111In-D2B IgG and 111In-capromab pendetide at 168 h p.i. (94.8 ± 
19.2% ID/g and 16.7 ± 2.2% ID/g, respectively), whereas uptake of 111In-D2B F(ab’)2 
and 111In-Fab fragments peaked at 24 h p.i. (12.1 ± 3.0% ID/g and 15.1 ± 2.9% ID/g, 
respectively). Maximum LNCaP tumor-to-blood ratios were 13.0 ± 2.3 (168 h p.i.), 6.2 
± 0.7 (24 h p.i.), 23.0 ± 4.0 (24 h p.i.), and 4.5 ± 0.6 (168 h p.i.) for 111In-D2B IgG, 111In-
F(ab’)2, 
111In-Fab, and 111In-capromab pendetide, respectively. LNCaP tumors were 
clearly visualized with microSPECT with all antibody formats.
Conclusion
This study demonstrates feasibility of D2B IgG, F(ab’)2 and Fab fragments for targeting 
PSMA-expressing prostate cancer xenografts.
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INTRODUCTION
Prostate cancer is the second leading cause of cancer-related deaths in men in the 
Western world and since metastatic prostate cancer is incurable, early diagnosis 
represents the most effective strategy with a change towards curative treatment 
options. Additionally, differentiation between malignant and nonmalignant prostate 
tissue is essential for the initiation of adequate treatment and the evaluation of 
response to therapy and relapse. 
At present, prostate cancer is usually diagnosed by transrectal ultrasound 
(TRUS)-guided biopsy. However, the ability of TRUS to delineate small cancer foci 
and differentiate between benign prostatic hyperplasia (BPH), atrophy, inflammatory 
processes and malignancies is limited. Magnetic Resonance Imaging (MRI) is used 
in many centers for primary diagnostic purposes of prostate cancer, while MRI is 
less suitable to determine metastatic spread. Positron Emission Tomography (PET) 
imaging is a useful imaging modality to detect metastatic disease in several cancers. 
However, 18F-FDG-PET is not suited for staging patients with prostate cancer, due 
to the relatively low avidity of prostate cancer for 18F-FDG. Therefore, the most 
commonly used approach to identify metastases or tumor cell-containing lymph 
nodes in prostate cancer patients is multi-detector computed tomography (MDCT). 
However, the sensitivity and specificity of this modality are still limited. Imaging with 
radiolabeled monoclonal antibodies (mAb) as tracers for SPECT or PET imaging could 
have additional diagnostic value. 
The prostate-specific membrane antigen (PSMA) is a type II membrane 
glycoprotein [1] which provides an excellent target for prostate cancer imaging due 
to its selective overexpression on the surface of prostate cancer cells [2]. Initial 
validation of PSMA as an in vivo target resulted from imaging with the 111In-labeled 
mAb capromab pendetide (7E11/CYT-356, Prostascint®) [3] which is FDA approved 
for diagnostic imaging in patients with biopsy-proven prostate cancer, who are at high 
risk for pelvic lymph node metastases [4]. However, capromab pendetide is directed 
against an epitope on an intracellular domain of PSMA [5]. Therefore, binding of 
this antibody to tumor cells requires uptake of the antibody into the cells. It has 
been postulated that capromab pendetide may only bind to dying or necrotic cells 
with cellular membranes that are permeable for IgG. The mAb J591 which is directed 
against an extracellular epitope of PSMA has shown great potential for radionuclide 
imaging and therapy in prostate cancer patients [6, 7].
In the present study, we use the new mAb D2B IgG, a murine IgG1 mAb directed 
against an epitope on the extracellular domain of PSMA [8]. We characterized the 
tumor targeting capacity of D2B IgG and compared it to those of F(ab’)2 and Fab 
fragments of D2B IgG to evaluate possible limitations such as low tumor-to-blood 
ratios that can occur due to relatively slow clearance of intact antibodies compared 
to fragments [9]. In these experiments capromab pendetide was used as a reference.
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MATERIALS AND METHODS
Production and purification of antibodies and fragments
The monoclonal antibody D2B (IgG1) was derived from mice that were immunized 
three times with a cell lysate of membranes of LNCaP cells. Mice were boosted with 
a recombinant form of PSMA produced in bacteria.
D2B IgG was purified from hybridoma culture supernatant by Protein A affinity 
chromatography. F(ab’)2 fragments were produced by pepsin digestion essentially as 
described earlier [10]. Briefly, after incubation of D2B IgG for 3 h at 37 °C with pepsin 
in 0.15 M sodium citrate (pH 3.8), digestion was stopped by adjusting the pH of the 
solution to pH 7.0 with 1.0 M Tris. F(ab’)2 fragments were purified using a cation 
exchange column (Mono-S H/R 5/5, Pharmacia, Uppsala, Sweden) that was eluted 
with 40 mM sodium acetate buffer (pH 6.0) with a 0 to 400 mM lithium chloride 
gradient. The F(ab’)2 fragment containing fractions were identified by sodium dodecyl 
sulfate−polyacrylamide gel electrophoresis (SDS−PAGE) and pooled. 
Fab fragments were generated by papain digestion (6 h at 37°C) of D2B IgG using 
papain immobilized on agarose resin according to the protocol of the manufacturer 
(Thermo Scientific, Pierce Fab Preparation Kit) followed by purification using protein 
A affinity chromatography and dialysis. 
Cell culture
The human prostate cancer cell lines PC3 (PSMA-) and LNCaP (PSMA+) derived from a 
bone metastasis and a supraclavicular lymph node, respectively, were used. Both cell 
lines were obtained from the ATCC and grown in RPMI 1640 medium, supplemented 
with 10% fetal calf serum (Life technologies, Bleiswijk, The Netherlands) and 
glutamine 2mM. 
Mouse models
Male BALB/c nude mice (Janvier, Le Genest Saint Isle, France), 8-9 weeks old, housed 
in filter-topped cages (5 mice per cage) under nonsterile standard conditions with free 
access to standard animal chow and water, were adapted to laboratory conditions for 
1 week before experimental use. Mice were subcutaneously inoculated with 3 x 106 
LNCaP cells (right flank) suspended in 200 µL of 33% complete RPMI 1640 medium 
with 67% Matrigel (BD Biosciences) and with 3 x 106 PC3 cells (left flank) suspended 
in 200 µL of 67% complete RPMI 1640 medium with 33% Matrigel. LNCaP cells were 
inoculated 7 days prior to PC3 cells and grew to approximately 0.1 g in 14 and 7 days 
after tumor cell inoculation respectively. 
All experiments have been approved by the institutional Animal Welfare 
Committee of the Radboud University Medical Center Nijmegen and were conducted 
in accordance to the principles set forth by the Revised Dutch Act on Animal 
Experimentation.
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Radiolabeling of D2B
The murine mAb D2B IgG and all fragments were conjugated with p-isothiocyanato-
benzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) (Macrocyclics) in 0.1 M 
NaHCO3, pH 9.5, with a  10-fold molar excess of ITC-DTPA (2.5 mg D2B IgG with 110 
μg ITC-DTPA, 4.5 mg F(ab’)2 with 250 μg ITC-DTPA and 0.75 mg Fab with 100 μg ITC-
DTPA). After incubation of 1 h at room temperature, the reaction mixture was dialyzed 
for 3 days in a Slide-A-Lyzer (20-kDa cutoff, Pierce) against 0.25 M NH4Ac, pH 5.4.
For biodistribution studies, D2B IgG-DTPA (28 µg), F(ab’)2-DTPA (22 µg), Fab-
DTPA (20 µg) and capromab pendetide (30 μg) were radiolabeled with 3.7 MBq 111In-
chloride  (Covidien, Petten, Netherlands) in 0.1 M MES buffer at pH 5.4 (three times 
the volume of 111In-chloride) and incubated during 30 min at room temperature under 
metal-free conditions. For SPECT/CT studies, D2B IgG-DTPA, F(ab’)2-DTPA, Fab-DTPA 
and capromab pendetide-DTPA were incubated with 160 MBq, 152 MBq, 150 MBq or 
340 MBq of 111In in 0.1 M MES buffer pH 5.4, respectively. Following incubation, 50 
mM EDTA was added to the final concentration of 5 mM to chelate unincorporated 
111In.
The labeling efficiency was determined by instant thin layer chromatography on 
silicagel strips (ITLC-SG; Gelman Sciences, Ann Arbor, MI, USA) using 15 mM citrate 
buffer, pH 6.0, as the mobile phase. For biodistribution, it was 95%, 58% 90% and 
95%, for 111In-labeled D2B IgG-DTPA, F(ab’)2-DTPA, Fab-DTPA and capromab-DTPA, 
respectively. For SPECT imaging, it was 70%, 79%, 97% and 95%, respectively.
 111In-labeled D2B IgG-DTPA, F(ab’)2-DTPA, Fab-DTPA, and capromab-DTPA were 
purified by gel filtration on a PD-10 column. The radiochemical purity was determined 
by ITLC and exceeded 97% for all preparations used in the studies.
Immunoreactivity
The immunoreactive fractions of the radiolabeled antibody/fragment preparations 
were determined using freshly trypsinized LNCaP cells, essentially as described by 
Lindmo et al. [11, 12]. The activity in the vials and in the cell pellet after washing 
with 500 µL binding buffer was determined in the γ-counter (Wizard 3” 1480, LKB-
Wallac, Oy, Finland) after incubation of 1 h at 37°C. Immunoreactive fractions of all 
radiolabeled preparations used in the experiments exceeded 80%. For 111In-capromab 
pendetide, the assay was carried out on live and permeabilized LNCaP cells using the 
Fix & Perm Cell Fixation and Permeabilization Kit (Invitrogen) to permeabilize the 
cells.
Competitive binding assay
The IC50 of D2B IgG, F(ab’)2 and Fab fragments was determined in a competitive 
binding assay on LNCaP cells using 111In-labeled D2B as a tracer. LNCaP cells were 
grown to confluency in six-well plates, and incubated on ice for 2 h in 1 mL of binding 
buffer with 1.85 kBq of 111In-labeled D2B IgG and increasing concentrations (0.005
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-300 nM) of unlabeled D2B IgG, F(ab’)2 and Fab fragments. Cells were washed with 
binding buffer after incubation and the cell-associated activity was measured in a 
γ-counter. IC50 values were calculated using GraphPad Prism software, version 5.03 
(GraphPad, La Jolla, USA).
Flow cytometric analysis
For cell surface staining, LNCaP cells were incubated with either the mAbs D2B IgG, 
capromab pendetide or an isotype control murine IgG (Jackson ImmunoResearch) 
in phosphate buffered saline (PBS) with 2% of bovine serum albumin (BSA) and 
2% human serum (HS) for 30 minutes on ice. Part of the cells were fixed in 2% 
paraformaldehyde and incubated in PBS, 2% HS, 0.1% saponin to permeabilize the 
cells. After the incubation, samples were washed three times in PBS or PBS and 
0.1% saponin and incubated for 20 minutes on ice with the secondary anti-mouse-
alexa 488 antibody for staining. Cells were analyzed in a FACSCalibur flow cytometer 
equipped with CellQuest software (BD Biosciences).
Biodistribution studies
The effect of mAb protein dose on the biodistribution of 111In-D2B in nude mice 
with subcutaneous LNCaP tumors was determined in groups of 5 mice that received 
different protein doses of 111In-D2B IgG (0.1, 1, 3, 10, 30 or 100 μg of D2B IgG per 
mouse, 0.4 MBq). Mice were euthanized with CO2/O2 asphyxiation 3 days after 
injection of 111In-D2B IgG. Blood samples were obtained by heart puncture and tissues 
(LNCaP tumor, muscle, lung, spleen, kidney, liver, pancreas, stomach, duodenum, 
and prostate) were dissected, weighed, and the radioactivity was measured in a 
γ-counter. For calculation of the uptake of radioactivity in each tissue as a fraction 
of the injected dose, an aliquot of the injection dose was counted simultaneously. 
In a subsequent study, 111In-D2B IgG (0.4 MBq, 3.0 μg/mouse), 111In-F(ab’)2 (0.4 
MBq, 2.2 μg/mouse), 111In-Fab fragments (0.4 MBq, 1 μg/mouse) or 111In-capromab 
pendetide (0.4 MBq, 5 μg/mouse) were injected i.v. into groups of 5 mice with 
subcutaneous PC3 tumors (left flank) and LNCaP tumors (right flank). In addition, 
for Fab and F(ab’)2, five mice per antibody format received an excess of unlabeled 
D2B IgG (300 µg/mouse) two days before injection of the 111In-labeled fragments 
into the mice. For D2B IgG and capromab pendetide, the excess of unlabeled D2B 
IgG or capromab was injected on the same day as the 111In-labeled antibodies. Mice 
were euthanized by CO2/O2 asphyxiation and the biodistribution of 
111In-D2B IgG 
was determined at 1, 2, 4, 24, 72 and 168 hours after injection. Because of their 
more rapid clearance, biodistribution of the 111In-F(ab’)2 and 
111In-Fab fragments was 
determined at 1, 2, 4 and 24 hours after injection. Activity concentrations in the 
tissues (percentage injected dose per gram, % ID/g) were determined as described 
above.
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MicroSPECT/CT imaging
Four groups of 5 mice with subcutaneous LNCaP (right flank) and PC3 (left flank) 
tumors were injected with 37 MBq of 111In-D2B IgG (3.0 μg/mouse), 111In-F(ab’)2 (1.5 
μg/mouse), 111In-Fab (1 μg/mouse), and 111In-capromab pendetide (5 μg/mouse), 
respectively. The mice that received 111In-labeled D2B IgG and capromab pendetide, 
SPECT/CT scans were imaged 0, 1, 3, and 7 days after injection using a small animal 
SPECT/CT scanner (U-SPECT II, MILabs, Utrecht, Netherlands) (acquisition time: 30-
90 minutes, depending on the time point) with a 1.0 mm diameter pinhole collimator 
tube. Mice injected with 111In-F(ab’)2 and 
111In-Fab fragments underwent SPECT/CT 
at 0, 1, and 2 days after injection. For Fab and F(ab’)2, two additional mice were 
injected with an excess of unlabeled D2B IgG 2 days before injection of the 111In-
labeled antibody fragments. For D2B IgG, the excess of unlabeled antibody formats 
was coadministered on the same day as 111In-D2B. 
After the last scan, mice were euthanized and biodistribution of the 111In-D2B, 
111In-F(ab’)2, 
111In-Fab, or 111In-capromab pendetide was determined as described 
above. Scans were reconstructed with MILabs reconstruction software (MILabs, 
Utrecht, Netherlands), which uses an ordered-subset expectation maximalization 
algorithm.
Statistical analysis
Statistical analyses were performed with Graphpad Prism, version 5.03 (GraphPad, 
La Jolla, USA). Results are presented as mean ± standard deviation (SD). Differences 
in tumor uptake of the antibody formats were tested for significance using the Two-
tailed t-test. A p-value below 0.05 was considered significant.
RESULTS
In vitro characterization
FACS analysis with live and permeabilized LNCaP cells revealed high binding of D2B 
IgG to live (95.9% ± 2.2) as well as to permeabilized cells (96.9% ± 1.7). In contrast, 
for capromab pendetide, binding to live cells was low (7.6% ± 0.7), while binding to 
permeabilized cells was high (96.1% ± 1.1), showing that D2B recognizes an epitope 
on the cell surface and capromab is directed against an intracellular epitope (figure 
1). 
For 111In-D2B IgG the immunoreactive fraction on live LNCaP cells was 84.1%, 
and the immunoreactive fractions of 111In-capromab pendetide on permeabilized 
LNCaP cells was 93.6%, indicating that the immunoreactivity of both antibodies was 
preserved during the labeling procedure.
The IC50 of D2B IgG and F(ab’)2 fragments was 3.7 nM (95% confidence interval 
(CI): 2.8 – 4.8 nM) and 1.9 nM (CI: 1.6 – 2.3 nM), respectively, whereas it was slightly
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Figure 1: FACS analysis of D2B IgG and 
capromab pendetide on live (black peaks) and 
saponin permeabilized (gray lines) LNCaP cells 
showing intracellular binding of capromab 
pendetide.
Figure 2: Competitive binding curves of IC50 determination of D2B IgG, F(ab’)2 and Fab 
fragments on PSMA-positive LNCaP cells.
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lower for Fab fragments (8.9 nM (CI: 7.1 – 11.0 nM) (figure 2), which could be due to 
the monovalency of Fab fragments.
Biodistribution studies
In the dose escalation study an inverse correlation between the D2B antibody protein 
dose and the uptake in the LNCaP tumor was observed: LNCaP tumor uptake of 111In-
D2B IgG decreased from 52 ± 5% ID/g at 0.1 µg/mouse to 26 ± 1.5% ID/g at 100 µg/
mouse. Highest tumor uptake (54 ± 4% ID/g) was observed at D2B doses ≤ 3 µg/
mouse at 3 days p.i. (figure 3). At that time point, tumor-to-blood ratios ranged from 
4.3 (at 0.1 µg/mouse) to 1.8 (at 100 µg/mouse). Tumor weight was 0.04 g ± 0.02 g 
(D2B IgG group), 0.08 g ± 0.03 g (F(ab’)2 group), 0.07 g ± 0.02 g (Fab group), and 0.10 
g ± 0.02 g (capromab group).
For biodistribution studies, 111In-D2B IgG (0.4 MBq, 3.0 μg/mouse), 111In-F(ab’)2 
(0.4 MBq, 2.2 μg/mouse), 111In-Fab fragments (0.4 MBq, 1 μg/mouse) or 111In-
capromab pendetide (0.4 MBq, 5 μg/mouse) were injected inravenously. All three 
111In-labeled D2B antibody formats specifically accumulated in the s.c. PSMA+ LNCaP 
tumors (right flank), while uptake in PSMA- PC3 xenografts (left flank) remained low. 
Figure 3: Biodistribution results of the dose escalation of 111In-D2B in mice (n=5) with 
subcutaneous LNCaP xenografts. Data are presented as mean ± SD.
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LNCaP tumor uptake increased for 111In-D2B IgG from 2.2 ± 2.0% ID/g at 1 h p.i. to 
94.8 ± 19.2% ID/g at 168 h after injection, the latter representing the highest tumor 
uptake observed in these studies (figure 4). For 111In-F(ab’)2 and 
111In-Fab, LNCaP 
tumor uptake ranged from 1.6 ± 0.6% ID/g and 4.1 ± 0.9% ID/g at 1 h p.i. to 12.1 ± 
3.0% ID/g and 15.1 ± 2.9% ID/g at 24 h after injection, respectively. For 111In-labeled 
capromab pendetide, LNCaP tumor uptake ranged from 0.7 ± 0.4% ID/g at 1 h p.i. to 
16.7 ± 2.2% ID/g at 168 h after injection, reaching a maximum of 17.4 ± 2.8% ID/g 
three days after injection.
Tumor uptake of the three D2B formats could be blocked by coinjection of an 
excess of unlabeled mAb. The uptake of 111In-D2B IgG decreased from 60.9 ± 11.0% 
ID/g to 12.3 ± 7.1% ID/g at 72 h p.i.. The LNCaP uptake of 111In-F(ab’)2, decreased 
from 4.8 ± 2.1% ID/g to 3.5 ± 1.8% ID/g (4 h p.i.), while the LNCaP uptake of 111In-Fab 
decreased from 8.5 ± 2.4% ID/g to 3.9 ± 0.4% ID/g, respectively at 4 h p.i.. Maximum 
uptake in the PSMA- PC3 tumor was 9.1 ± 1.3 (24 h p.i.), 6.8 ± 1.3 (4 h p.i.) and 6.3 
± 1.1% ID/g (2 h p.i.) for 111In-labeled IgG, F(ab’)2 and Fab, further confirming the 
specific uptake of the D2B antibody formats in the PSMA+ tumor.
Maximum LNCaP tumor-to-blood ratio for 111In-D2B IgG was 13.0 ± 2.3 (168 h p.i.). 
For D2B Fab and F(ab’)2 fragments, high tumor-to-blood ratios were reached faster 
compared to tumor-to-blood ratios of D2B IgG, with a maximum of 23.0 ± 4.0 and 6.2 
± 0.7, respectively 24 h after injection (table 1). 
Figure 4: Ex vivo biodistribution of nude mice bearing subcutaneous PSMA-negative 
PC3 and PSMA-positive LNCaP xenografts at several time points after intravenous 
injection of a) 111In-D2B IgG, b) 111In-F(ab’)2, c) 
111In-Fab fragments and d) 111In-capromab 
pendetide. Data are presented as mean ± SD.
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Figure 5: Representative SPECT/CT 
images of mice bearing subcutaneous 
PSMA-negative PC3 (left flank, green 
arrows) and PSMA-positive LNCaP (right 
flank, blue arrows) prostate cancer 
xenografts at several time points after 
intravenous injection of 111In-D2B IgG, 
111In-F(ab’)2, 
111In-Fab fragments and 
111In-capromab pendetide.
111In-D2B IgG                                                           Excess unlabeled
 a) 24h p.i.           b) 48h p.i.          c) 168h p.i.                d) 24h p.i.         e) 48h p.i.          f) 168h p.i.
111In-D2B F(ab’)
2
                                                      Excess unlabeled
 a) 4h p.i.            b) 24h p.i.           c) 48h p.i.                  d) 4h p.i.           e) 24h p.i.          f) 48h p.i.
111In-D2B Fab                                                           Excess unlabeled
 a) 4h p.i.            b) 24h p.i.           c) 48h p.i.                  d) 4h p.i.           e) 24h p.i.          f) 48h p.i.
111In-capromab pendetide                                                         
 a) 24h p.i.           b) 48h p.i.          c) 168h p.i.  
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The highest LNCaP tumor-to-blood ratio of 111In-labeled capromab pendetide was 
4.5 ± 0.6, reached seven days after injection. LNCaP tumor-to-muscle ratio for 111In-
D2B IgG (168 h p.i.), 111In-F(ab’)2 (24 h p.i.), 
111In-Fab (24 h p.i.), and 111In-capromab 
pendetide (168 h p.i.) were 94.8 ± 19.2,  12.1 ± 3.0, 15.1 ± 2.9, and 16.7 ± 2.2, 
respectively.
MicroSPECT/CT imaging
SPECT/CT images of all 111In-labeled antibody formats in mice in prone position with 
subcutaneous PSMA+ LNCaP and PSMA- PC3 tumors are displayed in figure 5. At 24 h 
p.i., LNCaP tumors were clearly visualized with all formats. The optimal time point for 
imaging with 111In-D2B IgG and 111In-capromab pendetide was 168 h p.i. and for 111In-
F(ab’)2 and 
111In-Fab this was 48 h p.i.. Tumor uptake was specific for 111In-D2B IgG, 
111In-F(ab’)2 and 
111In-Fab since tumor uptake was markedly lower in mice coinjected 
with an excess of unlabeled D2B IgG (figure 5). Uptake in the PSMA- PC3 tumors 
remained low for all antibody formats at all time points. 
For D2B F(ab’)2 and Fab fragments, high accumulation of 111In in the kidneys, 
especially the renal cortex, was observed, indicating that these antibody preparations 
were cleared via the kidneys apparently with tubular reabsorption of the 111In-labeled 
metabolites.  
DISCUSSION
In the present study, the in vivo tumor targeting characteristics of 111In-D2B IgG, 111In-
F(ab’)2, and 
111In-Fab fragments for targeting of prostate cancer were examined in 
mice with human prostate cancer xenografts using 111In-labeled capromab pendetide 
as a reference.
Since intact antibodies clear slowly from the circulation and maximum tumor 
uptake is reached at 3 - 7 days after injection, we included F(ab’)2 and Fab fragments 
of D2B in our studies to investigate whether further improvements in prostate cancer 
targeting would be possible by using D2B antibody fragments. The slow accumulation 
of intact antibodies has been attributed to the slow blood clearance of intact IgG 
in combination with the presence of various physiological barriers between the 
circulation and the tumor cell surface [18]. It has been pointed out that the vascular 
endothelium, the relatively large transport distances in the tissue and the enhanced 
interstitial fluid pressure in the tumor tissue hamper the penetration of antibodies 
into the tumor tissue to bind to their target antigen. Antibody fragments such as 
F(ab’)2 and Fab fragments are cleared more rapidly from the blood, mainly because 
they lack the CH2 domain, which causes IgG molecules to recycle into the bloodstream 
via the FcRn receptor [19]. On the other hand, the sustained blood levels of intact 
IgG molecules are the driving force for their accumulation in tumors. Therefore, the 
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uptake of antibody fragments in tumors is lower than that of intact IgGs as was also 
observed in the present study. Because the diffusion rate of a molecule is linearly 
correlated to its molecular size [20], antibody fragments diffuse more rapidly in the 
interstitial fluid. Due to the more rapid blood clearance, higher tumor-to-blood ratios 
are obtained. With the antibody fragments, tumors can be visualized more rapidly: 
optimal images can be acquired within 24 h p.i., whereas intact IgG can be used when 
high concentrations of the antibody in the tumor are required (e.g. in therapeutic 
applications when high payloads of toxic agents should be targeted to the tumor). 
Here, we observed that the tumor uptake of 111In-D2B IgG was higher than that 
of 111In-F(ab’)2 and 
111In-Fab at all time points, even as early as 24 h after injection. 
However, at early time points after injection, tumor-nontumor ratios of 111In-F(ab’)2 
and 111In-Fab were higher than those of 111In-D2B IgG indicating that the antibody 
fragments are preferred for imaging purposes. For the evaluation of response to 
therapy, when imaging early after tracer injection is required, and to determine 
tracer uptake before and shortly after intervention, antibody fragments should be 
used.
In contrast to 111In-D2B IgG, the renal clearance of 111In-F(ab’)2 and 
111In-Fab resulted 
in high accumulation in the kidneys, most likely due to tubular reabsorption after 
glomerular filtration of these antibody preparations. Usually, the threshold for 
glomerular filtration is approximately 60 kDa, suggesting that the antibody fragments 
are catabolized into smaller molecules in the kidneys [21]. Renal clearance and 
accumulation of F(ab’)2 and Fab fragments might be a disadvantage, since it might 
interfere with visualization of malignant tissue located in the vicinity of the kidneys 
and the urinary bladder. 
For the characterization of the tumor targeting capacities of 111In-D2B IgG, 111In-
F(ab’)2 and 
111In-Fab fragments, 111In-labeled capromab pendetide was used as a 
reference in this study. Since capromab pendetide targets an intracellular epitope of 
PSMA, internalization or uptake into the cell by another process is required to bind 
to PSMA. It has been postulated that capromab pendetide may only bind dying or 
necrotic cells with cellular membranes that are permeable for IgG [22]. Therefore, 
111In-capromab pendetide has low sensitivity for viable tumor lesions which makes 
it a suboptimal agent for diagnostic imaging of prostate cancer. Still, specific tumor 
targeting of the PSMA+ LNCaP tumors was observed with 111In-labeled capromab 
pendetide, although at a much lower level than 111In-D2B IgG.
Overall, the new mAb D2B IgG has excellent in vivo tumor targeting characteristics. 
In addition, 111In-F(ab’)2 and 
111In-Fab fragments of D2B IgG are feasible for SPECT or 
PET imaging of PSMA-expressing prostate cancer. The preparations based on antibody 
fragments allow imaging at early time points after injection, while the preparation 
based on intact D2B IgG has a higher absolute uptake in the tumor.
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CONCLUSION
111In-labeled D2B IgG can be used for imaging of PSMA-expressing cancer, as shown 
in mice with s.c. PSMA-expressing tumors. The xenografts were clearly visualized in 
SPECT/CT with specific differentiation between PSMA- and PSMA+ tumors. Compared 
to 111In-capromab pendetide, higher tumor-to-blood ratios were obtained. Due to 
renal accumulation of F(ab’)2 and Fab fragments visualization of malignant tissue 
located in the vicinity of the kidneys might be hampered. However, especially in 
settings where multiple images within a short time interval are required, 111In-D2B 
F(ab’)2 and Fab fragments can be used.
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ABSTRACT                       
Background
TF12 is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab fragments 
and one anti-histaminesuccinyl-glycine (HSG) Fab fragment. The TROP-2 antigen is 
found in many epithelial cancers, including prostate cancer (PC), and therefore this 
bispecific antibody could be suitable for pretargeting in this cancer. In this study, 
the characteristics and the potential for pretargeted radioimmunoimaging and 
radioimmunotherapy with TF12 and the radiolabeled di-HSG peptide IMP288 in mice 
with human PC were investigated.
Methods
The optimal TF12 protein dose, IMP288 peptide dose, and dose interval for PC 
targeting were assessed in nude mice with s.c. PC3 xenografts. Immuno-positron 
emission tomography (PET)/CT was performed using TF12/68Ga-IMP288 at optimized 
conditions. The potential of pretargeted radioimmunotherapy (PRIT) using the TF12 
and 177Lu-IMP288 was determined.
Results
TF12 and 111In-IMP288 showed high and fast accumulation in the tumor (20.4 ± 0.6% 
ID/g at 1 h postinjection (p.i.)) at optimized conditions, despite the internalizing 
properties of TF12. The potential for PRIT was shown by retention of 50 % of the 
111In-IMP288 in the tumor at 48 h p.i.. One cycle of treatment with TF12 and 177Lu-
IMP288 showed significant improvement of survival compared to treatment with 
177Lu-IMP288 alone (90 vs. 67 days, p<0.0001) with no renal or hematological toxicity.
Conclusion
TROP-2-expressing PC can be pretargeted efficiently with TF12, with very rapid 
uptake of the radiolabeled hapten-peptide, IMP288, sensitive immuno-PET, and 
effective therapy.
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INTRODUCTION
Prostate cancer (PC) causes significant morbidity and still is the second leading 
cause of cancer-related deaths in men in the Western world. Approximately 17 % 
of American men will be diagnosed with PC during their lifetime, and 20 % of them 
will die of the disease. While curable when diagnosed in an early stage and treatable 
in the hormone-dependent stage, PC treatment options are limited in advanced 
stages. In view of this, it is essential to differentiate between metastatic and non-
metastatic disease to predict disease outcome and to determine treatment options. 
Furthermore, an accurate imaging method for determining the location, extent, and 
biological potential of PC could improve patient outcome by directing therapy more 
accurately both in surgery and radiation therapy. Transrectal ultrasound (TRUS) and 
conventional magnetic resonance imaging (MRI) can be used for the diagnosis of 
the primary tumor, but adequate detection of metastatic spread leaves room for 
further improvement. Positron emission tomography (PET) imaging is a widely 
used imaging modality to detect metastatic disease in several cancers. However, 
18F-fluorodeoxyglucose (FDG) PET is not suited for staging patients with PC, since 
sensitivity is low due to artifacts related to its renal excretion and due to the relatively 
low avidity of differentiated PC for 18F-FDG [1, 2]. Several other radiotracers have 
been developed for imaging metastasized PC, but all of them have disadvantages, 
such as low sensitivity or practical considerations, such as the need for an on-
site cyclotron for the 11C tracers. Antibody imaging in humans has been reported 
with several radiolabeled monoclonal antibodies, such as 7E11-C53 (ProstaScint®, 
capromab pendetide) and J591 [2]. Due to the long circulatory half-lives of imaging 
agents based on intact antibody molecules, lesions can only be depicted several days 
after injection. 
hRS7 is a humanized IgG1 monoclonal antibody directed against TROP-2, 
also known as epithelial glycoprotein-1 (EGP-1), GA733-1, gp50/T16, and tumor-
associated calcium signal transducer 2 (TACSTD2). TROP-2 is a 46 kDa transmembrane 
glycoprotein expressed in carcinomas of the lung, bladder, breast, cervix, ovary, 
stomach, and prostate [3]. Most normal human tissues do not express TROP-2, but 
it is found at low levels in several normal glandular cells, including glands in the 
bronchus, breast, prostate and skin, and ducts and acini of the pancreas [4]. Given 
its expression in PC, we studied the potential targeting ability of hRS7 IgG in a nude 
mouse-human PC model [5], showing excellent in vivo targeting of PC3 xenografts 
with 89Zr- and 111In-hRS7 IgG within 3 days. The slow clearance from the circulation 
results in low tumor-to-background ratios at earlier time points after i.v. injection. 
For earlier imaging, we explored a pretargeting approach using the bispecific 
monoclonal antibody (bsAb) TF12, a trivalent bsAb that consists of two anti-TROP-2 
Fab fragments and one anti-histaminesuccinyl-glycine (HSG) Fab fragment [6]. 
In pretargeting, unlabeled TF12 is injected i.v., and when it has cleared from the
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blood, an HSG-substituted radiolabeled hapten-peptide is injected. This hapten-
peptide will be trapped in the tumor by the anti-HSG arm of the bsAb or is rapidly 
cleared from the body. 
In this study, the characteristics and the potential for pretargeted 
radioimmunoimaging and radioimmunotherapy with TF12 and the radiolabeled di-
HSG peptide, IMP288, in mice with human PC xenografts were investigated.
MATERIALS AND METHODS
The anti-TROP-2 x anti-HSG bsAb TF12 was produced using the dock-and-lock 
technology (DNL®) as described previously [7]. The production and characterization 
of the anti-TROP-2 mAb hRS7 have been described previously [3]. The DOTA-
conjugated hapten-peptide IMP288 [DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2] 
was prepared as described by McBride et al. [8].
Cell culture
The human PC cell line PC3 is an androgen-independent cell line, originally derived 
from a PC bone metastasis. Cells were obtained from American Type Culture 
Collection (CRL 1435, Manassas, VA, USA) and were grown in RPMI 1640 medium 
(GIBCO®, Life Technologies Corporation, Carlsbad, CA, USA), supplemented with 
10 % fetal calf serum (FCS, Life Technologies, Grand Island, NY, USA). Before s.c. 
inoculation of mice to induce PC3 xenografts, tumor cells were washed with 0.9 % 
NaCl, disaggregated with trypsin, and resuspended in 67 % complete RPMI 1640 
medium and 33 % Matrigel (BD Biosciences, San Jose, CA, USA) to the appropriate 
concentration (3×106 cells/200 μl).
Mouse model
All experiments were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Center Nijmegen and were conducted in accordance 
with the principles set forth by the Revised Dutch Act on Animal Experimentation. 
Male BALB/c nude mice (Janvier SAS, Le Genest Saint Isle, France), 8–9 weeks 
old, were adapted to laboratory conditions for at least 1 week before experimental 
use. Mice were housed under non-sterile standard conditions in filtertopped cages 
(five mice per cage), with free access to animal chow (Sniff Voer®) and water. The 
mice were inoculated s.c. in the flank with 200 μl of PC3 cell suspension (3×106 
cells). The s.c. PC3 tumors grew to approximately 0.1 g in 10 days after tumor cell 
inoculation, as determined by caliper measurements in three dimensions using the 
formula V=4/3π (length/2 × width/2 × height/2), assuming that the density of tumor 
tissue is 1 g/cm3. The radiolabeled preparations (0.2 ml) were injected intravenously.
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Radiolabeling of IMP288 and hRS7
The DOTA-conjugated IMP288 was radiolabeled with 111In (Covidien, Petten, The 
Netherlands), 177Lu (IDB Holland BV, Baarle-Nassau, The Netherlands), or with 
68Ga from a TiO2-based 68Ge/68Ga generator (Cyclotron Co, Ltd., Obninsk, Russian 
Federation). Radiolabeling was performed essentially as described previously 
by Schoffelen et al. [9]. For 68Ga labeling, 84 MBq of 68GaCl3 was added to 1 μg of 
IMP288 in 1 M HEPES buffer (50 μl, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, Sigma-Aldrich, St. Louis, MO, USA). After incubation at 95 °C for 20 min, 50 
mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich, St. Louis, MO, USA) was 
added to a final concentration of 1 μM. The 68Ga-IMP288 preparation was purified 
on an Oasis® HLB cartridge (Waters, Milford, MA, USA) and eluted with 1 ml of 25 % 
ethanol essentially as described previously [10]. Before i.v. injection, the preparation 
was diluted at least 2.5 times with 0.5 % bovine serum albumin (BSA, Sigma-Aldrich, 
St. Louis, MO, USA) in phosphate-buffered saline (PBS). 
DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were 
performed essentially as described previously [3, 5]. The radiochemical purity 
(RCP) of the labeled IMP288 preparations was determined using instant thin-layer 
chromatography (ITLC) and reversed phase high-performance liquid chromatography 
(RP-HPLC), as described previously [9]. ITLC was performed to determine the fraction 
of unbound 111In, 177Lu, or 68Ga (mobile phase 1:1 0.1 M ammonium acetate (Merck, 
Darmstadt, Germany) and 0.1 M EDTA) and the fraction of colloid (mobile phase 1:1 
methanol (Merck, Darmstadt, Germany) and 0.25 M ammonium acetate, pH 5.5). 
For RP-HPLC, the C18 column (Zorbax Rx-C18, 5 μm, 4.6×250 mm, Agilent 
Technologies, Amstelveen, The Netherlands) was eluted with a mixture of 97 % of a 
0.1 % trifluoroacetic acid in H2O solution (TFA, Labscan, Analytical Sciences, Brussels, 
Belgium) with 3 % of a 0.1 % TFA in acetonitrile solution (Lab-scan, Analytical Sciences, 
Brussels, Belgium) with a linear gradient to 100 % of the latter solution over 10 min at 
a flow rate of 1 ml/min. RCP of all labeled IMP288 preparations always exceeded 97 
%; the RCP of 177Lu-hRS7 exceeded 98 %.
Radiolabeling of TF12
The bsAb TF12 was radioiodinated with 125I according to the iodogen method [11]. 
Twenty micrograms of TF12 and 3.7 MBq Na125I (GE Healthcare Europe, Den Bosch, The 
Netherlands) in 50 mmol/L phosphate buffer, pH 7.4, were incubated in an Eppendorf 
vial coated with 50 μg of iodogen (1,3,4,6-tetrachloro-3,6-diphenylglycoluril; Pierce 
Biotechnology, Inc., Rockford, IL, USA) for 10 min at room temperature. 125I-TF12 was 
purified on a PD-10 column (GE Healthcare, London, UK) eluted with PBS, 0.5 % BSA.
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Immunoreactivity
The anti-TROP-2 reactivity of radiolabeled TF12 and hRS7 was determined using freshly 
trypsinized PC3 cells, as described by Lindmo et al. [12] with minor modifications. 
The bispecific immunoreactivity of TF12 was demonstrated by incubating PC3 cells 
with TF12 (10 μg/ml) and subsequent incubation with 111In-IMP288 (200 Bq/ml). 
After 1 h at 37 °C, the total activity and the activity in the cell pellet were determined 
in a gamma counter. More than 70 % of the added hapten-peptide specifically bound 
to the PC3 cells.
Biodistribution studies
The effect of the TF12 dose on tumor uptake of a fixed amount (0.25 nmol=400 ng) of 
111In-labeled IMP288 in mice with s.c. PC3 tumors was determined by administering 
1.25, 2.5, 5.0, and 12.5 nmol (231, 462, 924, and 2,310 μg) of TF12 i.v., and then 16 
h later 0.4 MBq of 111In-IMP288 was injected. Two hours later, mice were dissected 
and tissue uptake was determined (five mice/group). Subsequently, the optimal 
amount of IMP288 that can be given after administering a fixed dose of TF12 (2.5 
nmol=462 μg) was determined. Four doses of IMP288 were examined: 25, 50, 100, 
and 200 nmol, each given 16 h after TF12. Two hours after injection of 0.4 MBq of 
111In-IMP288, mice were euthanized and necropsied (five mice/group). The optimal 
interval between TF12 and 111In-IMP288 injection was assessed at the preselected 
optimal TF12 (2.5 nmol) and IMP288 doses (0.1 nmol). The following intervals were 
tested: 12, 14, 16, 18, 20, 24, and 36 h. Lastly, under optimized conditions (2.5 nmol 
TF12, 0.1 nmol IMP288, 16h interval), the retention of 111In-IMP288 in the tumor was 
monitored over the course of 3 days.
Pretargeted immuno-PET
Groups of five mice with s.c. PC3 tumors were injected i.v. with 2.5 nmol of TF12 
and 16 h later with 5 ± 2 MBq (0.1 nmol) of 68Ga-IMP288. One hour after injection 
of 68Ga-IMP288, mice were euthanized by O2/CO2 asphyxiation and PET/CT images 
were acquired with an Inveon® animal PET/CT scanner (Siemens Preclinical 
Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN, USA), having an 
intrinsic spatial resolution of 1.5 mm. The animals were placed in prone position. 
PET emission scans were acquired for 20 min, preceded by CT scans for anatomic 
reference (spatial resolution 113 μm, 80 kV, 500 μA, exposure time 300 ms). Scans 
were reconstructed using Inveon Acquisition Workplace software (version 1.2, 
Siemens Preclinical Solutions, Knoxville, TN, USA), with an ordered set expectation 
maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with the following 
parameters: matrix 256×256×159, pixel size 0.43×0.43×0.8 mm3, and a beta value of 
0.1. After imaging, tumors and organs were dissected, weighed, and counted in a 
gamma counter to determine the biodistribution of the radiolabel. The percentage 
injected dose per gram (% ID/g) tissue was calculated against an injection standard.
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Pretargeted radioimmunotherapy
The potential of pretargeted radioimmunotherapy (PRIT) with TF12 and 177Lu-IMP288 
was assessed in a therapy experiment in mice with PC3 xenografts (ten mice/group). 
Mice were treated with TF12/177Lu-IMP288 or 177Lu-hRS7 IgG 9 days after PC3 cell 
inoculation, when tumors weighed approximately 0.1 g. 
In the mice that were treated with PRIT, tumors were pretargeted with 2.5 nmol 
TF12 16 h before administration of the 177Lu-IMP288. The next day, mice received the 
maximum 177Lu activity dose that could be labeled to 0.1 nmol IMP288 (13.7 MBq). 
Another group was treated with the maximum tolerable dose of 177Lu-hRS7 (11.1 
MBq, 13.8 μg). One control group of PC3 tumor-bearing mice was injected i.v. with 
vehicle (200 μl PBS, 0.5 % BSA) twice instead of TF12 and IMP288. The other control 
group received vehicle instead of TF12 and was injected 16 h later with 13.7 MBq of 
177Lu-IMP288. 
Tumor size was measured in three dimensions with a caliper and body weight 
was determined twice weekly starting 7 days after tumor cell inoculation. Blood 
samples of 0.1 ml of all mice were collected via submandibular bleeding before 
therapy and 14, 21, 35, 42, 56, 70, and 88 days after administration of the agents 
to determine hemoglobin levels and leukocyte and platelet counts. Blood creatinine 
and blood urea nitrogen (BUN) levels were determined before and 4 and 7 weeks 
after start of the therapy. When the humane endpoint was reached (tumor size >2 
cm3 or animal discomfort level >3), mice were euthanized by O2/CO2 asphyxiation 
and dissected. At dissection, the tumor and kidneys were excised and weighed. The 
experiment was terminated 120 days after injection of the radiolabeled compounds 
and the remaining mice were euthanized and dissected.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows. 
Survival curves were compared using the log-rank test. The level of significance was 
set at a p value of less than 0.05.
RESULTS
Biodistribution studies
The optimal TF12 protein dose to pretarget the PC3 tumors was determined 
in a protein dose escalation study. Tumor uptake of 111In-IMP288 (0.25 nmol) 2 h 
after injection increased with increasing bsAb TF12 protein doses, as summarized 
in figure 1a. Highest uptake (7.4 ± 0.8% ID/g) was obtained when the tumor was 
pretargeted by injection of 12.5 nmol of TF12. The optimal amount of TF12 was 
determined to be 2.5 nmol, since there was only minor improvement of tumor 
uptake (1.5-fold increase) at the highest bsAb dose (5-fold increase). Following
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injection of increasing amounts of IMP288 at a fixed TF12 dose of 2.5 nmol, tumor 
uptake clearly decreased (figure 1b). Optimal uptake in the tumor (20–25% ID/g) was 
obtained at hapten-peptide doses ≤0.1 nmol IMP288. Based on these results, 0.1 
nmol of IMP288 was used in further experiments, since this amount of IMP288 could 
be labeled with activity doses required for pretargeted immuno-PET imaging (68Ga) 
and for pretargeted radionuclide therapy (177Lu). 
Recently, in vitro experiments have shown that TF12 is slowly internalized by 
the tumor cell after binding to TROP-2 [6]. To estimate the kinetics of internalization 
of TF12 in vivo, the biodistribution of bsAb TF12 labeled with 111In and 125I was 
studied in mice with s.c. PC3 tumors 16 h postinjection (p.i.). A clear and significant 
difference between uptake of 111In-TF12 (4.9 ± 0.6% ID/g) and 125I-TF12 (0.7 ± 0.2% 
ID/g, p<0.0001) in the tumor was observed 16 h after injection of the radiolabeled 
TF12, which could be explained by the internalizing characteristics of TF12. The 
biodistribution of the 111In-labeled TF12 indicated that the bsAb accumulated 
preferentially in the tumor (4.9 ±  0.6% ID/g, 16 h p.i.), while the blood level at 
that time did not exceed 0.4 ± 0.1% ID/g. The optimal interval between injection of 
TF12 and 111In-IMP288 was assessed by examining seven intervals: 12, 14, 16, 18, 
20, 24, and 36 h (three to five mice/group, figure 2). Extension of the time interval 
between injection of TF12 and injection of 111In-IMP288 from 16 to 36 h significantly 
decreased tumor uptake of the radiolabeled hapten, from 9.6 ± 1.3% ID/g to 1.0 ± 
0.5% ID/g (p<0.0001). Shortening the interval from 16 to 14 or 12 h did not improve
Figure 1: a) Biodistribution of a fixed dose of 111In-IMP288 (0.25 nmol, 0.4 MBq) injected 
i.v. 16 h after injection of escalating TF12 doses (1.25–12.5 nmol) in BALB/c nude mice 
with s.c. PC3 xenografts. The uptake was determined at 2 h after injection (n=5). b) 
Biodistribution of escalating 111In-IMP288 doses (0.025–0.2 nmol, 0.4 MBq) injected i.v. 16 
h after a fixed dose of TF12 (2.5 nmol) in BALB/c nude mice with s.c. PC3 xenografts. The 
uptake was measured at 2 h after injection (n=5).
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tumor uptake significantly (p=0.81 and p=0.14, respectively), while tumor-to-blood 
ratios were lower at the shorter intervals. Based on these observations an interval 
of 16 h between injection of TF12 and radiolabeled IMP288 was used. Retention 
of radiolabeled IMP288 in the tumor over time is particularly important in PRIT. 
Retention was determined at the optimal TF12 and 111In-IMP288 dose (16-h interval) 
during 3 days p.i. (five mice/group). Figure 3 shows that >50 % of the 111In label was 
still present in the tumor at 48 h after injection (5.8 ± 0.7% ID/g, t1/2=50 h). 
Figure 2: Biodistribution of 111In-IMP288 (0.1 nmol, 0.4 MBq) in BALB/c nude mice with 
s.c. PC3 xenografts measured at 2 h after injection (n=3–5). Prior to injection of 111In-
IMP288, mice were injected i.v. with 2.5 nmol of TF12 at increasing time intervals (12, 
14, 16, 18, 20, 24, and 36 h).
Figure 3: Tumor uptake at increasing time points (1, 2, 4, 24, 48, 70 h) after injection of 
TF12/111In-IMP288 (2.5 nmol/0.1 nmol, 0.4 MBq, 16-h interval, n=5).
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At the optimized conditions determined in the experiments described above, 111In-
IMP288 showed a rapid and high uptake in the tumor (20.4 ± 0.6% ID/g, 2 h p.i.), 
while concentrations in blood (0.9 ± 0.2% ID/g) and normal tissues were low (figure 
4). 111In-IMP288 cleared very rapidly from the blood via the kidneys. The healthy 
organs with the highest uptake (2.2 ± 0.1% ID/g) were the kidneys.
Pretargeted immuno-PET
With the same dosing schedule, similar results were obtained with TF12 and 
68Ga-IMP288, with slightly lower tumor uptake (12.2 ± 2.3% ID/g). To determine 
the potential of pretargeted immuno-PET to detect TROP-2-expressing tumors, 
microPET imaging of 68Ga-IMP288 was performed in nude mice with s.c. PC3 tumors 
of approximately 0.1 g. Images acquired as early as 1 h p.i. clearly showed the PC3 
tumors (figure 5). No accumulation of radioactivity in the other normal organs was 
observed, except for the kidneys and the bladder.
Pretargeted radioimmunotherapy
The potential of PRIT using the bsAb TF12 and 177Lu-labeled IMP288 was determined 
in a therapy experiment and compared to RIT with 177Lu-hRS7 (11.1 MBq, 13.8 
μg). PRIT with 2.5 nmol TF12 and 13.7 MBq 177Lu-IMP288 significantly improved 
the median survival of mice with s.c. PC3 tumors from 67 to 90 days (p<0.0001, 
figure 6). The control groups received either 177Lu-IMP288 without TF12 or 
vehicle. Median survival of the mice in both control groups was similar, indicating 
that there is no effect of administration of a high activity dose of 177Lu-IMP288
Figure 4: Biodistribution of 111In-IMP288 (0.1 nmol, 0.4 MBq) injected i.v. 16 h after 
i.v. injection of TF12 (2.5 nmol) in BALB/c nude mice with s.c. PC3 xenografts at 2 h 
after injection (n=5).
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Figure 5: Anterior 3D volume-rendering projection of a microPET/CT scan of a 
BALB/c nude mouse with s.c. PC3 tumor on the shoulder injected with TF12 and 
68Ga-IMP288 (0.1 nmol, 5 MBq), acquired 1 h after injection.
Figure 6: Survival of BALB/c nude mice with s.c. PC3 xenograft treated with 
TF12/177Lu-IMP288 (2.5 nmol/11.1 MBq, 0.1 nmol), 177Lu-hRS7 (13.7 MBq, 30 μg), 
177Lu-IMP288 without pretargeting (11.1 MBq, 0.1 nmol), or vehicle (n=10).
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alone. At the end of the experiment (120 days), all mice treated with 177Lu-hRS7 IgG 
were still alive. However, this increase in survival (median survival >120 days) was 
accompanied by a significant decrease in platelets (from 1,110 ± 230×109/L at t=−3 
days to 430 ± 250×109/L at t=14 days, p=0.0005) and leukocytes (from 3.2 ± 0.8×109/L 
at t=−3 days to 0.6 ± 0.3×109/L at t=14 days, p<0.0001), which was not observed in 
the mice treated with PRIT. Thus, treatment with 177Lu-hRS7 IgG appeared to be more 
effective, but also clearly more toxic. 
In PRIT, the kidney could also be the organ at risk. Therefore, creatinine and urea 
levels were examined in the experimental groups and the kidneys were examined 
histologically after completion of the experiment (120 days). Creatinine and urea 
levels, and histological analysis of the kidneys compared to age-matched control 
mice, did not show any indication of renal toxicity.
DISCUSSION
The present study shows the potential of pretargeted immuno-PET and PRIT of PC with 
the bsAb TF12 and the radiolabeled hapten-peptide IMP288. The dose optimization 
studies in mice with s.c. PC3 tumors revealed that the highest uptake of the 
radiolabeled hapten-peptide in the tumor was obtained at bsAb doses of ≥2.5 nmol 
and at lower IMP288 doses (≤0.1 nmol). The optimal time interval between injection 
of TF12 and 111In-IMP288 was 16 h. Most importantly, these experiments showed 
that internalization does not disqualify bsAbs for pretargeting as long as the dosage 
interval is carefully tuned, as shown previously by Sharkey et al. [6]. Retention of the 
radiolabel in the tumor was high: more than 50 % of the radiolabel that was present in 
the tumor at 1 h p.i. was still present after 48 h. In the TF2/IMP288 pretargeting system 
using the non internalizing anti-CEA x anti-HSG bsAb in mice with LS174T tumors only 
32 % of the radiolabeled IMP288 was retained in the tumor [9], suggesting that the 
internalizing characteristics of TF12 could cause better retention of the radiolabel 
in the tumor due to internalization of the TF12-IMP288 complex by the tumor cells. 
Retention in the tumor and rapid clearance from the blood enabled clear 
visualization of the tumor with PET as early as 1 h after injection. Some 68Ga activity 
in the kidneys and bladder was observed, due to the renal clearance of IMP288. 
Renal clearance might be a disadvantage when imaging PC, since physiological 
uptake in the urinary tract might conceal pathological uptake in the lower abdomen. 
However, renal clearance of radiolabeled IMP288 is very efficient, which may enable 
the distinction between physiological and pathological uptake. 
The PRIT experiment showed that TF12/177Lu-IMP288 significantly improved 
the median survival of mice with s.c. PC3 tumors without significant hematological 
or renal toxicity. The improved median survival in the group of mice treated with 
177Lu-hRS7 IgG was achieved at the expense of severe hematological toxicity. 
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In the therapy experiments, the maximum activity dose of 177Lu-IMP288 was used, 
which necessarily was below the maximum tolerated dose (MTD), due to the limited 
specific activity of the 177Lu-chloride used for labeling of the peptide. Currently, carrier-
free 177Lu-chloride has become available with improved specific activity. In future 
studies, we will determine the safety and efficacy of PRIT with higher activity doses 
of 177Lu-IMP288 and of multiple cycles of TF12/177Lu/90Y-IMP288, as accomplished by 
Schoffelen et al. with anti-CEA x anti-HSG bsAb TF2 [13].
CONCLUSION
The dosing of the pretargeting agents TF12 and IMP288 was optimized in mice with 
s.c. PC3 tumors. At optimized conditions, TROP-2-expressing PC3 tumors could be 
targeted efficiently and very rapidly with the radiolabeled hapten-peptide IMP288. 
This pretargeting system allows rapid and sensitive PET imaging of PC using 68Ga-
labeled hapten-peptide. TF12 together with 177Lu-labeled IMP288 could also be 
promising candidates for PRIT of TROP-2-expressing prostate tumors. Further PRIT 
studies at MTD with higher activity doses and/or multiple dosing are necessary to 
determine its application in the future.
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ABSTRACT
Background
A facile and rapid method to label peptides with 18F based on chelation of [18F]AlF has 
been developed recently. Since this method requires heating to 100 °C, it cannot be 
used to label heat-sensitive proteins. Here, we used a two-step procedure to prepare 
18F-labeled heat-labile proteins using the [18F]AlF method based on hot maleimide 
conjugation. 
Methods
1,4,7-Triazacyclononae-1,4-diacetate (NODA) containing a methyl phenylacetic 
acid group (MPA) functionalized with N-(2-aminoethyl)maleimide (EM) was used 
as a ligand which was labeled with [18F]AlF and then conjugated to the humanized 
anti-CEA antibody derivatives hMN-14 Fab’, hMN-14-(scFv)2 (diabody) and a Dock-
and-Lock engineered dimeric fragment hMN-14 Fab-AD2 at room temperature. The 
in vivo tumor targeting characteristics of the 18F-labeled antibody derivatives were 
determined by PET imaging of mice with s.c. xenografts.
Results
NODA-MPAEM was radiolabeled with [18F]AlF at a specific activity of 29-39 MBq/
nmol and a labeling efficiency of 94 ± 2 %. The labeling efficiencies of the maleimide 
conjugation ranged from 70% to 77%, resulting in [18F]AlF-labeled hMN14-Fab’, 
hMN14-Fab-AD2, or hMN14-diabody with a specific activity of 15-17 MBq/nmol. 
The radiolabeled conjugates were purified by gel filtration. For biodistribution and 
microPET imaging, antibody fragments were injected intravenously into BALB/c nude 
mice with s.c. CEA-expressing LS174T xenografts (right flank) and CEA-negative SK-
RC-52 xenografts (left flank). All [18F]AlF-labeled conjugates showed specific uptake 
in the LS174T xenografts with a maximal tumor uptake of 4.73 % ID/g at 4 h after 
injection. Uptake in CEA-negative SK-RC-52 xenografts was significantly lower. Tumors 
were clearly visualized on microPET images.
Conclusion
Using a [18F]AlF-labeled maleimide functionalized chelator, antibody fragments 
could be radiofluorinated within 4 h at high specific activity. Here, we translated 
this method to preclinical PET imaging studies and showed feasibility of [18F]AlF-
fluorinated hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and [18F]AlF-hMN-14-diabody 
for microPET imaging of CEA-expressing colonic cancer. 
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INTRODUCTION
Positron emission tomography (PET) has evolved as a prominent molecular imaging 
modality in oncology, since it allows high sensitivity, quantitative imaging of cellular 
features and processes [1]. 18F is an ideal radionuclide for PET imaging, because of its 
low positron energy, the lack of other emissions, and its half-life of 109.8 minutes. 
The most commonly used tracer for PET imaging of tumors is 2-[18F]fluoro-2-
deoxyglucose ([18F]FDG), which exploits the increased glucose metabolism of tumor 
cells. 
Previously, 18F-radiolabeling of peptides was a time-consuming and inefficient 
multistep process. By exploiting the strong bond between [18F]-fluoride and Al3+, 
18F-radiolabeling can be performed efficiently in one step by chelating [18F]AlF [2]. 
This method could only be applied to peptides and heat-stable proteins, because 
100 °C is the optimal labeling temperature. By separating the chelation of [18F]AlF 
(at 100 °C) from the conjugation to the targeting molecule (at room temperature), 
the labeling approach can now also be applied to label heat-sensitive proteins with 
18F [3]. In this approach, the [18F]AlF-chelating moiety 1,4,7-triazacyclononae-1,4-
diacetate (NODA) with a methyl phenylacetic acid group (MPA) functionalized with 
N-(2-aminoethyl)maleimide (EM) is used. NODA-MPAEM can be labeled efficiently 
with 18F (at 100-110 °C) and subsequently be conjugated with the heat-sensitive 
protein at room temperature via a maleimide-thiol reaction. 
Although intact antibodies are not suitable for imaging of cancer with 18F 
because their accumulation in tumors generally takes several days, smaller antibody 
fragments such as Fab’, F(ab’)2, and scFv, allow imaging of tumor lesions within 
several hours after injection, which is compatible with the half-life of 18F. Since Fab’ 
fragments bind monovalently to target regions, which might have a negative impact 
on the tumor uptake and retention, we included the divalent (scFv)2 diabody format 
of hMN-14 in our studies, which may provide more avid binding to the target. 
In this study, we applied the 2-step method to prepare [18F]-AlF-fluorinated 
NODA-MPAEM-hMN-14-Fab’, NODA-MPAEM-hMN-14-Fab-AD2, and NODA-MPAEM-
hMN-14-diabody and evaluated the in vitro characteristics and the in vivo tumor 
targeting capacities of these tracers in nude mice with CEA-expressing LS174T human 
colon carcinoma xenografts.
 
MATERIALS AND METHODS
Antibody derivatives
The monoclonal antibody hMN-14 (labetuzumab) and hMN-14-Fab’, hMN-14-Fab-
AD2, and hMN-14-diabody (figure 1) were obtained from Immunomedics, Inc. 
(Morris Plains, NJ, USA).
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Synthesis of NODA-MPAEM
NODA-MPAEM (methyl phenyl acetamido ethyl maleimide, figure 2) was synthesized 
as described by McBride et al. [2]. Briefly, (tBu)2NODA-MPAA NHS ester (128.3 mg, 
0.213 mmol) in CH2Cl2 (5 ml) was added to a solution of N-(2-aminoethyl) maleimide 
trifluoroacetate salt (52.6 mg, 0.207 mmol) in 250 µl dimethylformamide (DMF) 
and 20 µl N,N-diisopropylethylamine (DIEA). After three hours of incubation, the 
conjugation was evaporated and treated with 2 ml trifluoroacetic acid (TFA). In the 
following, the product was diluted with water and purified by preparative RP-HPLC 
using Waters PrepLC 4000 system with Sunfire Prep C18 optimal bed density (OBD) 
reverse-phase column (150 × 30 mm, 5 μm), using a linear gradient of 100% A (0.1% 
TFA) to 15% B (90% acetonitrile, 10% water, 0.1% TFA) over 80 min at a flow rate of 
45 mL/min (absorbance 220 nm).
Figure 1: Schematic representation of hMN-14 Fab’, hMN-14 Fab-AD2 and hMN-14-
diabody. To represent incomplete 18F-labeling due to limited amount of 18F that was used, 
18F was added to only half of the Al moieties in this schematic drawing.
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Figure 2: Labeling of NODA-MPAEM with 18F. The nitrogen atom coordination with Al is 
not illustrated in this figure. 
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18F radiolabeling of NODA-MPAEM
18F dissolved in water (BV Cyclotron VU, Amsterdam, The  Netherlands) was passed 
through a SepPak CM cartridge (Waters, Etten-Leur, The Netherlands) and Sep-Pak 
QMA cartridge (Waters, Etten-Leur, The Netherlands), that were both preconditioned 
with 10 ml metal-free water. After removing the CM cartridge, 18F was eluted from 
the QMA cartridge with 0.9% NaCl. Subsequently, 75 µL eluate (1.94 - 2.05 GBq) was 
mixed with AlCl3 (40 nmol in 30 µL 2 mM NaAc (pH 4.2)) and dissolved in 1.0 M NaAc 
(pH 4.2). After 10 min incubation at room temperature, acetonitrile (300 µL) and 
NODA-MPAEM ligand (40 nmol), dissolved in 2 mM NaAc (pH 4.2) were added and 
incubated for 20 min at 106 °C. After incubation, the labeling mixture was evaporated 
to dryness and 100 µL PBS was added. Labeling efficiency was determined by RP-
HPLC (Agilent 1200 Series, Amstelveen, Netherlands) on a C18 Onyx monolithic 
column (4.6 x 100 mm, Phenomenex, Torrance, USA) in a gradient from H2O/0.1 % 
TFA to acetronitrile/0.1 % TFA. 
Conjugation of [18F]AlF-NODA-MPAEM to anti-CEA antibody 
fragments
 [18F]AlF-NODA-MPAEM (22-23 nmol, 538-625 MBq) was conjugated to humanized 
anti-CEA antibody fragments, hMN-14 Fab’ (20 nmol), hMN-14-Fab-AD2 (20 nmol), 
and hMN-14-diabody (20 nmol) in 100 µl PBS, 2 mM EDTA. After incubating for 20 
min at room temperature, labeling efficiency was determined by instant thin-layer 
chromatography, with 0.1 mol/L citrate buffer (pH 6.0), as the mobile phase. The 
reaction mixture was purified on a PD-10 column (GE Healthcare, Little Chalfont, United 
Kingdom) eluted with PBS, 0.5% bovine serum albumin (BSA). In all experiments, 
the labeling efficiency of the 18F-labeled antibody preparations was determined by 
instant thin layer chromatography and exceeded 95%. Radiochemical purity of the 
[18F]AlF fluorinated antibody fragments was determined by FPLC analysis using an 
ÄKTApurifier UPC-10 FPLC system (GE Healthcare Life Sciences, Little Chalfont, UK) 
with BioSEP SEC s3000 column (300 x 7.8 mm, Phenomonex, Torrance, California, 
USA) using PBS as eluent at a flow rate of 1 ml/min. For all [18F]AlF fluorinated 
antibody fragments, single peaks have been observed on FPLC analysis.
Cell culture
The human colorectal carcinoma cell line LS174T (CEA-positive) and the renal cell 
carcinoma cell line, SK-RC-52 (CEA-negative), were used. Both cell lines were cultured 
in RPMI 1640 medium, supplemented with 10% fetal calf serum (Life technologies, 
Bleiswijk, The Netherlands) and 2mM glutamine.
Immunoreactivity and IC
50
The immunoreactive fractions of the 18F-labeled antibody preparations were 
determined using freshly trypsinized LS174T cells, as described by Lindmo et al. [4] 
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with minor modifications: after 1 hour of incubation at 37 °C, the activity in the vials 
and after washing with 500 µL of binding buffer in the cell pellet, was determined 
in the γ-counter (Wizard2 Automatic Gamma Counter, PerkinElmer, Waltham, MA). 
The IC50 of hMN-14 IgG, hMN-14-Fab’, hMN-14-Fab-AD2, and hMN-14-diabody 
was determined in a competitive binding assay on LS174T cells that were grown to 
confluency in six-well plates. Cells were incubated on ice for 2.5 h in 1 mL of binding 
buffer with 1 kBq of the 111In-labeled hMN-14 IgG. A concentration range from 0.1 
– 300 nM of hMN-14 IgG, hMN-14-Fab’, hMN-14-Fab-AD2, or hMN-14-diabody was 
added immediately before addition of 111In-labeled hMN-14 IgG. After incubation, 
cells were washed with binding buffer and cell-associated activity was measured in 
a γ-counter. IC50 values were calculated using GraphPad Prism software, version 5.03 
(GraphPad, La Jolla, USA).
Mouse model
Female BALB/c nude mice (Janvier, Le Genest Saint Isle, France), 8-9 weeks old, were 
housed in IVC cages (5 mice per cage) under nonsterile standard conditions with free 
access to standard animal chow and water. After one week of adaption to laboratory 
conditions, mice were inoculated subcutaneously with 1 x 106 CEA-expressing 
LS174T cells (right flank) and with 3 x 106 CEA-negative SK-RC-52 cells (left flank), 
both suspended in 200 µL of complete RPMI 1640 medium. SK-RC-52 cells were 
inoculated 10 days prior to LS174T cells. Both tumors grew to approximately 0.1 g 
in 21 and 11 days after tumor cell inoculation, respectively. All experiments were 
approved by the institutional Animal Welfare Committee of the Radboud University, 
and were conducted in accordance to the principles set forth by the Revised Dutch 
Act on Animal Experimentation.
Biodistribution studies
To evaluate the in vivo tumor targeting characteristics and perform microPET imaging 
of the [18F]AlF-labeled antibody preparations, 1 nmol of [18F]AlF-hMN-14-Fab’ (14 
MBq/mouse, n = 5), [18F]AlF-hMN-14-Fab-AD2 (17 MBq/mouse, n = 5), and [18F]AlF-
hMN-14-diabody (15 MBq/mouse, n = 4) were injected i.v. into mice bearing LS174T 
tumors and SK-RC-52 xenografts. One additional group of 4 mice received [18F]FDG 
(15.0 MBq/mouse) intravenously. 
In addition, for all antibody fragment preparations, separate groups of 3-5 mice 
received an excess of unlabeled hMN-14 IgG (3.2 nmol/mouse) three days before 
injection of the [18F]AlF-labeled antibody preparation. Mice were euthanized by CO2/
O2 asphyxiation and the biodistribution of the antibody preparations was determined 
4 h after injection. Blood samples were obtained by cardiac puncture and tissues were 
dissected, weighed, and the radioactivity measured in a γ-counter. For calculation of 
the uptake of radioactivity in each tissue as a fraction of the injected dose, an aliquot 
of the injection dose was counted simultaneously. 
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MicroPET imaging
The above described groups of female BALB/c nude mice were imaged on an Inveon 
microPET/CT scanner (Siemens Preclinical Solutions, Knoxville, TN) at 4 h after 
injection. MicroPET images were acquired under general anesthesia (isoflurane/
O2) for 20 min. After the scanning procedure, mice were euthanized by CO2/O2 
asphyxiation and the biodistribution of the radiolabel was determined. Activity 
concentrations in the tissues (percentage of the injected dose per gram; % ID/g) 
were determined as described above. The microPET scans were reconstructed with 
Inveon Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions), 
using a 3-dimensional fast maximum a posteriori algorithm with the following 
parameters: matrix, 256 x 256 x 161; pixel size, 0.4 x 0.4 x 0.8 mm; and β-value of 1.5 
mm resolution with uniform variance. 
Statistical analysis
Statistical analyses were performed with Graphpad Prism, version 5.03 (GraphPad, 
La Jolla, CA). Results are presented as mean ± standard deviation (SD). Differences 
in tumor uptake of the antibody preparations were tested for significance using 
the statistical tests as indicated in the results section. A p-value below 0.05 was 
considered significant.
RESULTS
Radiolabeling
The NODA-MPAEM ligand could be labeled rapidly (<60 min) and efficiently at 
a specific activity of 29-39 MBq/nmol with a labeling efficiency of 94 ± 2 %. The 
efficiencies of the maleimide conjugation were 70% ([18F]AlF-hMN-14-Fab’), 77% 
([18F]AlF-hMN-14-Fab-AD2), and 77% ([18F]AlF-hMN-14-diabodies), respectively, 
resulting in [18F]AlF-labeled hMN-14 antibody fragment derivatives with a specific 
activity of 15-17 MBq/nmol (table 1). Radiochemical purity exceeded 95%.
Immunoreactivity and IC
50
The immunoreactive fractions of [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, 
and [18F]AlF-hMN-14-diabodies as determined in vitro exceeded 60%. The IC50 of 
hMN-14 IgG, which was included as a reference, was 8.3 ± 1.5 nM. The IC50 values of 
hMN-14-Fab’ (11.2 ± 1.3 nM), and hMN-14-diabody (7.9 ± 1.2 nM) were comparable 
to that of hMN-14 IgG, while the IC50 of hMN14-Fab-AD2 (IC50 26.9 ± 1.3 nM) was 
slightly higher (table 1).
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MicroPET imaging
3D-rendered microPET images of all [18F]AlF-labeled antibody formats in mice 
with tumors are displayed in figure 3. At 4 h after injection specific uptake of 
the antibody formats was observed in the CEA+ LS174T tumors (right flank). 
Tumors were imaged clearly with all three [18F]AlF-fluorinated antibody formats. 
However, based on visual non-quantitative analysis, clearest visualization of 
the CEA+ tumors with specific contrast to background tissue has been obtained 
with the [18F]AlF-hMN-14-Fab’ and [18F]AlF-hMN-14-Fab-AD2 formats which is 
in concordance to the observed higher tumor-to-blood ratios of these formats. 
In addition, for all three antibody formats, high kidney and liver uptake was 
observed. The uptake in the CEA- SK-RC-52 xenografts (left flank) remained low 
for all antibody formats and could not be visualized with microPET imaging. 
Biodistribution studies
The results of the biodistribution studies with [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-
14-Fab-AD2, and [18F]AlF-hMN-14-diabodies in nude mice with s.c. CEA+ LS174T 
xenografts (right flank) and CEA- SK-RC-52 xenografts (left flank) after dissection 
are summarized in figure 4. The biodistribution of [18F]FDG was determined in the 
same model as a reference. At 4 h after injection, all antibody preparations showed 
preferential accumulation in the CEA+ LS174T tumors, reaching 1.85 ± 0.36% ID/g, 
2.10 ± 0.46% ID/g, and 4.61 ± 0.67% ID/g for [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-
14-Fab-AD2, and [18F]AlF-hMN-14-diabody (figure 4). Uptake in the negative control 
tumors remained significantly lower for all antibody formats, indicating the specific 
targeting of the antibody formats to CEA-expressing tumor. For all fragments, tumor 
uptake could be blocked by injection of an excess of unlabeled hMN14 IgG, resulting 
in non-CEA-mediated uptake of 0.59 ± 0.12% ID/g,  0.68 ± 0.13% ID/g, and 1.37 ± 
0.04% ID/g for [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and [18F]AlF-hMN-
14-diabody, respectively, at 4 h after injection.
Table 1: Summary of the results of radiolabeling of [18F]ALF-NODA-MPAEM and hot 
conjugation with the hMN14 antibody fragments Fab’, Fab-AD2, and diabody. The IC50 of 
hMN14-IgG was 8.3 ± 1.5 nM and serves as a reference for the antibody fragments.
[18F]AlF-hMN14-
Fab’
[18F]AlF-hMN14-
Fab-AD2
[18F]AlF-hMN14-
diabody
Specific activity (MBq/nmol)
Overall labeling efficiency (%)
Yield after purification (%)
Immunoreactive fraction
IC
50
 value (nM)
18
66
49
> 60 > 60 > 60
11.2 ± 1.3 26.9 ± 1.3 7.9 ± 1.2
23
71
59
20
71
66
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Tumor-to-blood ratios at 4 h after injection were significantly higher for [18F]AlF-
hMN-14-Fab’ and [18F]AlF-hMN-14-Fab-AD2 compared to the [18F]AlF-hMN-14-
diabody format, reaching 5.87 ± 0.93 (p<0.005), 6.15 ± 1.58 (p=0.01), and 2.75 ± 
0.18, respectively. Tumor-to-blood ratios of [18F]FDG were 3.70 ± 0.38, which is 
significantly lower compared to those of [18F]AlF-hMN-14-Fab’ (p<0.005) and 
[18F]AlF-hMN-14-Fab-AD2 (p<0.05).
CEA+-to-CEA- tumor uptake ratios (localization index) for [18F]AlF-hMN-14-Fab’, 
[18F]AlF-hMN-14-Fab-AD2, [18F]AlF-hMN-14-diabody, and [18F]FDG, were 3.1 ± 0.9, 
2.7 ± 0.7, 2.5 ± 0.3, and 2.1 ± 0.4, respectively (figure 5). Tumor-to-muscle ratios 
obtained with the [18F]AlF-hMN-14-diabody format, [18F]AlF-hMN-14-Fab’ and [18F]
AlF-hMN-14-Fab-AD2 were comparable with 15.5 ± 2.3, 14.3 ± 3.9, and 14.0 ± 5.3, 
respectively. 
All antibody preparations showed high kidney retention. Renal accumulation was 
highest for [18F]AlF-hMN-14-Fab-AD2 (122.6 ± 9.4% ID/g), while kidney uptake of [18F]
AlF-hMN-14-Fab’ was lower (90.7 ± 7.0% ID/g) (p<0.005). Lowest renal accumulation 
was observed for the [18F]AlF-hMN-14-diabody format (57.4 ± 5.5% ID/g) (p<0.01). 
Figure 3: 3D-rendered microPET scans of a) [18F]AlF-NODA-MPAEM-hMN-14-Fab’, b) [18F]
AlF-NODA-MPAEM-hMN-14-Fab-AD2, and c) [18F]AlF-NODA-MPAEM-hMN-14-diabody in 
mice with s.c. LS174T (right flank, green arrows) and SK-RC-52 (left flank) xenografts. The 
white arrows indicate the liver.
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All [18F]AlF-labeled antibody derivatives showed high hepatic uptake. Liver uptake 
of [18F]AlF-hMN-14-Fab’ (4.36 ± 0.57% ID/g) and [18F]AlF-hMN-14-Fab-AD2 (4.32 ± 
0.35% ID/g) was significantly lower compared to the liver uptake of the [18F]AlF-hMN-
14-diabody format (11.1 ± 1.0% ID/g) (p<0.05).
DISCUSSION
In this study, we applied a 2-step method to prepare [18F]-AlF-fluorinated NODA-
MPAEM-hMN-14-Fab’, NODA-MPAEM-hMN-14-Fab-AD2, and NODA-MPAEM-hMN-
14-diabody, and evaluated the in vitro characteristics and the in vivo tumor targeting 
capacities of these tracers in nude mice with CEA-expressing LS174T human colon 
carcinoma xenografts in order to show the applicability of [18F]AlF-fluorination for 
heat-sensitive biomolecules and to characterize the optimal antibody formats to 
image CEA-expressing colorectal cancer.
The immunoreactivity of the [18F]AlF-fluorinated antibody formats was 
preserved during the labeling procedure. The IC50 analyses indicated that the 
Figure 4: Biodistribution of [18F]-FDG, [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and 
[18F]AlF-hMN-14-diabody in several tissues and subcutaneous LS174T and SK-RC-52 tumor 
xenografts in mice. For [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and [18F]AlF-hMN-
14-diabody, an excess of unlabeled hMN-14 IgG (500 µg/mouse, xs) was injected 3 days 
before injection of the [18F]AlF-labeled antibody fragment preparation.
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affinities of hMN-14-Fab’ and hMN-14-diabodies for CEA were comparable to that 
of hMN-14 IgG while the affinity of hMN-14-Fab-AD2 to CEA was slightly lower. 
Theoretically, the combination of [18F]AlF and the diabody formats is particularly 
promising because the diabody fragment might benefit from bivalent binding.
In vivo, preferential localization of all [18F]AlF-fluorinated antibody formats 
in the CEA+ xenografts was observed, demonstrating feasibility of these [18F]
AlF-fluorinated antibody derivatives for imaging of CEA-expressing tumors. 
For hMN-14-Fab’ and [18F]AlF-hMN-14-Fab-AD2, tumor-to-blood ratios 
were significantly higher compared to those of [18F]AlF-hMN-14-diabody.
Liver uptake of both [18F]AlF-hMN-14-Fab’ and [18F]AlF-hMN-14-Fab-AD2 
fragments was significantly lower compared to that of the diabody. Apparently, the 
diabody cleared partly via the hepatobiliary route. Consequently, visualization of 
liver metastases or tumors located in the liver can be obscured. Therefore, future 
studies will have to focus on decreasing the hepatic uptake of [18F]AlF-fluorinated 
antibody formats. 
In contrast, renal accumulation of the [18F]AlF-hMN14-diabody derivative 
was significantly lower compared to that of the [18F]AlF-hMN-14-Fab’ and [18F]AlF-
hMN-14-Fab-AD2 fragments. The high accumulation in the kidneys most likely is 
a consequence of tubular reabsorption after glomerular filtration of the [18F]AlF-
fluorinated antibody formats. This renal retention of [18F]AlF-fluorinated antibody 
derivatives might hamper the visualization of tumors located in the vicinity of the
Figure 5: a) CEA+-to-CEA- tumor, and b) tumor-to-blood ratios of [18F]-FDG, [18F]
AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and [18F]AlF-hMN-14-diabody (t-test: 
* p=0.0032, ** p=0.0132).
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kidneys. The lower renal accumulation of the [18F]AlF-hMN14-diabody derivative is 
most likely due to the bivalency of the derivative leading to slower clearance from 
the blood which consequences in lower renal accumulation at early time points after 
injection.
With the development of new molecular imaging agents, the number of 
applications for diagnostic PET imaging continues to increase. Several positron-
emitting radionuclides are used for PET imaging, such as 64Cu, 68Ga, 124I, 86Y, and 89Zr. 
Labeling of Fab’, F(ab’)2, and scFv antibody fragments as well as mini- and diabodies 
with these radioisotopes has been described by several groups [5-8]. Smith-Jones 
et al. chelated 68Ga to DOTA-conjugated F(ab’)2 fragments of the anti-HER2 antibody 
Herceptin (trastuzumab) (68Ga-DCHF) to demonstrate that 68Ga-DCHF can be used to 
serially image HER2 expression in breast cancer xenografts [9].
Eder et al. [7] evaluated the role of several recombinant anti-EpCAM scFv 
antibody fragments and diabodies for imaging of EpCAM-expressing tumors with 
68Ga. They demonstrated that PET imaging of solid tumors with a 68Ga-labeled anti-
EpCAM diabody format is feasible using N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]
ethylenediamine-N,N′-diacetic acid (HBED-CC) as a chelate.
Wu and colleagues [10] evaluated the tumor targeting capacity of the anti-CEA 
minibody based on the T84.66 antibody labeled with 64Cu, using DOTA as a chelate, 
in mice with s.c. LS174T tumors, and showed feasibility of this format to image 
colorectal cancer with PET, although hepatic uptake was relatively high. However, 
the half-life of 64Cu (12.7 hours) might be too long for certain in vivo imaging studies. 
Sundaresan et al. [11] compared the tumor targeting capacity of the 124I-labeled anti-
CEA T84.66 minibody to that of the 124I-labeled T84.66 diabody in the same model, 
and demonstrated specific visualization of the CEA+ xenografts with PET imaging with 
both 124I-labeled formats. 
The most widely used radionuclide for PET is 18F. 18F has ideal properties for PET 
due to its low positron energy of 635 keV that reveals optimal spatial resolution of 
PET images [12]. In addition, the lack of other emissions and wide availability of the 
cyclotron-produced 18F are advantageous for PET. Moreover, the half-life of 109.8 
minutes permits more complex and time-consuming synthetic manipulations and 
biological studies. However, in general the labeling of biomolecules of 18F is cumbersome. 
Labeling procedures for 68Ga in contrast are relatively straight-forward, because 68Ga 
can be chelated with macrocyclic chelates such as DOTA or NOTA. In addition, 68Ga is 
generated by a 68Ge/68Ga generator, allowing 68Ga generation on-demand without the 
need for an on-site cyclotron. However, 68Ge/68Ga generators are not widely available 
and the relatively short half-life of 67.6 minutes restricts the use of 68Ga. Additionally, 
68Ga has higher positron energy than 18F, which limits the resolution of the PET images. 
Despite these limitations, 68Ga has been used in in vivo studies with antibodies 
and antibody fragments more frequently than 18F, because of the more complex 
18F-labeling process, requiring labeling of a prosthetic group, deprotection and
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subsequent conjugation to a protein [13]. The most widely used approaches 
for 18F-labeling of biomolecules are based on the use of N-succinimidyl-4-[18F]
fluorobenzoate (SFB) [14] or [18F]fluorobenaldehyde [15].
The [18F]AlF labeling method developed by McBride et al. [2] provides a promising 
alternative to previous 18F radiolabeling methods, as it can be efficiently performed in 
one step. However, this method requires a heating step to 100 °C to chelate [18F]AlF. 
This step limited the procedure to heat-stable peptides and molecules that tolerate 
high temperatures. Recently, McBride et al. showed that the method can be used 
to label heat-sensitive biomolecules using a two-step method [3]. In this method, 
the NODA-MPAEM ligand is labeled with [18F]AlF first, followed by conjugation to 
the biomolecule via its thiol group at room temperature. Here, we demonstrated 
feasibility of this two-step method to label heat-sensitive biomolecules with 18F in 
vitro and in vivo. 
Taken together, all three [18F]AlF-fluorinated antibody derivatives show high 
tumor-to-background ratios, allowing microPET imaging of CEA-expressing tumors. 
While CEA+/CEA- tumor ratios of all three antibody formats were comparable, 
significantly higher tumor-to-blood ratios were reached with the [18F]AlF-hMN-14-
Fab’ and [18F]AlF-hMN-14-Fab-AD2 fragments, which resulted in slightly clearer 
visualization of CEA-expressing tumors with [18F]AlF-hMN-14-Fab’ and [18F]AlF-hMN-
14-Fab-AD2. In addition, the lower hepatic uptake of [18F]AlF-hMN-14-Fab’ and [18F]
AlF-hMN-14-Fab-AD2, compared to the [18F]AlF-hMN-14-diabody format, might be 
advantageous for in vivo imaging of liver lesions. However, further research is needed 
to further decrease hepatic uptake of [18F]AlF-fluorinated antibody fragments.
CONCLUSION
We demonstrated an efficient two-step method to label heat-sensitive biomolecules 
with 18F and translated this method to preclinical PET imaging studies. In vitro and 
in vivo tumor targeting characteristics of [18F]AlF-fluorinated hMN-14-Fab’, [18F]AlF-
hMN-14-Fab-AD2, and [18F]AlF-hMN-14-diabody showed that all three antibody 
formats are promising candidates for PET imaging of CEA-expressing colorectal 
cancer.
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ABSTRACT
In oncology, sensitive and reliable detection tumor tissue is crucial to prevent 
recurrences and to improve surgical outcome. Currently, extensive research is focused 
on the use of radionuclides as well as fluorophores to provide real-time guidance 
during surgery to aid the surgeon in the identification of malignant tissue. Particularly, 
dual-modality approaches combining radionuclide and near-infrared fluorescence 
(NIRF) imaging have shown promising results in preclinical studies. Radionuclide 
imaging allows sensitive intra-operative localization of tumor lesions using a gamma 
probe, whereas NIRF imaging allows more accurate real-time visualization of tumor 
delineation. Consequently, both radionuclide and NIRF imaging might complement 
each other and dual-modality image-guided surgery may overcome limitations of the 
currently used single-modality imaging techniques.
In this review, a comprehensive overview on recent preclinical advances in 
tumor-targeted radionuclide and fluorescence dual-modality imaging is provided. 
Subsequently, the clinical applicability of dual modality image-guided surgery is 
discussed.
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INTRODUCTION
Cancer is the leading cause of death worldwide accounting for 7.6 million cases in 
2008 [1]. Despite tremendous improvements in molecular imaging strategies, the 
detection of small tumor lesions remains challenging. Small cancer foci, micro-
metastases, and tumor cell-containing resection margins, in particular, often remain 
undetected, leading to understaging and undertreatment, which may result in 
disease progression and/or recurrence.
Currently, the most commonly used imaging modalities to detect tumor lesions 
are computed tomography (CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET), and single photon emission computed tomography 
(SPECT). While CT and MRI imaging provide high anatomical resolution of bony and 
soft tissue, respectively, PET and SPECT allow highly sensitive and specific visualization 
of tumor tissue. Since each technique has its specific advantages and limitations, the 
combination of imaging modalities could have additional value.
In addition to the need for sensitive and specific imaging methods for diagnostic 
purposes, accurate localization of tumor tissue during surgery may aid to optimize 
tumor resection. For surgery, radical tumor resection is of utmost importance for 
treatment outcome and patient survival [2, 3]. Therefore, the visualization of 
micro-metastases and tumor cell-containing resection margins is pivotal to prevent 
recurrence of the disease. Nuclear imaging performed prior to surgery can provide 
information on the spread of the malignant manifestations and may aid the surgeon 
in localizing (and complete resection of) small tumor lesions. The intra-operative 
discrimination between malignant and healthy tissue is currently still largely based 
on visual inspection and palpation by the surgeon. With the development of gamma 
probes, intra-operative nuclear imaging and radio-guided surgery have become 
available and provide the possibility to map tumor lesions within the surgical field. 
Since its introduction, radio-guided surgery has tremendously expanded and has 
evolved into what is now considered an established discipline in the operating 
theater, revolutionizing the surgical management of several types of malignancies 
[4]. Radio-guided surgery has significant impact on the surgical management of 
cancer as it provides real-time information on the location and extent of disease to 
the surgeon. Additionally, it allows minimization of the invasiveness of the surgical 
procedures, while maintaining maximum benefit to the cancer patient. Radio-guided 
surgery using gamma probe technology has been used for the detection of primary 
tumors and the location of sentinel lymph nodes [5]. However, gamma probes are 
not suited for accurate tumor delineation during surgery. For this purpose, intra-
operative fluorescence-based imaging appears to be a better option as it allows exact 
delineation of tumor lesions during and following resection and can provide real-
time visualization that is directly correlated to the surgical field. 
Recently, extensive research has been focused on the development of probes
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for dual-modality imaging. Dual-modality imaging can be performed either with 
agents that are dual-labeled with a fluorescent dye and a radionuclide or by co-
injection of the radiotracer and the fluorescent probe, each conjugated to the same 
targeting molecule [6]. One limitation of the co-injection approach for dual-modality 
imaging is the fact that the biodistribution pattern of the probe might be altered 
when fluorescent dyes are conjugated to that molecule [7]. Thus, the radio signal 
and the fluorescent signal might not necessarily originate from the exact same 
location. Dual-labeled imaging agents, however, provide coherent imaging signals 
that originate from one and the same targeting molecule.
Two categories of dual-modality approaches can be distinguished: non-targeted 
and targeted approaches. While non-targeted approaches using dual-labeled probes 
have proven valuable for sentinel lymph node mapping, these agents are not tumor 
specific and therefore  not suited for detection of tumor lesions and resection margins 
[8]. Targeted approaches, for instance using antibodies directed against tumor-
associated cell surface antigens, can overcome these limitations. Here, we provide a 
comprehensive review on the preclinical advances and analyze the applicability for 
clinical translation of image-guided surgery in the rapidly evolving field of targeted 
dual-modality near-infrared fluorescence (NIRF) and radionuclide imaging of cancer.
INTRA-OPERATIVE RADIONUCLIDE IMAGING
PET and SPECT radionuclide imaging is based on detection of highly penetrating 
γ-photons (25 – 511 keV) produced during radioactive decay. Consequently, imaging 
with radionuclides is usually not hindered by limited penetration depth and is 
generally considered to be highly sensitive. However, application of radionuclide 
imaging is restricted by the inherited dangers of ionizing radiation, the relatively 
low spatial resolution, and the lack of anatomical references. In addition, a given 
radioisotope needs to match the intended clinical procedure as the half-life of 
commonly used radioisotopes for imaging ranges from minutes to months.
While pre-operative radionuclide imaging is highly useful for diagnostic 
purposes, the intra-operative use of radionuclide imaging is limited to specific 
applications. The hand-held gamma probe is one of the most frequently used 
devices for intra-operative radionuclide detection and radio-guided surgery. Since its 
introduction, radio-guided surgery has improved the surgical management of various 
malignancies and evolved into an established discipline in the operating theater. 
Radio-guided surgery provides real-time information on the location and the extent 
of disease. While this technique was originally used for the evaluation of primary 
tumors, radio-guided surgery using gamma probes is currently mainly applied for 
sentinel lymph node detection in various cancer, including breast cancer [9], cervical 
cancer [10], head and neck cancer [11], melanoma [12], and prostate cancer [13].
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Major limitation of the hand-held gamma probe is the fact that this technique 
solely provides an acoustic signal which could guide the surgeon to the malignant 
lesion without providing an image of its exact localization. Therefore, its capacity for 
accurate tumor delineation is relatively low.
INTRA-OPERATIVE NIRF IMAGING
In contrast to radionuclide imaging, fluorescence imaging provides the possibility for 
more precise delineation of tumor lesions during surgery. Fluorescent tracers can 
be excited by absorption of light of a specific wavelength. When falling to its ground 
state, the fluorophore emits light of higher wavelength. In principle, fluorophores 
have extended half-lives and can be repeatedly activated. Furthermore, fluorescence 
imaging is a relatively low-cost imaging modality with high sensitivity and resolution 
[14]. However, due to limited tissue penetration depth caused by tissue absorption 
and scattering of photons, fluorescence imaging is limited to specific applications. 
The penetration depth of fluorescent light is improved when fluorophores are 
applied that emit light in the near-infrared (NIR) region (650 – 900 nm). Photons in 
the NIR region show higher tissue penetration than photons in the visible light range 
(400 – 600 nm) [15], resulting in a tissue penetration depth limited to the centimeter 
range [16]. 
So far, only a few fluorescent agents such as methylene blue (MB) and 
indocyanine green (ICG), which are both non-target specific, are approved for clinical 
use by the Food and Drug Administration (FDA). Whereas the far-red emitter MB has 
mainly been used to stain sentinel lymph nodes for dissection [17] and to identify 
colon polyps [18], the fluorophore ICG (emission peak at 830 nm) [19] has been used 
for intra-operative purposes such as mapping of blood vessel patency or tumor-
draining lymph nodes [20]. 
A new approach to deal with one of the major challenges of NIRF imaging, 
the limited tissue penetration of light, is the combination of this technique with 
radionuclide imaging. Dual-modality approaches using both a radiolabel and a 
fluorescent dye can be applied for different approaches. First, the radionuclide aids 
the surgeon to intra-operatively localize the tumor using a gamma probe. Second, 
the fluorescent label may be used to detect micro-metastases and precisely evaluate 
resection margins during surgery.
NON-TARGETED DUAL-MODALITY RADIONUCLIDE AND 
NIRF IMAGING
The first clinical proof-of-concept studies of dual-modality imaging were provided 
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using dual-modality nanocolloids to identify the tumor draining lymph nodes in 
several malignancies, such as prostate cancer [21, 22], breast cancer [23], melanoma 
[24], and head and neck cancer [25]. For these purposes, ICG is combined with 
radiotracers into so-called nanocolloids that are injected in or near the primary 
tumors to assess lymph vasculature. However, several limitations of ICG restrict its use 
as a fluorescent agent, such as insufficient photostability in buffer and physiological 
conditions, small Stokes shift, the formation of aggregates in aqueous media, and 
the lack of a functional group to conjugate targeting moieties [26]. Obviously, the use 
of non-targeted imaging to assess resection margins for residual tumor tissue is far 
from ideal. For this purpose, targeted dual-modality imaging approaches have shown 
promising preclinical results.
TARGETED DUAL-MODALITY RADIONUCLIDE AND NIRF 
IMAGING
The development of NIRF dyes containing functional groups that are suitable for 
established chemical conjugation to biomolecules represent a promising opportunity 
for the design of target-specific fluorescent probes for molecular imaging. Many 
targeted optical probes have been developed which target cell surface and hormone 
receptors, metabolic pathways, or apoptotic markers [27]. When developing a dual-
modality targeting agent, the following issues should be addressed: 1. which targeting 
agent, 2. which fluorophore, and 3. which type of coupling chemistry can be used.
1. Targeting molecules
Effective targeting molecules need to fulfill several criteria: First, the targeting 
agent has to reach its target in an efficient way, which is determined by the specific 
properties of the probe and the affinity of the targeting agent for its target. Second, 
the target needs to be present in sufficient amounts and non-specific binding of the 
targeting molecule should be low. In addition, the pharmacokinetics of the imaging 
agent and its excretion route should be taken into account. 
At present, various targeting molecules are available for preclinical and clinical 
imaging purposes, such as antibodies or peptides [19]. Intact monoclonal antibodies 
such as bevacizumab, cetuximab, or trastuzumab as well as antibody fragments 
represent excellent candidates for targeted dual-modality imaging due to their 
high target-specificity, the abundance of suitable reactive amino acid residues for 
conjugation purposes, and the availability of clinical-approved antibodies [26]. Other 
promising candidates for dual-modality imaging are peptide ligands that bind with 
high affinity to the corresponding receptors on tumor cells, such as somatostatin 
analogues (SSTR), gastrin-releasing peptide receptor (GRPR) ligands, folate analogues, 
PSMA ligands, or matrix metalloproteinases (MMP). Peptide ligands usually are 
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chemically more robust than proteins and are easier to produce as clinical agents 
[26].
2. NIRF dyes 
The ideal NIRF dye should have specific characteristics [28]. First, the stokes shift 
should be large to gain a minimum of interference between excitation and emission 
wavelengths. In addition, the molar absorption coefficient and the quantum yield 
should be high enough to acquire a fluorescent signal. Moreover, the agent should 
be water soluble to avoid dye aggregation in aqueous solutions and it should be 
chemically and photo-stable in biological solutions [28]. In addition, as mentioned 
above, suitable functional groups need to be present to allow conjugation to targeting 
molecules. At present, two main categories of NIR fluorophores can be distinguished, 
inorganic and organic NIR dyes [28]. While inorganic NIRF dyes are mainly associated 
with quantum dots and other nanoparticles, organic NIRF dyes can be covalently or 
noncovalently conjugated with various molecules such as oligonucleotides, peptides, 
or antibodies [28]. 
3. Conjugation reactions
The fluorescent dye and the targeting molecule are usually coupled via a linker, 
which can be an alkyl chain with a functional group on each side. One of the most 
commonly used strategies to develop imaging probes is amide bond formation 
between a primary amino group (NH2) and a carboxylic acid (COOH), as these groups 
are found in various fluorophores and in various targeting molecules [14]. To allow 
amide formation, N-acetylation between N-hydroxysuccinimide (NHS) activated 
carboxylic acid and a primary amino group is a commonly used approach [14]. Many 
of the NIRF dyes that are commercially available can be purchased as NHS esters, 
such as Cy5.5-NHS, Cy7-NHS, or IRDye800CW-NHS. Another conjugation reaction is 
the maleimide reaction with thiol groups. In this reaction, maleimides react with 
cysteine residues at neutral pH to generate a stable thioether bond.
One essential challenge in coupling fluorophores to targeting molecules 
is the lipophilicity of the fluorophores. It has been observed that the in vivo 
behavior of targeting agents can be affected by the conjugation of a fluorescent 
dye. In a study performed by Cohen et al., a substitution ratio of more than one 
molecule of IRDye800CW to one molecule of the antibody caused alterations in the 
pharmacokinetics of the targeting molecule, especially enhancing the liver uptake 
of the conjugate [7]. One explanation for this effect might be the lipophilicity of 
IRDye800CW. High accumulation of tracer in the liver can obscure small tumor 
nodules and metastases located in or in the vicinity of the liver. In addition, rapid 
and high tracer accumulation in the liver can reduce tumor uptake. Reduced hepatic 
uptake may be achieved by limiting the substitution ratio to one fluorescent dye per 
targeting molecule [7].
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Preclinical studies using co-injection strategies
As described earlier, targeted dual-modality radionuclide and NIRF imaging can 
be performed either by co-injection strategies or by dual-label strategies. In co-
injection strategies, the same targeting molecule, e.g. an anti-tumor antibody, is 
labeled with either a fluorescent dye or a radionuclide and these tagged antibodies 
are co-administered as a mixture. At first glance, co-injection of two single-labeled 
compounds seems to be simpler compared to dual-labeling strategies, where one 
targeting molecule is labeled with both a fluorescent dye and a radionuclide. Most 
NIR fluorophores are organic molecules with molecular weight of approximately 
1,000 Da, while chelated radionuclides usually are polar molecules of a size of 
around 300-400 Da [26]. As a consequence, conjugation of a targeting molecule to 
different tracer dyes or chelators can cause alterations in pharmacokinetics, binding 
affinities, and biodistributions [7]. As a result, radio-signal and fluorescent signal may 
not necessarily originate from the same location. 
Terwisscha van Scheltinga et al. compared optical imaging with PET in mice 
that received a co-injection of the anti-VEGF antibody bevacizumab labeled with 89Zr 
and bevacizumab conjugated with IRDye800CW and reported specific VEGF-tumor 
targeting and tumor visualization with both the radiolabeled and fluorescent-labeled 
antibody [6]. Moreover, IRDye800CW-trastuzumab was used for intra-operative 
guidance during surgical removal of subcutaneous SK-Br-3 tumor lesions from tumor 
bearing mice [6]. For both IRDye800CW-trastuzumab and IRDye800CW-bevacizumab, 
even submillimeter intraperitoneal tumor lesions could be distinguished intra-
operatively by the emission of fluorescent signal and could be removed from the 
peritoneum based on the fluorescent signal [6]. 
In another study, optical and radionuclide imaging was performed in mice that 
received either trastuzumab dual-labeled with both 111In and ICG or co-injection of a 
mixture of 111In-trastuzumab and ICG-trastuzumab [34]. Both approaches, revealed 
specific tumor visualization with flurorescence imaging. 
Preclinical studies using dual-label targeting molecules
In contrast to co-injection strategies, dual-labeled imaging conjugates allow for 
coherent visualization of both imaging signals which originate from the same 
targeting molecule. For this purpose, the targeting molecule needs to be labeled 
with both the NIRF dye and a radionuclide. Several dual-labeled targeting molecules 
have been studied so far, with encouraging results.
1. Dual-labeled bevacizumab for imaging of VEGF-A expressing cancers
A promising target that has been studied for imaging of cancer is the vascular 
endothelial growth factor (VEGF) as it plays a pivotal role in the formation 
of blood vessels (neoangiogenesis). Bevacizumab (Avastin®) is a humanized 
anti-VEGF monoclonal antibody approved for treatment of colorectal cancer, 
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renal cell cancer, and glioblastoma [29]. 
Cohen et al. described the coupling of IRDye800CW to 89Zr-labeled bevacizumab 
and cetuximab (anti-EGFR) to evaluate its behavior in vivo in mice bearing A431 or 
FaDu xenografts [7]. In this study, antibody-desferal conjugates were first labeled with 
89Zr, followed by conjugation to IRDye800CW. Excellent tumor targeting was achieved 
with dual-labeled antibodies at low substitution ratios of antibody molecule and 
IRDye800CW. The relatively long half-life of 89Zr (78.4 hours) offers the opportunity 
to perform serial PET imaging with 89Zr-labeled antibodies during a period of several 
days.
The use of radionuclides with a shorter half-life, such as 64Cu (12.7 hours), allows 
imaging studies in which repeated injections of the labeled conjugate are required. 
Recently, bevacizumab was labeled with both 64Cu and IRDye800CW for serial PET 
and NIRF imaging of mice with subcutaneous U87MG glioblastoma xenografts [30]. 
In this study, 0.8 IRDye800CW molecules were substituted to each bevacizumab 
molecule. Persistent and VEGF-specific uptake of 64Cu-NOTA-bevacizumab-800CW in 
the U87MG xenografts was demonstrated, reaching a tumor uptake of 20.7 ± 3.7% 
ID/g at 72 h  post injection.
2. Dual-labeled trastuzumab for imaging of HER-expressing cancers
The intracellular signaling pathways regulating cellular growth and differentiation of 
many cancer types are regulated by members of the human epidermal growth factor 
receptor (HER) family, which consists of several transmembrane receptor tyrosine 
kinases. One of these kinases, HER2, is of particular interest for cancer research 
as it is associated with aggressive tumor progression of breast and ovarian cancer 
[31]. Trastuzumab (Herceptin®) is a humanized anti-HER2 antibody approved for 
HER-2-overexpressing breast and metastatic gastric or gastroesophageal junction 
adenocarcinoma. 
During the last decade, trastuzumab has been labeled with several radionuclides 
and fluorophores to develop dual-labeling strategies for dual-modality imaging of 
cancer. The FDA-approved fluorophore ICG was considered a promising fluorophore 
for this purpose. Ogawa et al. co-injected a cocktail of ICG-trastuzumab and 111In-
trastuzumab into mice with subcutaneous A431 and 3T3/HER2 tumors and compared 
the nuclear and optical imaging characteristics with dual-labeled trastuzumab with 
111In and ICG [32]. With both methods, they observed tumor uptake in the 3T3/HER2 
tumors on nuclear and NIRF images. In addition, high uptake in the liver was observed, 
even though the average number of ICG molecules per antibody was kept below 
1. This might be due to dissociation of ICG from the antibody after administration 
which might consequence in binding of the water-soluble ICG to albumin in plasma. 
Subsequently, the ICG-albumin complex is taken up by hepatocytes and cleared from 
the body through the hepatic route [32, 33].
With the development of the next generation NIR fluorophore IRDye800CW,
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which can be functionalized with either NHS or maleimide, a broad variety of targeting 
molecules could be conjugated with IRDye800CW. In 2007, Sampath et al. labeled 
trastuzumab with 111In and IRDye800CW for sequential NIRF and SPECT/CT imaging. 
They validated this dual-label agent in a subcutaneous HER2-positive human breast 
cancer mouse model showing specific tumor targeting of the agent in vivo [34]. 
In a subsequent study, Sampath et al. demonstrated the ability to detect HER2-
expressing metastases with (64Cu-DOTA)-trastuzumab-(IRDye800) using PET and NIRF 
imaging in mice with orthotopic 4T1.2neu/R tumors in the mammary fat pad [35]. 
In addition, comparison with 18FDG-PET imaging was performed. It was shown that 
PET with (64Cu-DOTA)-trastuzumab-(IRDye800) as a tracer has greater sensitivity 
in detecting HER2 expressing metastases than FDG. In addition, non-specific liver 
uptake was observed which was attributed to the interaction of the Fc portion of the 
antibody with hepatocytes [35]. In this study, the average substitution ratio was 2.2. 
3. Dual-labeled TRC105 for imaging of CD105-expressing cancers
CD105 is almost exclusively expressed on proliferating endothelial tumor cells [36] 
and overexpression of CD105 is strongly related to poor prognosis in more than 
10 cancer types [37]. Therefore, CD105 represents a promising marker for tumor-
related angiogenesis. 
TRC105 is a chimeric human/murine IgG1 mAb with high affinity for human 
and murine CD105 [38]. Recently, this antibody was dual-labeled with 89Zr using 
desferal as a chelator and IRDye800CW as a fluorophore for dual-modality PET/NIRF 
imaging of CD105 expression in a subcutaneous 4T1 breast cancer xenografts [39]. 
In this study, Df-TRC105 was substituted with 0.7 800CW-NHS moieties per antibody 
molecule. Such a mild substitution ratio might not only be favorable for low hepatic 
uptake, but might also avoid self-quenching due to close proximity of IRDye800CW 
molecules to each other, as fluorescence resonance energy transfer only occurs 
when two IRDye800CW fluorophores are located within 10 nm, which is about the 
size of an antibody molecule [39]. In this study, tumor uptake of 89Zr-Df-TRC105-
800CW reached approximately 12% ID/g. In a similar study from the same group, the 
same dual-label tracer 89Zr-Df-TRC105-800CW was tested in a lung metastasis mouse 
model of breast cancer [40]. While significant uptake of 89Zr-Df-TRC105-800CW in 
the lung metastases was observed with PET imaging as early as 24 h after injection, it 
was not possible to delineate the tumors with NIRF imaging in vivo due to the limited 
penetration depth of NIRF imaging due to the deep location of the lung metastases in 
the thoracic cavity. However, ex vivo imaging was used to validate the PET images. In 
addition, Hong et al. performed image-guided resection of subcutaneous 4T1 breast 
tumors in mice subjected to NIRF imaging at 4 h and 24 h after intravenous injection 
of 89Zr-Df-TRC105-800CW. It was demonstrated that image-guided tumor removal 
was possible [40]. 
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Very recently, Zhang et al. [41] conjugated TRC105 to NOTA and subsequently coupled 
IRDye800CW to NOTA-TRC105 and labeled it with 64Cu to synthesize 64Cu-NOTA-
TRC105-800CW. In this study, on average 0.9 IRDye800CW moieties were conjugated 
per molecule of TRC105. Biodistribution studies and ex vivo PET/NIRF imaging with 
this 64Cu-NOTA-TRC105-800CW dual-labeled conjugate showed rapid and persistent 
CD105-specific uptake of 64Cu-NOTA-TRC105-800CW in fLuc-4T1 BC metastatic lung 
tumor nodules, reaching 13.9 ± 3.9% ID/g at 24 h after injection. In addition, proof-of-
principle for image-guided surgery with optical imaging using NOTA-TRC105-800CW 
was provided in this study in a subcutaneous 4T1 tumor model in nude mice [41].
4. Dual-labeling strategies for imaging of EpCAM-expressing cancers
The epithelial cell adhesion molecule (EpCAM) also known as CD362, EGP-2, ESA, and 
TROP-1, is a type I transmembrane glycoprotein that is overexpressed in many cancers 
and therefore represents a promising target for imaging. EpCAM is overexpressed in 
87% of the prostate cancers [42]. Recently, the anti-EpCAM antibody MAB9601 was 
conjugated with DOTA and was dual-labeled with 64Cu and IRDye800CW in order to 
develop a multimodality-imaging agent for the detection of lymph node metastases 
in a preclinical animal model of human metastatic prostate cancer [43]. In this study, 
the substitution ratio of MAB9601 with IRDye800CW was 2.3 dye molecules per 
antibody molecule. Hall et al. performed NIRF and PET/CT as well as DsRed imaging 
on mice with orthotopically implanted PC3 cells expressing the fluorescent gene 
reporter DsRed. In this study, PC3-DsRed lymph node metastases developed at 10-
12 weeks after implantation. The detection rates by NIRF and PET/CT imaging were 
similar, indicating the multimodality imaging capability of the dual-labeled agent for 
the detection of lymph node metastases in prostate cancer. 
To evaluate the effect of binding affinity and the pharmacodynamics of 
antibody-based probes and to increase the accuracy for the detection of cancerous 
foci, a subsequent study was performed. In this study, the potential of several newly 
synthesized dual-labeled antibodies was evaluated [44]. The 64Cu and IRDye800CW 
dual-labeled antibody MAB9601 was compared to a few other anti-EpCAM antibodies 
regarding their accuracy for the detection of cancer cell containing lymph nodes with 
NIRF and PET/CT imaging in an orthotopic mouse model of prostate cancer [44]. Hall 
et al. demonstrated that the in-house produced murine IgG1 monoclonal antibodies 
7 (KD 2.3 nM) and 153 (KD 0.54 nM) had superior affinity for EpCAM compared to 
MAB9601 (KD 15.4 nM) and the accuracy in the detection of cancer cell containing 
lymph nodes for mAb 7 was higher compared to that of MAB9601 on NIRF as well 
as on PET/CT imaging. The authors concluded that antibodies with affinities in the 
low nanomolar range represent promising candidates for dual-modality PET/NIRF 
imaging.
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5. Dual-labeling strategies for imaging of PSMA-expressing cancers
Prostate-specific membrane antigen (PSMA) is selectively overexpressed in prostate 
cancer in all stages of the disease and as such represents an excellent target for 
prostate cancer imaging [45]. The type II integral membrane glycoprotein PSMA is an 
enzyme of which the natural ligand is still unknown. For imaging purposes, various 
high affinity ligands for PSMA have been developed [46]. Recently, Banerjee et al. 
synthesized the first dual-modality SPECT/NIRF imaging agent with affinity for PSMA, 
based on glutamate urea compound conjugated with both DOTA and IRDye800CW 
for targeting PSMA-expressing prostate cancer in mice with s.c. PC3-PIP tumors [47]. 
They observed radiotracer uptake ex vivo and clear visualization of the tracer in the 
PSMA-expressing subcutaneous PC3-PIP prostate cancer xenografts (16.4 ± 3.7% 
ID/g, 5 h p.i.), while uptake in the PSMA-negative PC3-flu control tumors was low 
(1.9 ± 0.2% ID/g, 5 h p.i.). In addition, intense radiotracer uptake was observed the 
kidneys, which the authors contribute to the tracer’s route of excretion and to its 
specific uptake due to expression of PSMA in kidneys [48].
6. Dual-labeling strategies for targeting CD20
CD20 is a phosphoglycoprotein expressed on the surface of B cells. At present, 
anti-CD20 mAbs are clinically used for treatment of non-Hodgkin’s lymphomas and 
rheumatoid arthritis. Paudyal et al. [49] used the murine anti-CD20 mAb NuB2 for 
targeting CD20-positive tumors and labeled it via DOTA with 64Cu along with the 
fluorophore Alexa Fluor 750. They performed ex vivo biodistribution and in vivo PET/
NIRF imaging and demonstrated that 64Cu-DOTA-NuB2-Alexa Fluor 750 specifically 
binds to CD20-expressing tumor xenografts (16.34 ± 2.75% ID/g, 48 h p.i.).
Clinical translation
Image-guided surgery using tumor-targeting dual-label agents could potentially 
facilitate surgical resection of tumors. Complete resection of tumors and metastases 
may be improved in particular when tumor tissue cannot be easily discriminated 
from normal tissue, when scar tissue obscures the discrimination between normal 
and tumor tissue, or when multiple small metastases need to be removed. 
So far, a considerable number of preclinical studies has focused on the 
development of dual-labeled radionuclide and fluorescent targeting agents for 
dual-modality imaging. However, until now, no targeted dual-modality imaging 
approaches have been introduced into the clinic. To the best of our knowledge, so 
far, only one targeted fluorescence imaging approach has been translated to a clinical 
study. Van Dam et al. conjugated folate with fluorescein isothiocyanate (folate-FITC) 
for targeting the folate receptor-α with a real-time multispectral intra-operative 
fluorescence imaging system [50]. In this study, the first clinical results of intra-
operative tumor-specific fluorescence imaging for real-time surgical visualization
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of tumor tissue in ovarian cancer patients during laparotomy were described in a 
series of 10 patients intra-operative tumor-specific fluorescence imaging of folate-
FITC, that was administered systemically, provided specific and sensitive detection of 
tumor tissue in real-time settings during surgery in patients with folate receptor-α-
expressing ovarian cancer. 
Recently, the first clinical trial using a fluorescently tagged anti-VEGF antibody 
(clinicaltrials.gov, NCT01508572) was started, aiming to show the feasibility of intra-
operative NIRF imaging in breast tumor patients.
While the first targeted fluorescence imaging studies show promising results, 
the next step would be to introduce targeted dual-label approaches into the clinic. 
Using this approach, three major applications could be combined within one single 
approach and improve oncological surgery: The targeted radionuclide activity could 
be used to pre-operatively visualize tumor tissue (first) and intra-operatively localize 
tumor nodules with a gamma probe (second). Third, after surgical resection of tissue 
layers that may cover the tumor tissue, the fluorescent component of the dual-
modality probe could aid the surgeon in the precise delineation and resection of 
tumor lesions. A schematic representation of how this dual-modality approach could 
be performed is provided in figure 1.
Clinical applications of these dual-modality approaches are looming, but 
a few hurdles have to be overcome. Particularly, the preparation of fluorescently 
labeled targeting molecules needs to be further standardized and validated [7]. 
Once these fluorescent agents are found to be safe, they can be conjugated to the 
radiolabeled dual-label targeting agent and should then be synthesized according
Figure 1: Schematic representation of a dual-modality radionuclide and NIRF imaging 
approach.
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to GMP standards. In addition, it has to be determined, if open laparotomy or 
laparoscopic surgical procedures in which a laparoscope is equipped with an optical 
imaging system, is more sensitive for dual-modality radionuclide and NIRF imaging. 
In particular, the role of dual-label constructs for image-guidance during surgery 
needs further evaluation regarding sensitivity and specificity in the detection of small 
lesions or positive resection margins.
An important challenge in oncological surgery is to completely resect invasive 
tumor strands to obtain tumor cell negative resection margins [8]. To detect invasive 
tumor strands, NIRF imaging systems are required that have a high sensitivity and 
enable detection of tumor strands in resection margins. While, as mentioned earlier, it 
has been shown that both IRDye800CW-trastuzumab and IRDye800CW-bevacizumab 
are feasible for detection of tumor lesions in the millimeter range in intra-operative 
settings and that these intraperitoneal lesions could be resected completely based 
on the fluorescent signal preclinically [6], the value of such dual-modality approaches 
for the evaluation of resection margins still needs to be assessed. Subsequently, this 
finding needs to be confirmed in a clinical setting to evaluate the sensitivity and 
specificity of dual-label targeting agents for small amounts of tumor tissue. Another 
challenge that needs to be addressed in future studies is tumor heterogeneity. 
Tumors consist of various cell types that may display variable phenotypes [8]. To 
establish the dual-modality imaging approach, preferably a target antigen should be 
chosen that is homogeneously expressed throughout the whole tumor. In addition, 
dual-modality image-guided surgery needs to be correlated to the gold standard 
histology for margin assessment and the additional value of dual-modality NIRF and 
radionuclide imaging needs to be evaluated. 
CONCLUSION
With the emergence of dual-labeling strategies and hybrid NIRF and radionuclide 
tracers, the first steps have been made for the combination of these powerful imaging 
techniques which might complement each other and improve the intra-operative 
detection and surgical removal of cancer tissue. So far, several preclinical studies 
demonstrated the potential value of combining these imaging modalities for image-
guidance during surgery. However, further studies are needed to correlate dual-
modality image-guided surgery to histology and to further evaluate the additional 
value of this dual-modality approach for overall survival. First clinical studies that 
aim to determine the value of NIR fluorescently labeled targeting molecules for 
diagnostic imaging are looming. 
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ABSTRACT
Background
Both radionuclide imaging and near-infrared fluorescence (NIRF) imaging have a high 
sensitivity to detect tumor lesions in vivo. The combination of these modalities using 
dual-labeled antibodies may allow both pre- and intra-operative tumor localization 
and could be used in image-guided surgery to ensure complete resection of tumor 
tissue. Here, we evaluated the potential of dual-modality imaging of prostate cancer 
with the monoclonal antibody D2B, directed against an extracellular domain of 
prostate-specific membrane antigen (PSMA). For these studies, D2B was labeled 
both with 111In and the near-infrared fluorescent dye IRDye800CW.
Methods
D2B was conjugated with NHS-IRDye800CW and ITC-DTPA and subsequently 
radiolabeled with 111In. For biodistribution and NIRF imaging, 111In-DTPA-D2B-
IRDye800CW (2 µg, 0.55 MBq/mouse) was injected intravenously into BALB/c nude 
mice with subcutaneous (s.c.) PSMA-expressing LNCaP tumors (right flank) and 
PSMA-negative PC3 tumors (left flank). The biodistribution was determined at 1, 
2, 3, and 7 days after injection. In addition, microSPECT/CT and NIRF imaging with 
111In-DTPA-D2B-IRDye800CW (3 µg, 8.5 MBq/mouse) was performed in mice with 
intraperitoneally growing LS174T-PSMA tumor nodules.
Results
111In-DTPA-D2B-IRDye800CW specifically accumulated in s.c. xenografted PSMA-
positive LNCaP tumors (45.8 ± 8.0% ID/g at 168 h p.i.), whereas uptake in s.c. 
PSMA-negative PC3 tumors was significantly lower (6.6 ± 1.3% ID/g at 168 h p.i.). 
Intraperitoneal (i.p.) LS174T-PSMA tumors could be visualized specifically with both 
microSPECT/CT and NIRF imaging at 2 days p.i., and the feasibility of image-guided 
resection of i.p. tumors was demonstrated in this model.
Conclusion
Dual-label 111In-DTPA-D2B-IRDye800CW enables specific and sensitive detection of 
prostate cancer lesions in vivo with microSPECT/CT and NIRF imaging. In addition to 
pre-operative microSPECT/CT imaging to detect tumor lesions, NIRF imaging enables 
image-guided surgical resection. These preclinical findings warrant clinical studies 
with 111In-DTPA-D2B-IRDye800CW to improve tumor detection and resection in 
prostate cancer patients.
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INTRODUCTION
Despite improvements in diagnostic and therapeutic approaches, prostate cancer 
remains one of the leading causes of cancer-related death in men in the Western world. 
For patients with low- and intermediate-risk localized prostate cancer and selected 
patients with high-risk localized disease, surgical removal of the cancerous foci is 
currently regarded as the treatment option of choice [1]. In radical prostatectomy 
tissue specimens obtained after surgical removal of localized prostate cancer, positive 
surgical margins are reported in 11 – 48% of the cases [2-4]. While the role of positive 
surgical margins on cancer-specific mortality remains controversial, positive surgical 
margins are recognized as a risk factor for prostate-specific antigen (PSA)-defined 
biochemical recurrence [5], which is associated with need for secondary therapy and 
may have considerable impact on patient’s quality of life. 
At present, several methods are clinically used to identify malignant tissues 
during surgery: First, cancerous tissue can be distinguished from benign structures 
visually based on color, texture and morphology. In addition, tactile palpation can 
aid the surgeon in the detection of tumor tissue due to differences in elasticity or 
plasticity [6]. However, the detection of tumor cells in resection margins and micro-
metastases remains extremely challenging. Therefore, imaging techniques that can 
aid the identification of small cancer foci are needed.
Recently, progress has been made in the field of intra-operative detection of 
malignant tissue with fluorescence imaging, a sensitive technique that could improve 
visualization of positive surgical margins during surgery using fluorescent dyes which 
accumulate in tumor tissues. Van Dam et al [7]. reported the first-in-human use 
of intra-operative tumor-specific fluorescence imaging for real-time visualization 
of tumor tissue in patients with ovarian cancer. In this study, ovarian cancer 
overexpressing the folate receptor is targeted and visualized with folate conjugated 
to the fluorescent dye fluorescein isothiocyanate (FITC). 
However, a shortcoming of fluorescence imaging is the limited penetration 
depth of emitted light in tissue. When tumor nodules are covered by other tissue, 
the fluorescent signal might not be visible and tumors may be missed. The use of 
near-infrared fluorescent (NIRF) dyes, which emit light in the near-infrared region 
(650 – 900 nm), can improve the tissue penetration depth to several millimeters [8]. 
Recently, the first clinical trial using the antibody bevacizumab tagged to the NIRF 
dye IRDye800CW (clinicaltrials.gov, NCT01508572) has started, aiming to show the 
feasibility of intra-operative fluorescence imaging in breast cancer patients.
A new approach to deal with the limited tissue penetration of NIRF imaging is 
the combination of this technique with radionuclide detection. Both radionuclide 
and NIRF imaging are highly sensitive in the detection of cancer lesions. A dual-label 
targeting agent with both a radionuclide and a fluorescent moiety could be used for 
three purposes: First, the radionuclide allows pre-operative assessment of the tumor
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burden by SPECT or PET imaging. Secondly, the radionuclide could aid the surgeon 
to intra-operatively localize the tumor using a gamma probe. Finally, the optical label 
could be used to precisely evaluate resection margins during surgery and detect 
micro-metastases once the surgical field is exposed to the surface.
 As the prostate-specific membrane antigen (PSMA) is selectively overexpressed 
on the surface of prostate cancer cells, it represents an attractive target for antibody-
guided targeting of cancer cells with radionuclides and fluorophores [9]. In the 
present study, we applied this new imaging strategy and evaluated the tumor imaging 
characteristics of the newly developed anti-PSMA monoclonal antibody (mAb) D2B 
labeled with both 111In and IRDye800CW to provide proof-of-principle for the use 
of the described dual-label imaging approach in mice with subcutaneous prostate 
cancer xenografts. In addition, we evaluated whether this dual-labeled D2B antibody 
preparation can be used to improve intra-operative visualization and to perform 
image-guided resection of tumor lesions in mice with intraperitoneally growing, 
PSMA-expressing tumor nodules. 
MATERIALS AND METHODS
The anti-PSMA monoclonal antibody D2B (IgG1) [10] was purified from hybridoma 
culture supernatant by Protein A affinity chromatography. The antibody secreting 
cells were obtained according to the hybridoma technology from mice that were 
immunized with a cell lysate of membranes of LNCaP cells. Mice were injected three 
times (day 0, day 14 and day 28) i.p. with 800 µg of lysate and Freund’s adjuvant 
(Sigma-Aldrich, St. Louis, MO, USA). The last three days before the spleen of the 
mice was harvested, mice were boosted with 10 µg of recombinant PSMA protein 
(Novagen, Milan, Italy) intravenously.  
Mouse tumor models
Male BALB/c nude mice (Janvier, Le Genest Saint Isle, France), 7-8 weeks old, were 
housed in filter-topped cages (5 mice per cage) under nonsterile standard conditions 
with free access to standard animal chow and water. After one week of adaptation to 
laboratory conditions, 3 x 106 PSMA-expressing LNCaP cells were suspended in 200 
µL of 33% complete RPMI 1640 medium with 67% Matrigel (BD Biosciences, Franklin 
Lakes, NJ) and injected subcutaneously (right flank). PSMA-negative PC3 cells were 
suspended in 200 µL of 67% complete RPMI 1640 medium with 33% Matrigel. LNCaP 
cells were inoculated 7 days prior to PC3 cells and tumors grew to approximately 0.1 
g in 14 and 7 days, respectively. Both cell lines were grown in RPMI 1640 medium, 
supplemented with 10% fetal calf serum (Life technologies, Carlsbad, CA) and 2 mM 
glutamine.
141
DUAL-MODALITY IMAGING OF PROSTATE CANCER
3.2
For the intraperitoneal tumor model, LS174T colon carcinoma cells were transfected 
with human PSMA, using the plasmid pcDNA3.1-hPSMA [11]. Cells were transfected 
using X-tremeGENE 9 DNA transfection reagent (Roche Applied Science, Mannheim, 
Germany). After transfection, single clones stably expressing PSMA were selected 
and grown in the presence of 0.3 mg/ml G418. PSMA expression of LS174T-PSMA 
cells was confirmed by FACS analysis. LS174T-PSMA cells were grown in RPMI 1640 
medium, supplemented with 10% fetal calf serum and glutamine in the presence of 
0.3 mg/ml G418. 1 x 106 LS174T-PSMA cells were injected intraperitoneally in 200 µL 
of complete RPMI 1640 medium and grew for 21 days after tumor cell inoculation.
For FACS analysis, stably transfected LS174T-PSMA cells (150,000 cells per 
well in a V-bottom 96 well plate) were washed twice and incubated on ice for 30 
minutes with 25 µl of either PBS, 0.5 %, an isotype control (mouse IgG (H+L) (5 µg/
ml) purified (Jackson ImmunoResearch Europe Ltd., Suffolk, UK), or the D2B antibody 
at 5 µg/ml in PBS, 0.5 % BSA. Untransfected LS174T cells were included as a negative 
control and the PSMA expressing prostate cancer cell line LNCaP was included as 
a positive control for PSMA expression. After incubation, cells were washed three 
times and incubated on ice for 30 minutes under light-protected conditions with 25 
µl of secondary fluorescently labeled antibody (goat-anti-mouse-IgG(H+L)-Alexa488, 
2.5 µg/ml (Life Technologies)), in PBS, 0.5 % BSA. Cells were washed again three 
times and measured on a FACS-Calibur system with CELLQuest software (both from 
Beckton Dickinson Immunocytometry Systems, San Diego, CA). 
All experiments were approved by the institutional Animal Welfare Committee 
of the Radboud University Medical Center and were conducted in accordance to the 
principles set forth by the Revised Dutch Act on Animal Experimentation.
Synthesis of DTPA-D2B-IRDye800CW 
The murine mAb D2B IgG (5 mg) was conjugated with N-hydroxysuccinimide (NHS)-
IRDye800CW (Li-Cor, Biosciences, Lincoln, NB) in 2 ml 0.1 M NaHCO3, pH 8.5, with a 
16-fold molar excess of NHS-IRDye800CW (620 μg). After 2 h of incubation at room 
temperature on an orbital shaker in the dark, IRDye800CW-D2B was purified by gel 
filtration on a PD10 column eluted with 0.1 M NaHCO3, pH 8.5. The conjugation ratio 
of the purified conjugate was determined on a Ultrospec 2000 spectrophotometer 
(Pharmacia Biotech) at wavelengths 280 nm and 774 nm and the substitution 
ratio was calculated using the formula: substitution ratio = 0.875*E774/(E280-
(0.03*E774)). The substitution ratio of the conjugate used in these studies was 1.2. 
Subsequently, p-isothiocyanatobenzyl-diethylene¬triamine¬penta¬acetic acid (ITC-
DTPA) (Macrocyclics, Dallas, USA) was added to the conjugate in 0.1 M NaHCO3, pH 
9.5 (2.5 ml), in a 27-fold molar excess (4.1 mg IRDye800CW-D2B with 481 μg ITC-
DTPA). After 1 h of incubation at room temperature on an orbital shaker in the dark, 
the reaction mixture was dialyzed for 3 days in a Slide-A-Lyzer (10-kDa cutoff, Pierce) 
against 0.25 M NH4Ac, pH 5.4.
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Radiolabeling of DTPA-D2B-IRDye800CW 
For biodistribution studies, IRDye800CW-D2B-DTPA (100 µg) was radiolabeled with 
32 MBq 111In (Covidien, Petten, the Netherlands) in 0.1 M MES buffer pH 5.4 (three 
times the volume of 111In-chloride) and incubated during 30 min at room temperature 
under metal-free conditions. For SPECT/CT studies, IRDye800CW-D2B-DTPA (35 
µg) was incubated with 280 MBq of 111In in 0.1 M MES buffer pH 5.4. Following 
incubation, 50 mM EDTA was added to the final concentration of 5 mM to chelate 
unincorporated 111In.
The labeling efficiency was determined by instant thin layer chromatography 
(ITLC) using 0.15 M citrate buffer, pH 6.0, as the mobile phase. The labeling efficiency 
was 85% for the biodistribution studies and 36% for the microSPECT/CT study. 111In-
DTPA-D2B-IRDye800CW was purified by gel filtration on a PD-10 column, and the 
radiochemical purity of the final dual label tracer was ≥ 97%, which was determined 
by ITLC.
Immunoreactivity
The immunoreactive fraction of the dual-labeled 111In-DTPA-D2B-IRDye800CW was 
compared to that of 111In-DTPA-D2B using freshly trypsinized LNCaP cells, essentially 
as described by Lindmo et al. [12, 13]. Briefly, a serial dilution of LNCaP cells (6.3 x 
105 to 1.0 x 106 cells/ml)  in 0.5 ml RPMI medium containing 0.5% BSA was incubated 
at 37 °C for 1 h with 0.002 pmol 111In-DTPA-D2B-IRDye800CW (350 Bq). To determine 
nonspecific binding, an excess of unlabeled DTPA-D2B-IRDye800CW (160 pmol) was 
added to a duplicate of the lowest cell concentration. After incubation, cells were 
centrifuged and washed with 500 µL RPMI medium containing 0.5% BSA. The activity 
in the vials and in the cell pellet was determined in the gamma counter (Wizard 3” 
1480, LKB-Wallac, Oy, Finland). The inverse of the specific cell bound activity was 
plotted against the inverse of the cell concentration, and the immunoreactive fraction 
was calculated from the y-axis intercept using GraphPad Prism software (version 5.03 
for Windows; GraphPad Software, La Jolla, USA).
Competitive binding assay
The IC50 of D2B IgG was determined in a competitive binding assay on LNCaP cells 
using 111In-labeled D2B as a tracer. LNCaP cells were grown to confluency in six-well 
plates, and incubated on ice for 2 h in 1 mL of binding buffer with 1.85 kBq of 111In-
labeled D2B IgG and increasing concentrations (0.005-300 nM) of unlabeled D2B IgG. 
Cells were washed with binding buffer after incubation and the cell-associated activity 
was measured in a gamma counter. IC50 values were calculated using GraphPad Prism 
software, version 5.03.
Biodistribution and NIRF imaging in mice with subcutaneous tumors
For biodistribution studies, four groups of male BALB/c nude mice bearing LNCaP
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(right flank) and PC3 (left flank) xenografts were intravenously injected into the tail 
vein with the dual-label conjugate 111In-DTPA-D2B-IRDye800CW (0.55 MBq, 2.0 μg/
mouse). Three additional mice (control group) were co-injected intravenously with 
an excess of unlabeled D2B IgG (300 µg/mouse) to determine nonspecific uptake of 
111In-DTPA-D2B-IRDye800CW. 
At 24, 48, 72 and 168 h after injection, four mice per time point (5 mice at 168 
h p.i.) were euthanized with CO2/O2 asphyxiation and tissues of interest (LNCaP and 
PC3 tumors, muscle, lung, spleen, kidney, liver, pancreas, stomach, duodenum, and 
prostate) were dissected, weighed and the radioactivity was measured in a gamma 
counter. Blood samples were obtained by heart puncture. For calculation of the 
uptake of radioactivity in each tissue as a fraction of the injected dose, an aliquot of 
the injection dose was counted simultaneously. 
The mice that were scheduled for biodistribution at 48 h after injection were 
imaged with an IVIS imaging system (Xenogen VivoVision IVIS Lumina II, Caliper Life 
Sciences, Lincolnshire, United Kingdom; acquisition time 5 min) prior to dissection. 
The control group of mice that received an excess of unlabeled D2B IgG in addition to 
intravenously injected 111In-DTPA-D2B-IRDye800CW was euthanatized and dissected 
as described above at 72 h after injection.
Dual-modality microSPECT/CT and NIRF imaging and image-guided 
surgery
Four male BALB/c nude mice with intraperitoneally growing LS174T-PSMA tumor 
nodules were intravenously injected with the dual-labeled 111In-DTPA-D2B-
IRDye800CW (8.5 MBq and 3.0 μg/mouse) and imaged at 48 h after injection on both 
the IVIS imaging system (acquisition time 5 min) and a small-animal microSPECT/CT 
scanner (U-SPECT II, MILabs, Utrecht, Netherlands) with a 1.0 mm diameter pinhole 
collimator tube (acquisition time 30 min). MicroSPECT/CT scans were performed pre-
operatively, followed by NIRF imaging of the mice in supine position after surgical 
relocation of skin, abdominal muscle layers, and peritoneum. After IVIS image 
acquisition, the visualized tumor lesions were resected, followed by NIRF imaging 
to control whether residual tumor tissue and positive surgical margins are in situ. In 
addition, microSPECT/CT scans were performed after resection of the tumor lesions 
using the same scanning parameters that were used for pre-operative evaluation. 
Scans were reconstructed with MILabs reconstruction software, which uses an 
ordered-subset expectation maximalization algorithm.
Statistical analysis
Statistical analyses were performed with Graphpad Prism, version 5.03 (GraphPad, 
La Jolla, CA). Results are presented as mean ± standard deviation (SD). 
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RESULTS
In vitro characterization
The immunoreactive fractions of 111In-DTPA-D2B-IRDye800CW and 111In-DTPA-D2B 
were 75% and 84%, respectively, indicating that the immunoreactivity of the D2B 
antibody was largely preserved during the two conjugation procedures. 
The IC50 value of D2B IgG was 3.7 nM (95% confidence interval (CI): 2.8 – 4.8 
nM).
Biodistribution studies and imaging of subcutaneous tumors
111In-DTPA-D2B-IRDye800CW specifically accumulated in the s.c. PSMA-positive 
LNCaP tumors reaching 12.5 ± 4.9% ID/g (n=4) at 24 h p.i., 26.1 ± 7.4% ID/g (n=4) at 
48 h p.i., 40.2 ± 4.0% ID/g (n=4) at 72 h p.i., and 45.8 ± 8.0% ID/g (n=5) at 168 h after 
injection (figure 1a). Tumor uptake in PSMA-negative PC3 xenografts was significantly 
lower at 48, 72, and 168 h after injection, reaching 9.8 ± 2.8% ID/g (n=4) at 24 h p.i. (p 
= 0.3768), 10.6 ± 2.3% ID/g (n=4) at 48 h p.i. (p = 0.0071), 10.4 ± 1.2% ID/g (n=4) at 72 
h p.i. (p < 0.0001), and 6.6 ± 1.3% ID/g (n=5) at 168 h p.i. (p < 0.0001). 
The uptake of 111In-DTPA-D2B-IRDye800CW remained low in most normal 
tissues, uptake in the liver ranged from 25.6 ± 7.2% ID/g at 24 h p.i. to 6.8 ± 1.3% ID/g 
at 168 h after injection (figure 1a). 
Tumor-to-blood ratios of PSMA+ LNCaP xenografts were 1.3 ± 0.3 (24 h p.i.), 
2.9 ± 0.9 (48 h p.i.), 5.3 ± 0.8 (72 h p.i.), and 9.4 ± 1.5 (168 h p.i.). Tumor-to-blood 
ratios of the PSMA- PC3 xenografts were significantly lower at 48, 72, and 168 h after 
injection (p < 0.0001), reaching 1.0 ± 0.1 (24 h p.i.), 1.1 ± 0.1 (48 h p.i.), 1.4 ± 0.2 (72 
h p.i.), and 1.4 ± 0.3 (168 h p.i.) (figure 1b). PSMA+-to-PSMA- tumor ratios were 1.2 
± 0.2 (24 h p.i.), 2.5 ± 0.7 (48 h p.i.), 3.9 ± 0.7 (72 h p.i.), and 7.2 ± 2.0 (168 h p.i.). At 
48 h after injection, accumulation of 111In-DTPA-D2B-IRDye800CW could be visualized 
in subcutaneous PSMA-positive LNCaP tumors using the IVIS fluorescence imager, 
while PSMA-negative tumors showed no fluorescent signal (figure 1c).
Tumor uptake of 111In-DTPA-D2B-IRDye800CW could be blocked by coinjection 
of an excess of 300 µg of unlabeled D2B IgG, resulting in nonspecific (non-PSMA-
mediated) uptake of 11.0 ± 1.41% ID/g (n=3) and 9.5 ± 2.9% ID/g (n=3) at 72 h p.i. in 
LNCaP and PC3 xenografts, respectively. This further confirms the specific uptake of 
111In-DTPA-D2B-IRDye800CW in the PSMA-expressing tumor.
Dual-modality microSPECT/CT and NIRF imaging in mice with i.p. 
tumors
Five BALB/c nude mice with intraperitoneal LS174T-PSMA tumors were imaged 
with both the IVIS fluorescence scanner and the microSPECT/CT small animal 
scanner at 48 h after injection of dual-label 111In-DTPA-D2B-IRDye800CW. A typical 
microSPECT/CT acquisition with corresponding fluorescence image in supine
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3.2Figure 1: a) Biodistribution of 111In-DTPA-D2B-IRDye800CW (0.55 MBq, 2.0 μg/mouse) 
in mice with subcutaneous PSMA+ LNCaP and PSMA- PC3 xenografts at several time 
points after injection. An excess of unlabeled D2B IgG (300 μg/mouse) was coinjected 
in one group of mice as a negative control. LNCaP-to-PC3 tumor ratios at 48 h p.i. 
were 2.5 ± 0.7., b) PSMA+ and PSMA- tumor-to-blood ratios at several time points after 
injection of 111In-DTPA-D2B-IRDye800CW, t test: * p < 0.0001, ** p < 0.0001, *** p < 
0.0001, c) For illustration purposes, a NIRF image of a mouse bearing a PSMA+ LNCaP 
tumor on the right flank (green arrow) and a PSMA- PC3 tumor on the left flank (blue 
arrow) at 48 h after i.v. injection of dual-labeled 111In-DTPA-D2B-IRDye800CW.
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Figure 2: Dual-modality fluorescence and microSPECT/CT imaging with dual-labeled 
111In-DTPA-D2B-IRDye800CW at 48 h after injection in a mouse with intraperitoneally 
growing LS174T-PSMA tumors. a) NIRF image (acquisition time: 5 min), b) corresponding 
microSPECT/CT images in supine position, c) NIRF image of muscle sample (above) and 
tumor (below) after resection. The green arrows indicate the PSMA+ tumor nodules.
position is shown in figure 2. LS174T-PSMA tumor lesions were specifically visualized 
by both imaging modalities. In case tumor nodules were located deeper in the 
peritoneal cavity, the fluorescent signals detected were less intense or even absent 
due to tissue absorption of the emitted photons (figure 3). 
Image-guided resection of intraperitoneal tumor nodules
After pre-operative evaluation of tumor lesions by microSPECT/CT, image-guided 
surgery of the tumor lesions was performed in mice with intraperitoneally growing 
LS174T-PSMA nodules. First, the exact tumor location was identified by NIRF 
imaging. Subsequently, all detected tumors were resected and additional NIRF and 
microSPECT/CT imaging was performed to ensure radical surgical resection. In figure 
4, the applicability of the dual-modality probe for intra-operative image-guided 
resection of the intraperitoneal tumor nodules is shown.
Radiant Efficiency
p/sec/cm2/sr
µW/cm2
Epi-fluorescence Epi-fluorescence
Radiant Efficiency
p/sec/cm2/sr
µW/cm2
  a)                                                               b)                             c)                 
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Figure 3: Dual-modality fluorescence and microSPECT/CT imaging with dual-labeled 
111In-DTPA-D2B-IRDye800CW of a mouse with several intraperitoneal LS174T-PSMA 
tumor nodules located at different depth in the peritoneal cavity performed at 48 h after 
injection. a) NIRF image (acquisition time: 5 min), b) and c) corresponding microSPECT/
CT images in supine and left lateral position, showing the limited penetrations depth 
of NIRF imaging. The arrows indicate two tumor nodules that are located superficial 
enough to be visualized with fluorescence imaging. Tumors located deeper inside the 
peritoneal cavity are not visualized with fluorescence imaging.
DISCUSSION
This study provides proof-of-principle for targeting PSMA-expressing prostate cancer 
in vivo with the dual-labeled 111In-DTPA-D2B-IRDye800CW in a prostate cancer model 
with subcutaneous and intraperitoneal tumor lesions. In addition, dual-modality 
image-guided surgery based on this dual-labeled conjugate was performed.
During surgery, detection of small cancer foci or positive surgical margins 
remains challenging and may be enhanced by NIRF imaging, which allows real-time 
intra-operative visualization of malignant tissues [7]. Non-targeted NIRF imaging 
based on the use of fluorescent nanoparticles is frequently used for sentinel lymph 
node detection in patients with various malignancies [14]. The first clinical proof-
of-concept studies using this sentinel lymph node mapping technique with dual-
modality nanocolloids show promising results in prostate cancer [15]. However, 
non-targeted agents are not tumor selective and hence cannot be used for real 
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Figure 4: Dual-modality fluorescence and 
microSPECT/CT imaging with dual-labeled 
111In-DTPA-D2B-IRDye800CW of a mouse with 
intraperitoneally growing LS174T-PSMA tumors. 
a) microSPECT/CT image of three i.p. PSMA+ 
tumors (green and blue arrows), and b) merged 
photograph and NIRF image of the mouse before 
resection of the three tumors. c) microSPECT/
CT image and d) merged photograph and NIRF 
image of the mouse after resection of the tumors. 
e) merged photograph and NIRF image of the 
tumors after resection, and f) biodistribution of 
111In-DTPA-D2B-IRDye800CW in mice with i.p. 
LS174T-PSMA tumors at 48 h after injection.
time visualization of tumor cells in resection margins. The use of targeted imaging 
approaches could allow more sensitive and real-time detection of cancerous foci 
and positive surgical margins in the submillimeter range and would permit patient-
tailored surgical interventions. Several groups so far have reported the use of 
fluorophores conjugated to monoclonal antibodies that target receptors such as the 
epidermal growth factor (EGF) receptor [16], HER2/neu receptor [17] or the vascular 
endothelial growth factor (VEGF) [18]. 
Targeted NIRF imaging to identify prostate cancer cells in intra-operative settings 
using PSMA as a target was introduced by Liu et al. [19], who conjugated the low 
molecular weight PSMA ligand CTT-54.2 with Cy5.5 and demonstrated the tumor-
binding potential of the Cy5.5-CTT-54.2 conjugate in vitro. Recently, the humanized 
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anti-PSMA mAb J591 has been conjugated with an ICG derivative by Nakajima and 
colleagues. This conjugate showed specific targeting of the s.c. PSMA-expressing 
tumors in mice [20]. Chen et al. [21] conjugated the anti-PSMA monoclonal antibody 
YC-27 with IRDye800CW. In mice with s.c. PC3-PIP tumors, tumor-to-nontarget ratios 
of 10 were obtained. Recently, Banerjee et al. synthesized the first dual-modality 
SPECT/NIRF imaging agent with affinity for the center of PSMA based on glutamate 
urea compound conjugated with both DOTA and IRDye800CW for targeting PSMA-
expressing prostate cancer in a subcutaneous mouse model [22]. 
In the present study, we show that NIRF-SPECT dual-modality imaging allows 
specific visualization of both subcutaneous and intraperitoneal prostate cancer 
tumors and provide proof-of-principle for image-guided surgery with 111In-DTPA-
D2B-IRDye800CW in mice with intraperitoneally growing, PSMA-expressing tumor 
nodules.
Specific accumulation of 111In-DTPA-D2B-IRDye800CW in the PSMA-expressing 
s.c. and i.p. tumor lesions was observed, while uptake in the other tissues remained 
low, except for the liver. Enhanced hepatic uptake of IRDye800CW-conjugated 
antibodies has been reported in previous studies. Cohen et al. [23] reported 
enhanced liver uptake of the dual-labeled antibodies 89Zr-cetuximab-IRDye800CW 
and 89Zr-bevacizumab-IRDye800CW in vivo, which was attributed to the lipophilicity 
and charge of the antibody conjugate. In this study, a substitution ratio of <2 was 
found to be optimal to prevent enhanced blood clearance and hepatic liver uptake. 
All s.c. and i.p. PSMA-expressing tumor lesions were clearly visualized with 
microSPECT/CT. On the corresponding IVIS fluorescence scans in an intra-operative 
setting, all intraperitoneal tumor nodules that were located superficially could be 
visualized. However, tumor nodules which are located deeper inside the peritoneal 
cavity may not be visualized, due to absorption of the emitted fluorescent light in 
tissues. Although the absorption coefficient of biological tissue is relatively low in 
the near-infrared region (700-900 nm), light of this wavelength can only penetrate 
up to a few millimeters in tissue [24]. Therefore, in addition to pre-operative tumor 
localization, dual-labeled NIRF and radionuclide targeting agents allow intra-operative 
mapping of deeper laying malignant tissue with a gamma probe. Subsequently, the 
exact position can be determined with NIRF imaging, indicating the additive value of 
dual-modality imaging for detection of tumor lesions, their resection and real-time 
in vivo margin assessment. 
Taken together, we showed that PSMA-expressing prostate cancer can be 
visualized sensitively and specifically with dual-modality microSPECT/CT and NIRF 
imaging with the newly developed 111In-DTPA-D2B-IRDye800CW conjugate in 
mice with s.c. and i.p. prostate cancer xenografts. For translation of dual-modality 
imaging of 111In-DTPA-D2B-IRDye800CW into the clinic, this antibody construct has 
to be considered as a new medicinal product, which has to be studied extensively 
regarding toxicological aspects before it can be tested. 
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Major advantage for clinical use is the integration of both SPECT/CT and NIRF imaging 
modalities in intra-operative settings to improve image-guided surgery, which could 
be applied for both for open laparatomy as well as for endoscopic procedures. 
CONCLUSION
Here, we demonstrate the feasibility of targeting PSMA-expressing prostate cancer 
with the dual-labeled 111In-DTPA-D2B-IRDye800CW imaging agent and provide 
proof-of-principle that dual-modality image-guided surgery using this conjugate is 
feasible.  Prostate cancer lesions were specifically and sensitively detected in vivo 
in a mouse model with intraperitoneal PSMA-expressing tumor nodules. In this 
setting, radionuclide imaging may allow pre-operative detection and intra-operative 
localization of tumor lesions, while NIRF imaging enables subsequent accurate 
delineation of tumor lesions and real-time assessment of resection margins. These 
preclinical findings encourage future clinical studies with targeted dual-label imaging 
probes for pre- and intra-operative guidance of prostate tumor resection, to achieve 
radical tumor resection. 
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ABSTRACT
Background
Radical removal of malignant lesions may be improved using tumor targeted dual-
modality probes that contain both a radiotracer and a fluorescent label, to allow for 
enhanced intra-operative delineation of tumor resection margins. Since pretargeting 
strategies yield high signal-to-background ratios, we evaluated the feasibility of a 
pretargeting strategy for intra-operative imaging in prostate cancer using an anti-
TROP-2 x anti-HSG bispecific antibody (TF12), in conjunction with the dual-labeled 
diHSG peptide (RDC018) equipped with both a DOTA chelate for radiolabeling 
purposes and a fluorophore (IRdye800CW) to allow near-infrared optical imaging.
Methods
Nude mice implanted s.c. with TROP-2-expressing PC3 human prostate tumor cells 
or with PC3 metastases in the scapular and suprarenal region were injected i.v. 
with 1 mg of TF12 and, after 16h of tumor accumulation and blood clearance, were 
subsequently injected with 10 MBq, 0.2 nmol/mouse of either 111In-RDC018 or 111In-
IMP288 as a control. Two hours post injection, both microSPECT/CT and fluorescence 
images were acquired, both before and after resection of the tumor nodules. 
After image acquisition, the biodistribution of 111In-RDC018 and 111In-IMP288 was 
determined and tumors were analyzed immunohistochemically. 
Results
The biodistribution of the dual-label RDC018 showed specific accumulation in the 
TROP-2 expressing PC3 tumors (12.4 ± 3.7% ID/g at 2h p.i.), comparable to 111In-
IMP288 (9.1 ± 2.8% ID/g at 2h p.i.). MicroSPECT/CT and near-infrared fluorescence 
(NIRF) imaging confirmed this TROP-2-specific uptake of the dual-label 111In-RDC018 
in both the s.c. and metastatic growing tumor model. In addition, PC3 metastases 
could be visualized preoperatively with SPECT/CT and could subsequently be resected 
by image-guided surgery using intra-operative NIRF imaging.
Conclusion
We provide preclinical feasibility of a novel pretargeted dual-modality imaging 
approach in prostate cancer that allows for image-guided resection of TROP-2-
expressing tumors.
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INTRODUCTION
Despite advances in diagnostic procedures and clinical management prostate cancer 
remains associated with significant morbidity and is the second leading cause of 
cancer-related deaths in men in the Western world. 
At present, extensive research is focused on the development of new molecular 
imaging techniques to improve detection and staging of this disease. In this regard, 
radiolabeled antibodies that target prostate cancer-associated cell surface antigens 
appear to be particularly promising. This is supported by the clinical application 
of the PSMA-directed antibody capromab pendetide, also known as ProstaScint® 
(7E11-C53), or the antibody J591 [1]. However, antibodies typically show slow 
clearance from the circulation (t½ = 2-3 days), which requires a relatively long 
interval between time of injection of the radiolabeled antibody and subsequent 
image acquisition in order to achieve adequate contrast. In addition, the slow 
blood clearance results in limited target-to-background ratios. To overcome these 
limitations and to improve targeting of tumors, various pretargeting techniques 
have been developed. Previously, we reported a study in which we evaluated a 
pretargeting approach that targets TROP-2-expressing prostate cancer [2]. TROP-
2, also known as EGP-1 (epithelial glycoprotein-1), is a 46-kDa transmembrane 
glycoprotein expressed on diverse carcinomas, such as of the lung, bladder, breast, 
cervix, ovary, stomach and prostate [3]. We previously applied the trivalent bispecific 
antibody (bsAb) TF12, which consists of two anti-TROP-2 Fab fragments and one anti-
HSG (histamine-succinyl-glycine) Fab fragment. In this strategy, an unlabeled bsAb 
with affinity for both the tumor cell and a radiolabeled diHSG peptide was injected. 
After TF12 had accumulated in the tumor and was cleared from the blood, the 111In-
labeled diHSG peptide IMP288 was administered, which was rapidly and selectively 
trapped at the tumor. This method allowed for imaging within 1-2 h after injection of 
the radiolabeled peptide while yielding high target-to-background ratios. 
At present, surgical removal of prostate cancer lesions is the treatment of 
choice for patients with low- and intermediate-risk localized disease, and in selected 
patients with high-risk localized disease [4]. The use of intra-operative imaging might 
guide the surgeon in the detection of malignant tissue which might improve the 
outcome, and reduce morbidity and treatment-related side effects. However, the 
application of nuclear imaging-based pretargeting strategies appears to be limited 
for intra-operative imaging purposes as tumor tissue cannot be delineated precisely 
by radionuclide detection in the intra-operative setting. 
Near-infrared fluorescence (NIRF) imaging with fluorophores conjugated to 
tumor targeting agents is rapidly emerging as a new sensitive intra-operative imaging 
technique for improved and real-time detection of malignant lesions during surgery. 
However, the penetration depth of both excitation and emission light in tissues 
is usually limited to several millimeters [5]. One strategy to deal with this limited 
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penetration depth is combining NIRF and radionuclide imaging techniques. With this 
dual-modality approach, the burden of the disease could be assessed pre-operatively, 
followed by localization of the tumor lesions intra-operatively using a gamma probe, 
and subsequent intra-operative guidance for surgical removal of the tumor lesions 
based on the fluorescent component of the dual-label agent.
Here, we evaluated a bispecific antibody-based pretargeting strategy for 
prostate cancer preclinically, using a novel hapten, designated RDC018, which was 
equipped with both a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA) chelate for radiolabeling and the fluorophore IRDye800CW for NIRF imaging. 
The DOTA chelate of RDC018 was labeled with 111In. The pretargeting characteristics 
of the TF12/RDC018 approach were evaluated in a mouse tumor model bearing 
TROP-2-expressing prostate cancer metastases. In addition, the feasibility of this 
dual-label pretargeting strategy for image-guided surgery based on microSPECT/CT 
and NIRF imaging was investigated. 
MATERIALS AND METHODS
Pretargeting reagents TF12 and RDC018
BsAb TF12, having both TROP-2- and HSG-binding specificities, was produced 
using the Dock-and-Lock® technology as described previously by Rossi et al. [6]. 
The NIR fluorescent peptide RDC018 is a peptide-hapten derived from IMP288, a 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated D-Tyr-
D-Lys-D-Glu-D-Lys tetrapeptide, in which both lysine residues are substituted with an 
HSG moiety. In addition to the DOTA chelator for radiolabeling, RDC018 also contains 
a NIR fluorescent IRDye800CW moiety (figure 1).
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Cell Culture
The TROP-2-expressing human prostate cancer cell line PC3, originally derived 
from a prostate cancer bone metastasis was obtained from American Type Culture 
Collection (CRL 1435, Manassas, VA, USA). Cells were cultured in RPMI 1640 medium, 
supplemented with 10% fetal calf serum (Life technologies, Carlsbad, CA) and 2 mM 
glutamine.
Mouse Models
Male BALB/c nude mice (Janvier, Le Genest Saint Isle, France), 8-9 weeks old, housed 
in individual ventilated cages (5 mice per cage) under nonsterile standard conditions 
with free access to standard animal chow and water, were adapted to laboratory 
conditions for one week before experimental use. Mice were subcutaneously 
inoculated with 3 x 106 PC3 cells (right flank) suspended in 200 µL of 67% complete 
RPMI 1640 medium with 33% matrigel (BD Biosciences, Franklin Lakes, NJ). PC3 
xenografts grew to approximately 0.1 g in 7 days after tumor cell inoculation. To 
induce metastatic prostate cancer growth, mice were anesthetized with isoflurane 
and 5 x 105 PC3 cells in 50 µl of PBS were inoculated with a 30-gauge needle through 
the diaphragm into the left cardiac ventricle after midline incision [7]. PC3 metastases 
were allowed to grow for 10 - 12 weeks after tumor cell inoculation.
All experiments have been approved by the institutional Animal Welfare 
Committee of the Radboud University Medical Center and were conducted in 
accordance to the guidelines of the Revised Dutch Act on Animal Experimentation.
Radiolabeling of IMP288 and RDC018
IMP288 was labeled with 111In (Covidien, Petten, The Netherlands) at a specific 
activity of 60.5 MBq/nmol under strict metal-free conditions. Briefly, 60 MBq of 111In 
was added to 2.4 µg of IMP288 in 0.1 M MES buffer pH 5.4 (three times the volume 
of 111In-chloride) during 20 min of incubation at 95°C. Following incubation, 50 mM 
ethylenediaminetetraacetic acid (EDTA) was added to the labeling reaction to a final 
concentration of 1mM EDTA to chelate unincorporated 111In. The labeling efficiency, 
determined by instant thin layer chromatography on silicagel strips (ITLC-SG; Gelman 
Sciences, Ann Arbor, MI, USA) using 0.1 M ammonium acetate (NH4Ac) buffer with 
0.1 M EDTA (pH 5.5) as the mobile phase, reached 97%.
RDC018 was radiolabeled under metal-free conditions at a specific activity of 
25.5 MBq/nmol. For this reaction, 127 MBq of 111In was added to 7.2 µg of RDC018 
in 0.1 M MES buffer pH 5.4 (three times the volume of 111In-chloride) for 20 min of 
incubation at 95°C. For imaging and image-guided surgery, 2.5 µg of RDC018 was 
radiolabeled with 32 MBq (specific activity 18.5 MBq/nmol). After incubation, 50 
mM ethylenediaminetetraacetic acid (EDTA) was added to the labeling reaction to 
a final concentration of 1mM EDTA. The labeling efficiency for the RDC018 labeling 
reaction ranged between 87 and 97%. 
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Immunoreactivity
To demonstrate bispecific immunoreactivity of TF12, a serial dilution of PC3 cells 
in RPMI medium containing 0.5% BSA (1.6 x 106 to 2.6 x 107 cells in 0.5 ml) was 
incubated with TF12 (50 μg/ml) for 30 min at 37°C. Cells were washed twice in RPMI 
medium containing 0.5% BSA followed by incubation with 111In-RDC018 (250 Bq). 
To determine nonspecific binding, a duplicate of the lowest cell concentration was 
incubated without TF12. After incubation, cells were centrifuged and washed with 
500 µl RPMI medium containing 0.5% BSA. The activity in the vials and in the cell 
pellet was determined in a gamma counter (Wizard 3” 1480, LKB-Wallac, Oy, Finland).
 
Immunohistochemical analysis of TROP-2-expressing tumors
Expression of TROP-2 in subcutaneous PC3 tumors was determined 
immunohistochemically on 5-µm frozen tissue sections. The tissue sections were 
fixed with aceton (100%) for 10 min at -20°C. After overnight drying, the sections 
were blocked with 20% normal goat serum (Bodinco) for 30 minutes and stained with 
the anti-TROP-2 humanized monoclonal antibody hRS7 (4 µg/ml antibody in PBS 1% 
BSA) for 1 hour at room temperature under light-protected conditions. Subsequently, 
the tissue sections were washed in PBS and stained with a secondary goat-anti-
human HRP (Abcam, Cabridge, UK) at a dilution of 1:100 in PBS, 1% BSA, for 30 min at 
room temperature. After incubation, the tissue sections were washed with PBS three 
times. Finally, tumor sections were incubated with 0.019 g of 3,3-diaminobenzidine 
tetrahydro-chloride (DAB) substrate (Bright DAB, Immunologic, Duiven, Netherlands) 
in 25 ml PBS and 62.5 µl H2O2 for 10 min for development, followed by a hematoxylin 
counterstaining. Immunohistochemical analysis of the resected s.c. PC3 tumors 
revealed TROP-2 expression in all tumors (not shown).
Pretargeted immuno-SPECT/CT and NIRF imaging
In the first experiment, male BALB/c nude mice (n=4) with subcutaneous PC3 
xenografts in the right flank were intravenously injected into the tail vein with 
1 mg of TF12 (6.4 nmol) in 200 µl of PBS followed by i.v. injections of either 111In-
RDC018 (10 MBq, 0.6 µg (0.2 nmol)) or 111In-IMP288 (10 MBq, 0.4 µg (0.2 nmol)) 16 
h later. Two additional groups of mice (n=2) did not receive TF12 prior to injection 
of the radiolabeled peptide to determine the non-TF12-mediated localization of the 
peptide. One of these groups received only 111In-RDC018 (10 MBq, 0.6 µg/mouse) 
and one group received only 111In-IMP288 (10 MBq, 0.4 µg/mouse).
Two hours after injection of 111In-RDC018, mice were anesthetized with 
isoflurane and imaged on a small-animal microSPECT/CT scanner (U-SPECT II, 
MILabs, Utrecht, Netherlands) with a 1.0 mm diameter pinhole collimator tube 
(acquisition time 30 min) in prone position. After microSPECT/CT imaging, the mice 
were euthanized by O2/CO2 asphyxiation and NIRF images were acquired on an IVIS 
imaging system (Xenogen VivoVision IVIS Lumina II, Caliper Life Sciences, Lincolnshire, 
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United Kingdom; acquisition time 5 min, binning: medium, Fstop: 2, excitation: 745 
nm, excitation autofluorescence: 675 nm, emission: ICG, lamp level: high, FOV: D). 
MicroSPECT/CT scans were reconstructed with MILabs reconstruction software, 
which uses an ordered-subset expectation maximalization algorithm. 
Biodistribution of pretargeted 111In-RDC018 and 111In-IMP288
Subsequently, the biodistribution in mice (n=4) with s.c. PC3 tumors of 111In-RDC018 
was compared to that of 111In-IMP288. Tissues of interest (tumor, muscle, lung, 
spleen, kidney, liver, pancreas, stomach, duodenum and prostate) were dissected, 
weighed and the radioactivity was measured in a gamma counter to determine the 
biodistribution of 111In-IMP288 and 111In-RDC018. Blood samples were obtained by 
heart puncture. For calculation of the uptake of radioactivity in each tissue as a fraction 
of the injected dose, an aliquot of the injection dose was counted simultaneously. 
Dual-modality microSPECT/CT and NIRF image-guided surgery
In the second experiment, male BALB/c nude mice (n=20) with PC3 metastases 
in the submandibular, shoulder, and adrenal gland region that developed after 
injection of PC3 cells into the right cardiac ventricle were injected intravenously 
with the bsAb TF12 (1 mg/mouse), followed by i.v. injection of 111In-RDC018 (0.6 µg/
mouse, 20 MBq/µg) at 16 h after injection of TF12. Mice were imaged 2 hours later 
on both the IVIS imaging system  and a small-animal microSPECT/CT scanner with 
the same settings as in the first experiment. MicroSPECT/CT scans were performed 
pre-operatively, followed by NIRF imaging of the mice in the supine position after 
surgical removal of skin, abdominal muscle layers, and peritoneum. After NIRF image 
acquisition, the visualized tumor lesions were resected, followed by NIRF imaging 
to check whether residual tumor tissue was left in situ. In addition, microSPECT/CT 
scans were performed after resection of the tumor lesions, using the same scanning 
parameters that were used for pre-operative evaluation. 
Statistical analyses
Statistical analyses were performed with Graphpad Prism, version 5.03 (GraphPad, 
La Jolla, CA, USA). Results are presented as mean ± standard deviation (SD). To 
determine statistical differences, unpaired t-tests were used.
RESULTS
In vitro characterization
Analysis of the bispecific immunoreactivity of TF12 revealed that in the in vitro 
assay up to 82% of the added peptide specifically bound to the PC3 cells (results not 
shown). 
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Tumor growth and development of metastases
Subcutaneous PC3 tumors in the right flank reached a tumor size of approximately 
0.1 g at 7 days after tumor cell inoculation. To induce metastases, mice (n=20) 
received injections of PC3 cells into the left cardiac ventricle. The mice were 
dissected after 10-12 weeks and soft-tissue PC3 metastases were most frequently 
found in the submandibular, shoulder, and adrenal gland region. In addition, several 
PC3 metastases were found in the rectovesical pouch. Besides the formation of soft-
tissue PC3 metastases at different anatomical sites, microCT imaging showed the 
development of PC3 bone metastases in the vertebral column (n=3) and in the ribs 
(n=2) of the mice.
Biodistribution of 111In-RDC018 and 111In-IMP288
111In-RDC018 and 111In-IMP288 specifically accumulated in the s.c. TF12-pretargeted 
TROP-2-expressing PC3 tumors (right flank). Uptake of 111In-RDC018 and 111In-IMP288 
in the PC3 tumor was comparable at 2 h after injection (12.4 ± 3.7% ID/g (n=4) and 
9.1 ± 2.8% ID/g (n=4), respectively), figure 2a. Tumor uptake of 111In-RDC018 and 
111In-IMP288 in non-pretargeted tumors was significantly lower, reaching 2.1 ± 0.3% 
ID/g (p=0.020) and 2.2 ± 0.0% ID/g (p=0.029) for 111In-RDC018 and 111In-IMP288, 
respectively. Overall, the biodistribution profiles of 111In-RDC018 and 111In-IMP288 
show similar patterns (figure 2a). One essential difference in the biodistribution 
profiles of 111In-RDC018 and 111In-IMP288 after pretargeting with TF12 is renal 
accumulation. While the accumulation of 111In-IMP288 in the kidneys was relatively 
low (2.4 ± 0.6% ID/g), renal uptake of 111In-RDC018 was significantly higher, reaching 
7.6 ± 0.9% ID/g at 2 h after injection (p<0.0001). In addition, blood levels of 111In-
RDC018 were significantly higher compared to 111In-IMP288 (4.7 ± 0.6% ID/g and 1.7 
± 0.9% ID/g (p=0.0016), respectively), indicating slower blood clearance. Moreover, 
liver uptake of 111In-RDC018 and 111In-IMP288 differed significantly, reaching 2.8 ± 
0.3% ID/g for 111In-RDC018 and 1.1 ± 0.4% ID/g for 111In-IMP288 (p=0.0006). Tumor-
to-blood ratios of 111In-RDC018 and 111In-IMP288 in the TF12-pretargeted tumors 
were 2.6 ± 0.7 and 5.9 ± 2.0 (p=0.021), respectively. 
Pretargeted immuno-SPECT/CT and NIRF imaging
Five BALB/c nude mice with s.c. TROP-2-expressing PC3 tumors (right flank) were 
imaged by both fluorescence imaging and microSPECT/CT at 2 h after injection of 
111In-RDC018 (18 h after pretargeting with TF12). A typical microSPECT/CT image 
with the corresponding fluorescence image of a mouse in prone position is shown in 
figure 2b. The PC3 xenograft was clearly and specifically visualized with both imaging 
modalities. 
Dual-modality microSPECT/CT and NIRF image-guided surgery
BALB/c nude mice with PC3 metastases were imaged by both fluorescence imaging
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and microSPECT/CT at 2 h after injection of radiolabeled RCD018. A typical example 
of a microSPECT/CT image with corresponding NIRF image of a mouse with two bone 
metastases in the vertebral column is shown in figure 3. Another example of dual-
modality microSPECT/CT and NIRF imaging of a mouse with TF12-pretargeted bone 
metastases originating from the ribs is depicted in figure 4. 
After pre-operative evaluation of tumor lesions by microSPECT/CT, image-
guided surgery of the tumor lesions was performed. First, the exact tumor location 
was identified by NIRF imaging. Subsequently, these tumor lesions were resected 
and NIRF and microSPECT/CT imaging was repeated to ensure radical surgical 
resection. In figure 5, the feasibility of the dual-modality probe for intra-operative 
image-guided surgical resection of the metastatic tumor nodules is shown.
DISCUSSION
In the present preclinical study, the in vivo tumor targeting characteristics of the dual-
modality fluorescent 111In-labeled hapten RDC018 in TROP-2-expressing prostate 
Figure 2: a) Biodistribution of 111In-RDC018 and 111In-IMP288 in BALB/c nude mice with 
TF12-pretargeted s.c. PC3 xenografts (right flank) measured at 2 h after injection of the 
radiolabeled haptens (n=4). Two groups of mice did not receive TF12 prior to injection 
of the radiolabeled haptens to determine non-specific binding. Tumor uptake for both 
111In-RDC018 and 111In-IMP288 was significantly higher in the TF12-pretargeted tumors 
compared to non-pretargeted tumors. b) Representative SPECT/CT (panel 1) and NIRF 
image (panel 2) of a BALB/c nude mouse with a TF12-pretargeted s.c. PC3 xenograft (right 
flank) at 2 h after injection of 111In-RDC018. In addition to tumor uptake, rest activity 
originating from renal excretion of the hapten was observed on the SPECT/CT image.
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Figure 3: Sequentially acquired dual-modality microSPECT/CT and NIRF image with 111In-
RDC018 in a mouse with two TF12-pretargeted tumors. PC3 bone metastases located 
in 2 vertebrae with soft tissue outgrowth were visualized 2 h after injection of 111In-
RDC018. a) CT scan illustrating the alterations in bone structure in the two vertebrae, b) 
microSPECT/CT scan showing uptake in the bone metastases with soft tissue outgrowth, 
as well as accumulation in kidneys and bladder due to renal excretion of 111In-RDC018 c) 
corresponding NIRF image showing specific uptake in both PC3 metastases and kidneys.
Figure 4: Sequentially acquired dual-modality microSPECT/CT and NIRF image with 
111In-RDC018 (12 MBq, 0.5 µg/mouse) in a mouse with two TF12-pretargeted PC3 bone 
metastases originating from the ribs. Images were acquired 2 h after injection of 111In-
RDC018. a) MicroSPECT/CT scan showing kidneys, bladder and two tumor manifestations 
(green and blue arrow), b) photographs of exposed metastases, and c) corresponding 
NIRF images showing specific uptake of 111In-RDC018 in both PC3 metastases.
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cancer pretargeted with the trivalent bsAb TF12 were evaluated. The feasibility of 
this approach for image-guided surgery was demonstrated in mice bearing TROP-
2-expressing metastases. In a previous study, the potential for imaging pretargeted 
prostate cancer with the bsAb TF12 and the radiolabeled hapten IMP288 was 
evaluated [2]. It was shown in mice with s.c. PC3 tumors that this pretargeting 
approach allows for rapid and sensitive imaging of TROP-2-expressing prostate 
cancer. For intra-operative imaging purposes, radionuclide detection can be used to 
localize tumor nodules with a gamma probe; however, precise delineation of tumor 
lesions or assessment of tumor cell-containing surgical margins remains challenging 
with this modality. NIRF imaging is a sensitive technique that may be exploited to 
improve visualization of small to microscopic malignant lesions and potentially of 
positive resection margins during surgery. 
So far, several preclinical studies have evaluated methods to intra-operatively 
visualize tumor tissue and resection margins in prostate cancer [8-10]. Targeted 
approaches using antibodies or peptides are particularly promising to apply 
dual-modality imaging. Very recently, the first clinical trial using the anti-VEGF 
antibody bevacizumab tagged with the NIRF dye IRDye800CW (clinicaltrials.gov, 
NCT01508572) has begun, with the aim to show the feasibility of tumor-targeted 
intra-operative fluorescence imaging in breast cancer patients. Since the penetration 
depth of emitted light in tissue is limited to several millimeters, the combination with
Figure 5: MircoSPECT/CT and NIRF image-guided surgery with 111In-RDC018 in a TF-12 
pretargeted PC3 soft-tissue metastasis located below the scapular bone. Images were 
acquired at 2 h after injection of 111In-RDC018. a) microSPECT/CT image prior to resection, 
b) NIRF image before resection illustrating the limited penetration depth of the emitted 
fluorescent light, since the tumor is located below a bony structure, c) NIRF image after 
lifting the scapular bone to the left hand-side, exposing the tumor, d) microSPECT/CT 
image after resection, and e) corresponding NIRF image after resection.
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a radiolabel would allow intra-operative probe-guided tumor detection and image-
guided surgery. 
In the present study, analysis of biodistribution of 111In-RDC018 and 111In-
IMP288 showed that the addition of the IRDye800CW fluorophore to the IMP288 
diHSG peptide hapten only slightly affected the in vivo behavior of the molecule. The 
overall biodistribution profile of both peptides was similar, however, RDC018 showed 
enhanced hepatic uptake. Previously, this has also been observed for IRDye800CW 
conjugated antibodies [11] and may be due to the increased lipophilicity of RDC018 
compared to IMP288.
Biodistribution studies demonstrated high and specific PC3 tumor targeting 
for both 111In-RDC018 as well as 111In-IMP288. Using this subcutaneous tumor 
model, we provide proof-of-principle that 111In-RDC018 can be used for rapid dual-
modality imaging of TROP-2-expressing tumors. As early as 2 hours after injection, 
high tumor-to-background ratios were achieved. With both imaging modalities, 
the fluorescent 111In-labeled hapten-peptide RDC018 accumulated specifically in 
the TROP-2-expressing PC3 tumors, whereas no specific tumor targeting with 111In-
RDC018 was observed in mice with subcutaneous tumors that were not pretargeted 
with TF12. Accordingly, the non-pretargeted PC3 tumors were not visualized by NIRF 
imaging. These results clearly demonstrate that the accumulation of 111In-RDC018 
is TF12-mediated. While the uptake of 111In-RDC018 in other tissues remained low, 
intermediate accumulation in the kidneys was observed, which is most likely caused 
by renal clearance of the peptide. The enhanced renal retention of RDC018 compared 
to that of IMP288 suggests increased tubular reabsorption of the dual-labeled 
peptide in the kidneys. High accumulation of small-sized fluorescent tracers has been 
observed previously. Banerjee and colleagues synthesized a dual-label PSMA ligand 
(based on glutamate urea) which was tagged with both 111In and IRDye800CW for 
targeting PSMA-expressing prostate cancer in mice with subcutaneous xenografts 
[12]. In this study, high tumor uptake in the PSMA-expressing PC3-PIP xenografts was 
observed, while uptake in the PSMA-negative PC3-FLU tumors remained low. Both 
tumor cell lines were derived from PC3 human prostate cancer cells and only differ in 
their expression of PSMA (PIP: PSMA+, FLU: PSMA-). PSMA-expressing tumors could 
be visualized specifically on both SPECT/CT and NIRF imaging. However, intense 
radiotracer uptake was observed in the kidneys, which was attributed to the tracer’s 
route of excretion and specific uptake by PSMA expressed in the kidneys.
In addition to biodistribution and NIRF imaging experiments, we performed 
sequential dual-modality microSPECT/CT and NIRF imaging to demonstrate the 
feasibility of this pretargeting approach using the bsAb TF12 and the dual-label 
fluorescent hapten-peptide 111In-RDC018. Preferential accumulation of the dual-
label hapten-peptide 111In-RDC018 was confirmed with both NIRF and microSPECT/
CT imaging in TROP-2-expressing soft-tissue and bone metastases. PC3 metastases 
could be visualized clearly with both microSPECT/CT and NIRF imaging, showing
167
PRETARGETED DUAL-MODALITY IMAGING OF PROSTATE CANCER
3.3
accurate conformity of single tumor lesions by both imaging modalities. In addition, 
image-guided surgery based on microSPECT/CT and NIRF images was performed 
to provide proof-of-principle for feasibility of using this pretargeting approach for 
intra-operative detection of tumor lesions. It was shown that metastases imaged by 
microSPECT/CT and NIRF prior to surgery could be resected with image-guidance 
using this pretargeting approach. Moreover, NIRF imaging could be performed intra-
operatively to ensure that the tumor tissue was resected completely without leaving 
visible tumor-cell containing resection margins in situ. MicroSPECT/CT imaging, 
which was performed after surgery to exclude false negative observations from intra-
operatively conducted NIRF imaging, confirmed complete resection of all metastatic 
tumor lesions. 
In summary, we showed that TF12-pretargeted TROP-2-expressing prostate 
cancer can be visualized with both microSPECT/CT and NIRF imaging using the dual-
label near-fluorescent 111In-labeled hapten-peptide RDC018. In addition, proof-of-
principle was provided that this dual-label pretargeting approach can be used for 
image-guided surgery of TROP-2-expressing metastatic prostate cancer lesions. To 
translate this dual-modality pretargeting approach to the clinic, the safety, feasibility, 
and validity of this approach need to be evaluated.
CONCLUSION
Compared to targeting approaches using dual-labeled antibodies, pretargeting 
strategies may yield better signal-to-background ratios. Here, we show feasibility of 
the 111In-labeled near-infrared fluorescent hapten-peptide RDC018 for dual-modality 
detection of prostate cancer metastases in a mouse model of TROP-2-expressing soft-
tissue and bony prostate cancer metastases pretargeted with the bsAb TF12. Both 
soft-tissue as well as bony prostate cancer lesions were specifically and sensitively 
detected in vivo. While radionuclide imaging may allow pre-operative detection 
and intra-operative localization of tumor lesions, NIRF imaging enables subsequent 
accurate delineation of tumors and real-time assessment of resection margins. In 
addition, proof-of-principle for image-guided resection of metastatic lesions using 
this dual-modality pretargeting approach was provided. 
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GENERAL DISCUSSION
Prostate cancer is one of the most common causes for morbidity and mortality in men 
worldwide. One of the major reasons for the high mortality is the difficulty to detect 
prostate cancer in an early and potentially curable stage. The timely detection of 
prostate cancer requires reliable and highly sensitive imaging techniques. Currently, 
the most commonly used imaging technique for prostate cancer is transrectal 
ultrasound (TRUS), which is also used to perform image-guided biopsies. However, 
TRUS has only limited sensitivity and is unable to differentiate benign processes, such 
as benign prostatic hyperplasia (BPH), atrophy and inflammation, from malignant 
disease in the prostate gland. In case of negative biopsies, but persisting clinical 
suspicion for malignant involvement of the prostate, computed tomography (CT) and 
magnetic resonance imaging (MRI) may be applied [1]. While CT can be used for the 
detection of metastatic spread to lymph nodes, organs, and bones, MRI provides 
more accurate visualization of the prostate, which allows more reliable detection 
of malignant lesions. Currently, extensive research has been focused on magnetic 
resonance (MR)-guided biopsies to improve the sensitivity in the detection of cancer 
lesions compared to TRUS. Other innovative imaging techniques such as diffusion 
weighted MRI (DWI), MR spectroscopy (MRS), and dynamic contrast-enhanced 
MRI (DCE-MRI) allow functional assessment of the disease, which results in more 
precise staging and follow-up. With DWI, the restricted diffusion of water molecules 
in malignant tissue can be visualized. As prostate cancer usually has relatively tight 
glandular elements with increased cellular density and decreased extracellular 
space, high signal intensity foci on DWI can be obtained. However, differentiation 
between benign and malignant lesions remains challenging as benign lesions can 
show low water diffusion as well [2]. With DCE-MRI, tumor vascularization can be 
visualized by quantitative kinetic parameters that reflect blood flow and vascular 
permeability. However, visualization of small tumors in particular remains a challenge 
as angiogenesis might not be prominent in early stages. An advanced approach to 
detect malignant involvement of lymph nodes is high resolution MRI combined with 
lymphotropic superparamagnetic (ultra) small particles of iron oxide, (U)SPIO, which 
relies on visualization of macrophage activity. However, the clinical use of USPIO-MRI 
is limited by several disadvantages, in particular the limited sensitivity of USPIO-MRI 
in small lymph nodes (<5 mm) [3], but also by the requirement for specific expertise 
and its rather time consuming nature.
Positron Emission Tomography (PET) is another imaging technique that allows 
for visualization of cellular and molecular processes that are associated with 
biological features of tumors. The standard functional imaging agent for PET in 
oncology is 18F-FDG, which visualizes the enhanced glucose demand of malignant 
cells. Unfortunately, 18F-FDG based PET is not suitable for imaging of prostate 
cancer in early stages as a large fraction of prostate cancers show only a limited
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18F-FDG uptake [4]. Another tracer for PET imaging is choline which can be labeled 
with 11C or 18F. The use of choline relies on the fact that it is a key precursor in the 
biosynthesis of phosphatidylcholine, a major component of the cell membrane. 
Eschmann et al. [5] compared 11C-choline PET/CT with conventional whole-body MRI 
and reported a better overall diagnostic performance with 11C-choline PET/CT with 
a higher detection rate of lymph node metastases. However, 11C- or 18F-choline PET/
CT still has limited sensitivity and strongly depends on tumor configuration [6]. In 
addition, the specificity of this tracer in differentiation of prostate cancer tissue from 
benign pathologies is limited [7].
Therefore, other approaches need to be identified that are more suitable for 
the detection of prostate cancer lesions. Extensive research has focused on targeting 
prostate cancer with alternative radiolabeled metabolite tracers, receptor binding 
ligands, or antibodies against prostate cancer-associated cell surface antigens. 
Several promising targets for prostate cancer imaging have been identified, such 
as the prostate stem cell antigen (PSCA) or the gastrin releasing peptide receptor 
(GRPR). One of the first radiolabeled bombesin analogs which target GRPR, Cu-64-
DOTA-8-amino-octanoicacid-bombesin, was introduced by Rogers et al. [8]. In this 
study, specific tumor localization of 64Cu-labeled bombesin in mice with PC-3 prostate 
cancer xenografts was demonstrated by microPET imaging and biodistribution 
studies. However, clinical implementation was prevented by the high uptake of 64Cu-
labeled bombesin in normal tissues. So far, several bombesin agonists such as PESIN 
or AMBA and antagonists such as Demobesin-1 have been developed for targeting 
GRPR-expressing prostate cancer [9]. 
Another promising target for prostate cancer imaging is the prostate specific 
membrane antigen (PSMA) which is of particular interest due to its selective 
overexpression in prostate cancer in nearly all stages of the disease. Initial validation 
of PSMA as an in vivo target came from imaging trials with the 111In-labeled 
monoclonal antibody (mAb) capromab pendetide (7E11/CYT-356, Prostascint®) [10], 
which is an FDA approved agent for diagnostic imaging in patients with biopsy-proven 
prostate cancer who are at high risk for pelvic lymph node metastases [11]. However, 
capromab pendetide appears to be a suboptimal imaging agent for prostate cancer, 
as it is directed against an epitope on the intracellular domain of PSMA [12]. It has 
been postulated that capromab pendetide may only bind to dying or necrotic cells 
with cellular membranes that are permeable to the antibody. Our results confirm 
that capromab pendetide indeed binds to the intracellular domain of PSMA. 
Recently, new anti-PSMA monoclonal antibodies have been generated that bind to 
an extracellular domain of PSMA, including the mAb D2B. Our results demonstrate 
that mAb D2B binds to viable tumor cells without the need for internalization. This 
indicates that clinical application of D2B for imaging of prostate cancer is feasible.
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Previous studies indicated that tumor targeting can be further optimized by the use 
of antibody fragments instead of intact IgG antibodies [13, 14]. Intact antibodies 
clear relatively slowly from the circulation and usually reach maximum tumor uptake 
3 - 7 days after injection. The slow accumulation of intact antibodies has been 
attributed to the presence of various physiological barriers between antibodies in the 
circulation and the tumor cell surface [15]. Antibody fragments such as F(ab’)2 and 
Fab fragments are cleared more rapidly from the circulation, which on the one hand 
leads to lower uptake in the tumor compared to intact IgG molecules. On the other 
hand, high tumor-to-background ratios can be reached, because antibody fragments 
diffuse more rapidly in the interstitial fluid compared to intact antibodies and clear 
more rapidly from the nontarget tissues. In this thesis, we have shown that these 
principles apply for imaging of PSMA-expressing prostate cancer. The use of 111In-
F(ab’)2 and 
111In-Fab fragments derived from of D2B IgG might be advantageous in 
settings where imaging is required early after injection. Intact D2B IgG in contrast has 
a higher absolute uptake in the tumor, which may be desirable in diagnostic settings 
where detection of small lesions depends on high absolute tumor uptake.
Recently, several PSMA-targeting peptides have been developed that might further 
improve prostate cancer imaging, as these small-sized peptides are cleared from the 
circulation even faster compared to antibody fragments. So far, several high-affinity 
small-molecule inhibitors of PSMA have been developed that might be suitable 
for prostate cancer imaging, such as 123I-MIP-1072 or 123I-MIP-1095, which were 
first tested in the clinic in 2008 [16]. Feasibility of these molecules to detect tumor 
lesions in soft-tissue, bone and the prostate gland as early as 1-4 h after injection was 
demonstrated in patients with metastatic prostate cancer [17]. More recently, PSMA 
ligands/inhibitors labeled with other radionuclides have been developed and are 
now tested for prostate cancer imaging. The feasibility of 99mTc-MIP-1404 to detect 
the disease is being evaluated in an international phase 2 study in men scheduled for 
prostatectomy using histopathology as the gold standard (ClinicalTrials.gov Identifier 
NCT01667536). Another candidate for prostate cancer imaging is the PSMA ligand 
Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]. First clinical results have shown excellent 
visualization of suspicious prostate cancer lesions with high overall detection rates 
[18]. One of the limitations of this technique however, is renal clearance which might 
conceal cancer lesions.
Another very promising approach to improve tumor-to-background ratios in 
prostate cancer radionuclide imaging is pretargeting using bispecific antibodies 
and corresponding radiolabeled peptides. The value of this pretargeting system has 
been shown previously for colon cancer [19]. In this thesis, it was demonstrated 
that the pretargeting strategy using the anti-TROP2 x anti-HSG bispecific antibody 
TF12 in combination with the 111In-labeled peptide IMP288 is feasible for imaging
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of prostate cancer, especially at time points early after injection. This makes this 
imaging approach particularly suitable for PET imaging with radionuclides that have 
a relatively short half-life, such as 18F and 68Ga. 
In radionuclide imaging, the choice of the most suitable radionuclide is pivotal. 
For PET imaging, the most commonly used radionuclide is 18F as it has ideal properties 
such as a low positron energy (635 keV), which provides optimal spatial resolution 
to PET images [20]. Moreover, cyclotron-produced 18F is currently widely available. 
Another advantage of the use of 18F is its favorable half-life of 109.8 minutes, which 
permits more complex and time-consuming synthetic manipulations and imaging 
studies. However, so far, the labeling procedure of most biomolecules with 18F has 
been cumbersome and was restricted to heat-stable biomolecules as most labeling 
procedures require heating up to 100 °C. Recently, a two-step procedure to prepare 
18F-labeled heat-labile proteins using the [18F]AlF method based on hot maleimide 
conjugation was introduced. In this thesis, the feasibility of this approach to label 
heat-sensitive anti-CEA Fab’, (scFv)2 (diabody) and Fab-AD2 fragments with 
18F and 
their ability to target CEA-expressing tumors is demonstrated. 
While the timing of diagnosis of prostate cancer represents one of the major issues 
that determine prostate cancer mortality, the choice of appropriate treatment is 
essential, too. Currently, nerve sparing radical prostatectomy, involving the removal 
of the entire prostate gland, seminal vesicles and sufficient surrounding tissue to 
obtain negative resection margins is the surgical treatment strategy of choice for 
localized prostate cancer. However, positive surgical margins in radical prostatectomy 
tissue specimens obtained after surgical removal of localized prostate cancer, are 
reported in 10 – 48% of the cases [21]. While the role of positive surgical margins 
on prostate cancer-specific mortality remains controversial, positive surgical margins 
are recognized as a risk factor for prostate-specific antigen (PSA)-defined biochemical 
recurrence [22-24], which is associated with the need for secondary therapy and may 
have considerable impact on patient’s quality of life.
To improve the achievement of negative resection margins, highly sensitive intra-
operative imaging methods are needed to provide the surgeon with real-time visual 
information of resection margins. With the development of handheld gamma probes, 
antibody-based radionuclide imaging became available for intra-operative purposes. 
However, a major limitation of the use of gamma probes is the associated lack of 
visual information on the tumor location. In contrast, near-infrared fluorescence 
(NIRF) imaging does provide visual information on tumor lesions intra-operatively, 
albeit with rather limited tissue penetration. These limitations may be overcome in 
an approach where intra-operative radionuclide detection is combined with near-
infrared fluorescence imaging. In such a dual-modality approach the acoustic signal 
produced by the gamma probe and detailed image information obtained from the 
fluorescent dye typically originate from the same tracer molecule and as such may
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complement each other to improve intra-operative detection and resection of tumor 
tissue. 
In this thesis, the feasibility of dual-modality imaging and image-guided 
surgery of prostate cancer was shown in two approaches, first using a dual-labeled 
antibody and second, using a dual-label peptide in TF12-pretargeted prostate cancer 
xenografts. We demonstrated that tumor-selective targeting was achieved with both 
approaches and provided proof-of-principle that these approaches might be used for 
image-guided surgery of prostate cancer.
So far, no targeted dual-modality imaging approaches have been introduced into the 
clinic, but the first clinical studies are looming. To translate the results described 
in this thesis to the clinic, several aspects have to be considered. In particular, the 
preparation of fluorescently labeled targeting agents needs to be standardized and 
validated [25]. Once these fluorescent agents are found to be safe, they can be 
conjugated to radiolabeled dual-label targeting agents according to GMP standards. 
Furthermore, the role of dual-label agents for image-guided surgery requires further 
evaluation in terms of detection sensitivity and specificity of small lesions and 
accurate tumor margin assessment. In addition, dual-modality image-guided surgery 
needs to be compared to bench mark histology for margin assessment and the 
added value of dual-modality NIRF and radionuclide imaging needs to be evaluated 
in greater detail. Moreover, it has to be determined whether or not dual-modality 
imaging approaches can be used in laparoscopic surgical procedures in which a 
laparoscope is equipped with an optical imaging system.
The aim of the studies described in this thesis was to investigate approaches to 
improve prostate cancer imaging. Our preclinical results suggest that prostate cancer 
imaging might be improved by the use of antibody fragments and pretargeting using 
bispecific antibodies and corresponding peptides. In addition, it was demonstrated 
that dual-modality radionuclide and near-infrared fluorescence imaging approaches 
can improve both tumor detection and image-guided surgery of prostate cancer. 
Using these novel sensitive and specific imaging techniques, prostate cancer may 
be detected more accurately and in earlier stages of the disease, which may help to 
select patients that are still eligible for curative treatment. These preclinical findings 
warrant clinical studies to further investigate the added value of dual-modality 
imaging approaches in prostate cancer patients. However, as these imaging strategies 
have their specific advantages and limitations, it should be carefully evaluated 
which strategy is optimal in particular cases. In this respect, the newly developed 
imaging methods for sensitive and accurate detection of prostate cancer are aligned 
seamlessly with the concept of personalized medicine. 
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SUMMARY
The aim of the studies described in this thesis was to optimize antibody-based 
targeting strategies of prostate cancer and to develop dual-modality fluorescence 
and radionuclide-based imaging approaches to improve the detection and surgical 
resection of prostate cancer. 
In section 1 of this thesis, an introduction to prostate cancer is provided. In addition, 
the basic principles of radionuclide and fluorescence imaging are described together 
with the most commonly used imaging approaches.
In section 2 of this thesis, several strategies for the optimization of antibody-based 
radionuclide imaging of cancer are described. First, in chapter 2.1, the currently 
used imaging techniques for prostate cancer are reviewed. At present, the most 
commonly used imaging technique for prostate cancer is transrectal ultrasound 
(TRUS) which can be used for imaging-guided biopsy. Major limitations of TRUS are 
limited sensitivity and the fact that differentiation between benign processes such 
as benign prostatic hyperplasia (BPH), atrophy, or inflammation in the prostate gland 
cannot be distinguished from malignant disease. Other techniques, such as computed 
tomography (CT) or magnetic resonance imaging (MRI) have higher sensitivity in the 
detection of lesions. However, differentiation between malignancies and benign 
disease processes remains challenging. To overcome this limitation, radionuclide 
imaging modalities such as positron emission tomography (PET) or single photon 
emission tomography (SPECT) are suitable imaging modalities as they can be used to 
image tumor-specific processes or antigens with various tracers such as radiolabeled 
metabolite tracers, androgen receptor binding ligands, gastrin-releasing peptide 
receptor binding ligands, choline, amino acids, or antibodies against prostate cancer-
associated antigens. 
An attractive target for antibody-based imaging of prostate cancer is the prostate-
specific membrane antigen (PSMA). Due to its selective overexpression in prostate 
cancer, PSMA is an excellent target for imaging purposes. In chapter 2.2, the 
potential of the 111In-labeled anti-PSMA monoclonal antibody D2B for targeting of 
PSMA-expressing prostate cancer was evaluated in mice with subcutaneous PSMA-
expressing prostate cancer xenografts and compared to the targeting characteristics 
of 111In-labeled F(ab’)2 and Fab fragments of this antibody. In addition, the tumor 
targeting characteristics of D2B IgG, which binds to an extracellular domain of PSMA 
were compared with those of the clinically approved antibody capromab pendetide, 
which is directed against an intracellular epitope. 
It was demonstrated that all 111In-labeled antibody formats specifically 
accumulate in the PSMA-expressing tumors. Highest uptake was observed for 111In-
182
D2B IgG and 111In-capromab pendetide at 168 h p.i. (94.8 ± 19.2% ID/g and 16.7 ± 
2.2% ID/g, respectively).
Uptake of 111In-D2B F(ab’)2 and 
111In-Fab fragments peaked at 24 h p.i. (12.1 ± 3.0% 
ID/g and 15.1 ± 2.9% ID/g, respectively). Maximum tumor-to-blood ratios were 13.0 
± 2.3 (168 h p.i.), 6.2 ± 0.7 (24 h p.i.), 23.0 ± 4.0 (24 h p.i.), and 4.5 ± 0.6 (168 h p.i.) for 
111In-D2B IgG, 111In-F(ab’)2, 
111In-Fab, and 111In-capromab pendetide, respectively. The 
PSMA-expressing tumors were clearly visualized with microSPECT with all antibody 
formats. 
Overall, the new monoclonal antibody D2B IgG had excellent in vivo tumor 
targeting characteristics. Due to renal accumulation of F(ab’)2 and Fab fragments 
visualization of malignant tissue located in the vicinity of the kidneys might be 
hampered. However, especially in settings where multiple images within a short time 
interval are required, 111In-D2B F(ab’)2 and Fab fragments can be used.
In chapter 2.3, a pretargeting strategy was used to improve antibody-based 
imaging of prostate cancer. TF12 is a trivalent bispecific antibody which consists of 
two anti-TROP-2 Fab fragments and one anti-histaminesuccinyl-glycine (HSG) Fab 
fragment. TROP-2 is an antigen which is found in many epithelial cancers, including 
prostate cancer. As TF12 targets TROP-2, this bispecific antibody could be suitable 
for pretargeting of prostate cancer with the aim to reach high tumor-to-background 
ratios. In this chapter, the potential for pretargeted radioimmunoimaging and 
radioimmunotherapy with TF12 and the radiolabeled diHSG peptide IMP288 in mice 
with subcutaneous TROP-2-expressing prostate cancer xenografts was investigated. 
It was demonstrated that TF12 and 111In- or 68Ga-labeled IMP288 show high and fast 
accumulation in tumor tissue. One disadvantage of this pretargeting strategy might 
be the renal clearance of the diHSG peptide IMP288, as physiological uptake in the 
urinary tract might conceal pathological uptake in the lower abdomen. However, 
renal clearance of radiolabeled IMP288 is very efficient, which may enable the 
distinction between physiological and pathological uptake.
In addition, the feasibility of pretargeted radioimmunotherapy was investigated 
in mice with s.c. PC3 tumors. One treatment cycle with TF12 and 177Lu-labeled 
IMP288 showed significant improvement of survival compared to treatment with 
177Lu-IMP288 alone (90 vs. 67 days, p<0.0001), without renal or hematological 
toxicity. We concluded that TROP-2-expressing prostate cancer can be pretargeted 
efficiently with TF12, with very rapid uptake of the radiolabeled hapten-peptide, 
IMP288, sensitive immuno-PET, and effective therapy.
 Chapter 2.4 describes the application of a new labeling method that allows 
18F radiofluorination to heat sensitive molecules such as antibody fragments with the 
AlF method. Previously, 18F radiofluorination was restricted to heat-stable molecules 
since this method requires heating to 100 °C. Recently, a two-step procedure to 
prepare 18F-labeled heat-labile proteins using the [18F]AlF method combined with a 
hot maleimide conjugation was introduced. In this chapter, the two step method was
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applied to label heat sensitive anti-CEA Fab’, (scFv)2 (diabody) and Fab-AD2 fragments. 
Subsequently, the tumor targeting characteristics of these 18F-fluorinated antibody 
derivatives were evaluated in mice with subcutaneous colorectal cancer xenografts.
Biodistribution studies revealed that all [18F]AlF-labeled antibody conjugates 
specifically accumulated in the CEA-expressing xenografts. At 4 h, tracer uptake in 
the CEA-expressing tumors reached 1.85 ± 0.36% ID/g,  2.10 ± 0.46% ID/g, and 4.61 
± 0.67% ID/g for [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, and [18F]AlF-hMN-
14-diabody, respectively. Tumor-to-muscle ratios were 15.5 ± 2.3, 14.3 ± 3.9, and 
14.0 ± 5.3 for  [18F]AlF-hMN-14-diabody, [18F]AlF-hMN-14-Fab’ and [18F]AlF-hMN-14-
Fab-AD2, respectively. 
All antibody preparations showed high kidney retention. However, renal 
accumulation for the [18F]AlF-hMN-14-diabody format (57.4 ± 5.5% ID/g) (p<0.01) 
was significantly lower compared to that of [18F]AlF-hMN-14-Fab’ and [18F]AlF-hMN-
14-Fab-AD2. In addition, all 18F-fluorinated antibody derivatives showed high hepatic 
uptake. However liver uptake of [18F]AlF-hMN-14-Fab’ (4.36 ± 0.57% ID/g) and [18F]
AlF-hMN-14-Fab-AD2 (4.32 ± 0.35% ID/g) was significantly lower compared to that of 
the [18F]AlF-hMN-14-diabody format (11.1 ± 1.0% ID/g) (p<0.05).
CEA-expressing tumors were clearly visualized on microPET images with all 
18F-labeled antibody derivatives. Overall, based on the in vitro and in vivo tumor 
targeting characteristics of [18F]AlF-fluorinated hMN-14-Fab’, [18F]AlF-hMN-14-
Fab-AD2, and [18F]AlF-hMN-14-diabody, all three 18F-labeled antibody formats are 
promising candidates for PET imaging of CEA-expressing colorectal cancer.
Section 3 of this thesis focuses on the development and characterization of dual-
modality imaging approaches for prostate cancer. In addition, the feasibility of these 
techniques for image-guided surgery was evaluated. At present, surgery represents 
the treatment option of choice for various malignancies. For curative intentions, 
complete removal and the achievement of negative resection margins is pivotal.
In chapter 3.1, a comprehensive overview on recent preclinical advances in 
receptor-targeted radionuclide and near-infrared fluorescence (NIRF) dual-modality 
imaging of cancer is provided and their applicability for image-guided surgery in 
a clinical setting is described. Nuclear imaging can be performed prior to surgery 
and could provide information on the spread of the malignant manifestations. In 
addition it can aid the surgeon in localizing tumor lesions. However, the translation 
of pre-operatively acquired nuclear images to the surgical field may be challenging, 
particularly, when multiple small tumor nodules are present. With the development 
of gamma probes, intra-operative radio-guided surgery has become feasible. The 
impact of radio-guided surgery on the surgical management of cancer patients 
includes providing real-time information to the surgeon on the location and extent 
of disease. However, gamma probes cannot be used for accurate tumor delineation 
during surgery.
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Intra-operative imaging using near-infrared fluorescence represents a suitable 
option for this purpose as it allows precise delineation of tumor margins during and 
following resection and could provide real-time visualization directly correlated to 
the surgical field. This technique however is restricted by limited penetration depth 
of light in biological tissue. 
With the emergence of dual-modality imaging agents that are labeled with 
both a fluorescent dye and a radionuclide, these powerful imaging techniques that 
complement each other in the detection and surgical removal of cancer tissue are 
combined. So far, several preclinical studies have demonstrated the potential value of 
merging these imaging modalities. However, further studies are needed to evaluate 
sensitivity and specificity of this dual-modality approach. At present, first clinical 
studies are looming that aim to determine the value of NIR fluorescently labeled 
targeting molecules for diagnostic and therapeutic approaches. In chapter 3.2 of this 
thesis, both radionuclide and NIRF imaging were combined by dual-labeling the anti-
PSMA antibody D2B to 111In and the NIR fluorophore IRDye800CW. In this chapter, the 
potential of dual-modality SPECT/CT and NIRF imaging of prostate cancer using 111In-
DTPA-D2B-IRDye800CW was evaluated in mice with subcutaneous and metastatic 
PSMA-expressing tumor lesions. 
Biodistribution studies revealed specific accumulation of 111In-DTPA-D2B-
IRDye800CW in s.c. tumor lesions, reaching a tumor uptake level of 45.8 ± 8.0 %ID/g 
at 7 days after injection. While uptake in most other tissues remained low, the 
dual-labeled antibody showed enhanced hepatic uptake. This could be due to the 
increased lipophilicity of the fluorophore-conjugated antibody, which consequences 
in hepatic accumulation. To avoid this, mild substitution ratios of approximately 1 
IRDye800CW per antibody molecule are recommended. 
Both s.c. as well as intraperitoneal xenografts could be visualized specifically 
with both microSPECT/CT and NIRF imaging at 2 days after injection. In addition, the 
feasibility of image-guided resection of i.p. tumors was demonstrated in this model. 
Taken together, preclinical findings on the dual-modality targeting agent 111In-DTPA-
D2B-IRDye800CW for imaging of prostate cancer encourage clinical studies with 
targeted dual-label imaging probes for intra-operative guidance of prostate tumor 
resection, to achieve radical tumor resection.
Finally, Chapter 3.3 describes a dual-modality imaging approach using a 
pretargeting system. In this study, the feasibility of a pretargeting system for intra-
operative imaging of prostate cancer using an anti-TROP-2  x anti-HSG bispecific 
antibody (TF12), together with a newly developed dual-label diHSG peptide (RDC018) 
with a DOTA chelate for radiolabeling and a fluorophore (IRdye800CW) for optical 
imaging is evaluated.
The biodistribution of the dual-label diHSG peptide 111In-RDC018 and the 
single-label peptide 111In-IMP288 (control) showed specific accumulation in the 
TROP-2 expressing xenografts (12.4 ± 3.7% ID/g at 2 h p.i. and 9.1 ± 2.8% ID/g at 2 h
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p.i., respectively). While uptake in most other organs remained low, significant 
radiotracer uptake was observed in the kidneys, which probably is due to enhanced 
tubular reabsorption of this peptide as compared to IMP288.
MicroSPECT/CT and near-infrared fluorescence (NIRF) imaging showed specific 
uptake of the dual-label 111In-RDC018 in both s.c. and metastatic bony and soft tissue 
TROP-2-expressing tumor lesions. In addition, proof-of-principle was provided for image-
guided resection of TROP-2 expressing metastases using intra-operative NIRF imaging. 
The studies described in this thesis have added to the knowledge of antibody-based 
PET and SPECT imaging of prostate cancer. In addition, development and preclinical 
application of two different dual-modality NIRF and radionuclide imaging approaches 
have led to proof-of-principle that image-guided surgery of prostate cancer is feasible 
using either a dual-label antibody or a pretargeting strategy with a dual-label peptide. 
These preclinical findings encourage future clinical studies to further elucidate the 
added value of dual-modality imaging in prostate cancer patients. 
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SAMENVATTING
Het doel van de studies beschreven in dit proefschrift was het optimaliseren van 
antilichaam targeting strategieën van prostaatkanker. Daarnaast zijn gecombineerde 
fluorescentie/radionuclide imaging methoden ontwikkeld om de detectie en de 
resectie van prostaatkanker te verbeteren.
In sectie 1 van dit proefschrift worden de basisprincipes van radionuclide en 
fluorescentie imaging beschreven. 
Sectie 2 van dit proefschrift richt zich op de optimalisatie van radioimmunoimaging 
van kanker. Hoofdstuk 2.1 geeft een overzicht van de beschikbare imaging methoden 
voor prostaatkanker. De meest gebruikte imaging techniek voor prostaatkanker op 
dit moment is transrectal ultrasound (TRUS), dat ook gebruikt kan worden voor 
echogeleide biopsie. Het gebruik van TRUS wordt echter beperkt door de relatief lage 
sensitiviteit en het feit dat differentiatie tussen benigne veranderingen zoals benigne 
prostaathyperplasie (BPH), atrofie of ontstekingen in de prostaat en maligniteiten 
van de prostaat moeilijk is. Andere technieken zoals computed tomography (CT) of 
magnetic resonance imaging (MRI) hebben een hogere sensitiviteit voor de detectie 
van tumor laesies. Echter, de differentiatie tussen maligne en benigne aandoeningen 
met MRI blijft moeilijk. Radionuclide imaging technieken zoals positron emission 
tomography (PET) of single photon emission tomography (SPECT) kunnen 
bijdragen tot een betere diagnose van prostaatkanker, omdat met behulp van deze 
technieken tumor-specifieke processen in beeld kunnen worden gebracht. Voor 
detectie van prostaatkanker met radionuclide imaging kunnen verschillende tracers 
worden gebruikt, zoals radioactief gelabelde liganden van GRPR (gastrin releasing 
peptide receptor), androgeen receptor bindende liganden, choline, aminozuren of 
antilichamen gericht tegen prostaatkanker geassocieerde antigenen. 
Een veelbelovend target voor antilichaam-gebaseerd imaging van prostaatkanker 
is het prostate-specific membrane antigen (PSMA). De selectieve overexpressie 
van PSMA in prostaatkanker maakt dit eiwit een zeer geschikt target voor imaging 
doeleinden. In hoofdstuk 2.2 van dit proefschrift wordt de mogelijkheid onderzocht 
om PSMA-expresserende prostaattumoren in beeld te brengen met behulp van het 
111In-gelabeld anti-PSMA antilichaam D2B in muizen met subcutane prostaatkanker 
xenograften. De tumor targeting eigenschappen van D2B IgG werden vergeleken met 
die van 111In-gelabelde F(ab’)2 en Fab fragmenten van dit antilichaam. Bovendien 
werden de targeting karakteristieken van D2B IgG, dat gericht is tegen een epitoop 
op het extracellulaire domein van PSMA, vergeleken met de eigenschappen van 
het klinisch gebruikte antilichaam capromab pendetide, dat gericht is tegen een 
intracellulair epitoop. Alle 111In-gelabelde antilichaam vormen accumuleerden 
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specifiek in de PSMA-expresserende tumoren. De hoogste tumor opname werd 
gevonden met 111In-D2B en 111In-capromab pendetide (respectievelijk 94.8 ± 19.2% 
ID/g en 16.7 ± 2.2% ID/g, 7 dagen na injectie). De opname van 111In-D2B F(ab’)2 en 
111In-Fab fragmenten in de tumor was het hoogst 24 h na injectie (respectievelijk 
12.1 ± 3.0% ID/g en 15.1 ± 2.9% ID/g). De tumor/bloed opname ratio’s waren 
13.0 ± 2.3 (168 h p.i.), 6.2 ± 0.7 (24 h p.i.), 23.0 ± 4.0 (24 h p.i.) en 4.5 ± 0.6 (168 
h p.i.), respectievelijk voor 111In-D2B IgG, 111In-F(ab’)2, 
111In-Fab, en 111In-capromab 
pendetide. De PSMA-expresserende tumoren konden duidelijk worden afgebeeld 
met microSPECT met alle antilichaam formaten. Overall heeft het nieuwe 
monoclonale antilichaam D2B zeer goede in vivo tumor targeting eigenschappen. 
Als gevolg van hoge opname van F(ab’)2 en Fab fragmenten in de nieren kunnen 
maligne laesies in (de buurt van) de nieren moeilijk zichtbaar gemaakt worden. 
Echter, in gevallen waar meerdere images binnen korte tijd gemaakt moeten worden, 
kunnen 111In-D2B F(ab’)2 en Fab fragmenten juist uitstekend worden toegepast.
In hoofdstuk 2.3 werd een pretargeting strategie getest voor het afbeelden 
van prostaatkanker. TF12 is een trivalent bispecifiek antilichaam dat bestaat uit 
twee anti-TROP-2 Fab fragmenten en één anti-histaminesuccinylglycine (HSG) 
Fab fragment. TROP-2 is een antigeen dat tot expressie komt op verschillende 
carcinomen, waaronder prostaatkanker. Aangezien TF12 gericht is tegen TROP-2, zou 
dit bispecifiek antilichaam geschikt kunnen zijn voor pretargeting van prostaatkanker, 
met het doel om een hoge opname in de tumor te bereiken en tegelijkertijd een 
snelle klaring uit normale weefsels en bloed. In dit hoofdstuk werd de potentie 
van pretargeted radioimmunoimaging en radioimmunotherapie met TF12 en het 
radioactief gelabelde diHSG peptide IMP288 onderzocht in muizen met subcutane 
TROP-2-expresserende prostaat tumoren. Er werd aangetoond dat TF12 en 111In- 
of 68Ga-gelabeld IMP288 snel en efficient in de tumor accumuleerden. Een nadeel 
van deze pretargeting strategie zou de renale klaring van het diHSG peptide IMP288 
kunnen zijn, omdat fysiologische opname in de urinewegen de detectie van laesies 
in het abdomen zou kunnen bemoeilijken. De klaring van radioactief gelabeld 
IMP288 verloopt echter zeer snel en compleet, wat uiteindelijk de differentiatie 
tussen fysiologische en pathologische opname toch mogelijk zou kunnen maken. 
Verder werd in dit hoofdstuk de mogelijkheid van pretargeted 
radioimmunotherapie onderzocht in muizen met s.c. PC3 tumoren. Eén 
behandelingscyclus met TF12 en 177Lu-gelabeld IMP288 liet een significante 
verbetering van de overleving zien. De studie liet zien dat de pretargeting strategie 
met TF12 bij TROP-2 expresserende prostaatkanker effectief kan zijn, met snelle 
opname van het radioactief gelabelde IMP288 in de tumor.
Hoofdstuk 2.4 beschrijft de toepassing van een nieuwe labelingsmethode van hitte-
sensitieve moleculen (bv. antilichaam fragmenten) met F-18, gebruik makend van de
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AlF technologie. Tot voor kort kon 18F-fluoridering alleen worden toegepast 
op hitte-stabiele moleculen, omdat de labeling werd uitgevoerd bij 100 ºC. 
Recentelijk werd een twee-staps procedure ontwikkeld om hitte-labiele 
eiwitten te kunnen labelen met 18F. In dit hoofdstuk werd deze methode 
toegepast om anti-CEA Fab’, (scFv)2 (diabody) en Fab-AD2 fragmenten te 
labelen met 18F. De tumor targeting eigenschappen van deze 18F-gelabelde 
antilichaam fragmenten werden bepaalt in muizen met subcutane tumoren.
De biodistributiestudies lieten zien dat alle [18F]AlF-gelabelde antilichaam 
fragmenten specifiek accumuleerden in CEA-expresserende tumoren. Na 4 h was de 
concentratie in de CEA-expresserende tumoren 1.85 ± 0.36% ID/g,  2.10 ± 0.46% 
ID/g en 4.61 ± 0.67% ID/g van respectievelijk [18F]AlF-hMN-14-Fab’, [18F]AlF-hMN-
14-Fab-AD2 en [18F]AlF-hMN-14-diabody. Alle F-18-gelabelde antilichaam vormen 
vertoonden hoge opname in de nieren. Echter, de opname in de nieren van het 
[18F]AlF-hMN-14-diabody (57.4 ± 5.5% ID/g) was significant lager dan dat van [18F]
AlF-hMN-14-Fab’ en [18F]AlF-hMN-14-Fab-AD2 (p<0.01). Bovendien vertoonden alle 
18F-gelabelde antilichaam vormen relatief hoge opname in de lever. Echter, de lever 
opname van [18F]AlF-hMN-14-Fab’ (4.36 ± 0.57% ID/g) en [18F]AlF-hMN-14-Fab-AD2 
(4.32 ± 0.35% ID/g) was significant lager dan die van het [18F]AlF-hMN-14-diabody 
(11.1 ± 1.0% ID/g) (p<0.05). De CEA-expresserende tumoren worden duidelijk 
afgebeeld met microPET met alle 18F-gelabelde antilichaam vormen. Op basis van de 
in vitro en in vivo tumor targeting eigenschappen van [18F]AlF-gelabelde hMN-14-Fab’, 
[18F]AlF-hMN-14-Fab-AD2 en [18F]AlF-hMN-14-diabody kon worden geconcludeerd 
dat deze drie 18F-gelabelde antilichaam formaten gebruikt kunnen worden voor PET 
imaging van tumoren die CEA expresseren, zoals bijvoorbeeld dikkedarmkanker. 
In Sectie 3 van dit proefschrift wordt de ontwikkeling en karakterisering van dual-
modality imaging methoden voor prostaatkanker beschreven. Operatieve 
verwijdering van tumor laesies is voor diverse vormen van kanker de belangrijkste 
vorm van behandeling. Om volledige genezing te bereiken is complete verwijdering 
van de tumor essentieel. In hoofdstuk 3.1 wordt een overzicht van de meest recente 
ontwikkelingen op het gebied van receptor-targeted radionuclide en near-infrared 
fluorescentie (NIRF) dual-modality imaging van kanker gegeven. Inra-operatieve dual 
modality imaging zou de volledige verwijdering van tumoren kunnen verbeteren. 
Met de ontwikkeling van gamma probes werd intra-operatieve radiodetectie-geleide 
resectie van tumoren mogelijk. Hierdoor kan een chirurg tumorlaesies tijdens de 
operatie beter opsporen. Echter, de gamma probes is niet geschikt voor het detecteren 
van tumorcellen in de snijranden. Intra-operatieve beeldvorming met near-infrared 
fluorescentie daarentegen is hiervoor mogelijk wel geschikt. Een nadeel van deze 
techniek is echter dat de penetratie van licht in weefsel zeer beperkt is (1-2 mm).
Met dual-modality imaging technieken die gebruik maken van tracers die 
gelabeld zijn met zowel een fluorescerende stof als met een radionuclide worden de 
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sterke eigenschappen van beide imaging technieken gecombineerd. In de afgelopen 
jaren hebben diverse studies in muizenmodellen de waarde van de combinatie van 
deze beide technieken laten zien. 
In hoofdstuk 3.2 van dit proefschrift werd radionuclide imaging en NIRF imaging 
gecombineerd door het anti-PSMA antilichaam D2B te labelen met 111In en de 
fluorescerende stof IRDye800CW. In dit hoofdstuk werd de mogelijkheid van dual-
modality SPECT/CT and NIRF imaging van prostaatkanker bestudeerd in muizen 
met PSMA-expresserende tumoren. Biodistributie studies van 111In-DTPA-D2B-
IRDye800CW in muizen lieten zien dat 111In-DTPA-D2B-IRDye800CW specifiek 
accumuleerde in subcutane tumoren (45.8 ± 8.0% ID/g, 7 dagen na injectie). Het 
dubbelgelabelde antiichaam toonde ook een verhoogde opname in de lever. Dit 
zou het gevolg kunnen zijn van de verhoogde lipofiliciteit van de antilichamen die 
geconjugeerd zijn met het IRDye800CW.
De tumoren konden zichtbaar gemaakt worden met microSPECT/CT en NIRF 
imaging 2 dagen na injectie van de tracer. De 111In-DTPA-D2B-IRDye800CW tracer zou 
gebruikt kunnen worden voor de intra-operatieve detectie van prostaatkanker lesies.
In hoofdstuk 3.3 wordt een dual-modality imaging techniek beschreven waarin 
gebruikt gemaakt wordt van een pretargeting strategie. In deze studie werd intra-
operatieve beeldvorming van prostaatkanker met het anti-TROP-2 x anti-HSG 
bispecifieke antilichaam (TF12), in combinatie met het nieuwe dual-label diHSG 
peptide (RDC018) onderzocht. 
In de biodistributie van het dual-label diHSG peptide 111In-RDC018 en het single 
label peptide 111In-IMP288 (controle) accumuleerden beiden specifiek in de TROP-
2-expresserende tumoren (respectievelijk 12.4 ± 3.7% ID/g, 2 h p.i. en 9.1 ± 2.8% 
ID/g, 2 h p.i.). De concentratie van RDC018 in de nieren was significant hoger dan 
dat van IMP288. MicroSPECT/CT en NIRF imaging lieten specifieke opname van het 
dual-label 111In-RDC018 in de TROP-2 expresserende tumoren in muizen zien. In 
deze studie werd proof-of-principle geleverd voor beeldgeleide resectie van TROP-2 
expresserende tumor laesies met behulp van intra-operatieve NIRF imaging. 
De studies beschreven in dit proefschrift hebben bijgedragen aan de kennis over 
radioimmunodetectie van prostaatkanker met PET en SPECT. Bovendien werden twee 
dual-modality imaging methoden voor prostaatkanker getest in muizenmodellen 
en werd getoond dat deze methoden mogelijk gebruikt kunnen worden voor 
beeldgeleide resectie van tumor laesies.
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Ziel der in dieser Dissertation beschriebenen Studien ist die Optimierung von 
Antikörper-basierten Targeting Strategien für Malignome der Prostata und die 
Entwicklung von kombinierten Fluoreszenz und Radionuklid-basierten Methoden um 
die Detektion von Prostata Krebs zu verbessern.
In Sektion 1 dieser Dissertation wurden die Basisprinzipien von Radionuklid und 
Fluoreszenz Imaging am Beispiel von Prostata Krebs beschrieben. 
In Sektion 2 wurden Strategien für die Optimierung von Antikörper-basiertem 
Radionuklidimaging von Prostatakarzinomen evaluiert. Zunächst wurden die derzeit 
gängigsten bildgebenden Techniken für Karzinome der Prostata beschrieben (Kapitel 
2.1). Die derzeit am häufigsten verwendete Bildgebungsmethode bei Prostata Krebs 
ist der transrektale Ultraschall (TRUS) der Prostata, welcher auch zur bildgeleiteten 
Biopsie genutzt werden kann. Wesentliche Einschränkungen von TRUS sind 
begrenzte Sensitivität sowie die Tatsache, dass nur unzureichend zwischen gutartigen 
Prozessen der Prostata, wie benigner Prostatahyperplasie (BPH), Atrophie oder 
Entzündungen und Malignitäten unterschieden werden kann. Andere bildgebende 
Techniken wie Computertomographie (CT) oder Magnetresonanztomographie (MRT) 
weisen eine höhere Sensitivität im Nachweis von Tumorläsionen auf. Jedoch ist der 
Wert dieser Techniken in der Differenzierung zwischen benignen und malignen 
Krankheitsprozessen verbesserungswürdig. Mithilfe von Radionuklid Imaging 
Modalitäten wie Positronen Emissions Tomographie (PET) oder Single Photon 
Emission Computed Tomography (SPECT) kann die Differenzierung zwischen benignen 
und malignen Läsionen erheblich verbessert werden, da sie zur Visualisierung von 
tumorspezifischen Prozessen oder Antigenen genutzt werden können.
Ein attraktives Target für Imaging von tumorspezifischen Antigenen, die assoziiert 
sind mit Prostata Krebs, ist das prostate-specific membrane Antigen (PSMA). 
Durch seine selektive Überexpression in Karzinomen der Prostata stellt PSMA ein 
exzellentes Target für Imaging Zwecke dar. In Kapitel 2.2 wurde das Potential vom 
111In-gelabelten anti-PSMA monoklonalen Antikörper D2B evaluiert hinsichtlich 
dessen Fähigkeit spezifisch an PSMA-exprimierende Tumore der Prostata zu binden. 
Dies wurde in BALB/c Nacktmäusen mit subkutanen PSMA-exprimierenden Prostata 
Krebs Xenotransplantaten untersucht. Desweiteren wurden diese Eigenschaften 
verglichen mit den Targeting Eigenschaften von 111In-gelabelten F(ab‘)2 und Fab 
Fragmenten dieses Antikörpers. Da D2B IgG an ein extrazelluläres Epitop von PSMA 
bindet, wurden außerdem dessen Targeting Eigenschaften verglichen mit denen vom 
klinisch zugelassenen Antikörper Carpomab Pendetide, der gegen ein intrazelluläres 
Epitop gerichtet ist.
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Es wurde gezeigt, dass alle 111In-markierten Antikörperformate spezifisch im PSMA-
exprimierenden Tumorgewebe akkumulierten. Die höchste Tracer Aufnahme im 
Tumor wurde für 111In-D2B und 111In-Carpomab Pendetide 168 h p.i. beobachtet, 
wohingegen die höchste Aufnahme von 111In-D2B F(ab’)2 und 
111In-Fab Fragmenten 
nach 24 h erreicht wurde (12.1 ± 3.0% ID/g und 15.1 ± 2.9% ID/g). Die maximalen 
Tumor-zu-Blut Verhältnisse waren 13.0 ± 2.3 (168 h p.i.), 6.2 ± 0.7 (24 h p.i.), 23.0 
± 4.0 (24 h p.i.), und 4.5 ± 0.6 (168 h p.i.) für 111In-D2B IgG, 111In-F(ab’)2, 
111In-Fab, 
und 111In-Capromab Pendetide. Desweiteren konnten die PSMA-expressierenden 
Tumore mithilfe aller Antikörperformate mit SPECT/CT deutlich visualisiert werden. 
Zusammenfassend wurde gezeigt, dass der monoklonale Antikörper D2B über 
exzellente in vivo Tumor Targeting Charakteristiken verfügt. Als Folge renaler 
Akkumulation der F(ab’)2 und Fab Fragmente kann die Bildgebung von malignem 
Gewebe, dass sich in räumlicher Nähe zu den Nieren befindet, behindert werden. 
Dennoch sind 111In-D2B F(ab’)2 und Fab Fragmente für Zwecke der Bildgebung 
geeignet, vor allem wenn die Untersuchung mehrfach in kurzen Zeitabständen 
wiederholt werden soll. 
In Kapitel 2.3 wurde eine Pretargeting Strategie zur Verbesserung von antikörper-
basiertem Imaging von Prostata Krebs angewandt. TF12 ist ein trivalenter 
bispezifischer Antikörper bestehend aus zwei anti-TROP-2 Fab Fragmenten und 
einem anti-histaminesuccinyl-glycine (HSG) Fab Fragment. Das Antigen TROP-2 
kommt in verschiedenen Malignomen zur Expression, worunter auch Karzinome der 
Prostata. Da TF12 gegen TROP-2 gerichtet ist, stellt dieser bispezifische Antikörper 
ein geeignetes Target für Pretargeting von Karzinomen der Prostata dar. In diesem 
Kapitel wurde das Potential der Pretargeted Radioimmunbildgebung mit TF12 und 
dem radioaktiv markierten diHSG Hapten-Peptid IMP288 in Mäusen mit subkutanen 
TROP-2-expressierenden Prostata Karzinomen untersucht. Sowohl 111In als auch 
68Ga gelabeltes IMP288 akkumulierte spezifisch und schnell im Tumor Gewebe. 
Ein potentieller Nachteil dieser Pretargeting Strategie könnte allerdings die renale 
Ausscheidung vom diHSG Peptid IMP288 darstellen, da dessen physiologische 
Aufnahme in den Harnwegen eine pathologische Akkumulation im unteren 
Abdomen verdecken könnte. Da die renale Ausscheidung des radioaktiv markierten 
IMP288 jedoch sehr effektiv verläuft, könnte die Abgrenzung von physiologischem 
und pathologischen Uptake dennoch möglich sein. Desweiteren wurde in diesem 
Kapitel die Durchführbarkeit und Eignung von pretargeted Radioimmunotherapie 
in Mäusen mit subkutanen PC3 Tumoren evaluiert. Ein Behandlungszyklus mit 
TF12 und 177Lu-gelabeltem IMP288 zeigte eine signifikante Verbesserung des 
Überlebens im Vergleich zur Behandlung mit 177Lu-IMP288 ohne Gabe von TF12 (90 
vs. 67 Tage, p<0.0001). Darüberhinaus wurden weder renale noch hämatologische 
Toxizität beobachtet. Hieraus folgt, dass effizientes Pretargeting von TROP-2-
expressierenden Prostata Karzinomen möglich ist bei schnellem Uptake des radioaktiv 
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gelabelten Hapten-Petides IMP288. Darüberhinaus könnte dieses Peptid zusammen 
mit TF12 eine effektive therapeutische Variante darstellen. 
In Kapitel 2.4 wurde die Anwendung von einer neuen Markierungsmethode 
beschrieben, welche die Radiofluorinierung von hitzesensitiven Molekülen wie 
Antikörper Fragmenten mit AlF ermöglicht. Bisher war die 18F Radiofluorinierung auf 
hitzestabile Moleküle beschränkt, da für diese Labelingprozedur eine Erhitzung auf 
100 °C erforderlich war. Vor kurzem allerdings wurde eine Zwei-Schritt Methode zur 
18F Markierung entwickelt die auch für hitzelabile Moleküle geeignet ist und welche 
die [18F]AlF Methode mit einer heißen Maleimid Konjugation kombiniert. In diesem 
Kapitel wurde diese Zwei-Schritt Methode angewandt um hitzesensitive anti-CEA 
Fab’, (scFv)2 (diabody) und Fab-AD2 Fragmente zu mit 
18F zu markieren. Anschließend 
wurden die Tumor Targeting Eigenschaften von diesen 18F-fluorinierten Antikörper 
Formaten in Mäusen mit subkutanen Xenotransplantaten einer kolorektalkarzinom-
Zellinie evaluiert. 
Die Studien zur Biodistribution zeigten, dass alle [18F]AlF-gelabelten Antikörper 
Konjugate in spezifischer Weise an die CEA-expressierenden Xenotransplantate 
akkumulierten. Nach 4 h wurden Tracermengen in den CEA-expressierenden 
Tumoren von 1.85 ± 0.36% ID/g, 2.10 ± 0.46% ID/g, und 4.61 ± 0.67% ID/g für [18F]
AlF-hMN-14-Fab’, [18F]AlF-hMN-14-Fab-AD2, und [18F]AlF-hMN-14-diabody erreicht. 
Die Tumor-zu-Muskel Ratios waren 15.5 ± 2.3, 14.3 ± 3.9, und 14.0 ± 5.3 für [18F]AlF-
hMN-14-diabody, [18F]AlF-hMN-14-Fab’, beziehungsweise [18F]AlF-hMN-14-Fab-AD2.
Alle Antikörper Fragmente zeigten hohe Aufnahme in den Nieren. Jedoch war 
die renale Aufnahme für das [18F]AlF-hMN-14-diabody Format (57.4 ± 5.5% ID/g) 
(p<0.01) signifikant niedriger verglichen mit dem von den [18F]AlF-hMN-14-Fab’ und 
[18F]AlF-hMN-14-Fab-AD2 Fragmenten. Darüberhinaus zeigten alle 18F-fluorinierten 
Antikörper Derivate eine hohe Aufnahme in der Leber. Verglichen mit dem [18F]AlF-
hMN-14-diabody Format (11.1 ± 1.0% ID/g) zeigten jedoch sowohl [18F]AlF-hMN-
14-Fab’ (4.36 ± 0.57% ID/g) als auch [18F]AlF-hMN-14-Fab-AD2 (4.32 ± 0.35% ID/g) 
signifikant niedrigeren Uptake (p<0.05).
Die CEA-exprimierenden Tumore konnten mit microPET mit allen 18F-gelabeten 
Antikörper Derivaten deutlich visualisiert werden. Basierend auf den in vitro und in 
vivo Tumor Targeting Charakteristiken von [18F]AlF-fluoriertem hMN-14-Fab’, [18F]
AlF-hMN-14-Fab-AD2 und [18F]AlF-hMN-14-diabody wurde gezeigt, dass alle drei 
18F-gelabelten Antikörper Formate vielversprechende Kandidaten für PET Imaging 
von CEA-exprimierenden kolorektalen Karzinomen sind. 
In Sektion 3 dieser Dissertation wurde die Entwicklung und Charakterisierung von 
dualen Bildgebungsverfahren für Prostata Krebs behandelt. Zusätzlich wurde die 
Anwendbarkeit dieser Techniken für bildgeleitete Chirurgie bestimmt. Gegenwärtig 
repräsentiert die chirurgische Behandlung die Behandlungsoption der Wahl für
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zahlreiche Malignitäten. Insbesondere bei kurativem Ansatz sind die komplette 
Entfernung jeglichen Tumorgewebes sowie das Erzielen negativer Resektionsgrenzen 
ausschlaggebend für den Therapieerfolg. 
In Kapitel 3.1 wurde eine Übersicht über die neuesten präklinischen Fortschritte 
in dualer, Rezeptor-targeted Radionuklid und near-infrared Fluoreszenz (NIRF) 
Bildgebung von Malignomen erstellt und deren Wert zur Verbesserung bildgestützter 
Chirurgie im klinischen Alltag bestimmt. Während Radionuklidimaging präoperativ 
durchgeführt werden und Informationen zum Ausbreitungsgrad der Krankheit liefern 
könnte, stellt sich die Übertragung von präoperativ aufgenommen Szintigraphien 
auf das Operationsgebiet als Herausforderung dar, insbesondere bei multiplen 
kleinen Tumorläsionen. Mit der Entwicklung von Gamma Sonden allerdings wurde 
die intraoperative radiogeleitete Chirurgie verfügbar, welche die Identifizierung von 
Tumorläsionen in Echtzeit während der Operation ermöglicht. Gamma Sonden eignen 
sich allerdings nicht für eine akkurate Abgrenzung von Tumorgewebe. Desweiteren 
beruht die Nutzung von Gamma Sonden vor allem auf akustischen Signalen. 
Bildgebung im eigentlichen Sinne ist darum nicht gegeben. Für akkurate Abgrenzung 
von Tumorgewebe könnten intraoperative Bildgebungsverfahren die NIRF Imaging 
nutzen eine geeignetere Variante darstellen, da das operative Feld mithilfe dieser 
Technik visuell auf die Anwesenheit von Tumorgewebe überprüft werden könnte. Die 
Anwendung dieser Technik wird jedoch durch die eingeschränkte Penetrationstiefe 
von Licht in biologischem Gewebe limitiert. 
Mit der Entwicklung von Molekülen, die mit sowohl einem fluoreszierenden 
als auch mit einem radioaktiven Stoff markiert werden können, ist es möglich 
Radionuklid und NIRF Imaging zu kombinieren und von den Vorteilen beider 
Techniken zu profitieren. Bisher konnte der potentielle Wert dieser Verbindung in 
ersten präklinischen Studien angezeigt werden. Gegenwärtig laufen erste klinische 
Studien an, die darauf zielen den Wert von fluoreszent markierten spezifischen 
Molekülen für diagnostische und therapeutische Zwecke einzuschätzen. 
In Kapitel 3.2 dieser Dissertation wurden Radionuklid und NIRF Imaging kombiniert 
durch Doppelmarkierung des anti-PSMA Antikörpers D2B mit sowohl 111In als 
auch dem Fluorophor IRDye800CW. In dieser Studie wurde das Potential von 
dualer Bildgebung mit SPECT/CT und NIRF Imaging für Prostata Krebs mithilfe von 
111In-DTPA-D2B-IRDye800CW in Mäusen mit subkutanen und intraperitonealen 
PSMA-exprimierenden Tumorläsionen charakterisiert. Studien zur Biodistribution 
zeigen spezifische Akkumulation von 111In-DTPA-D2B-IRDye800CW in subkutanen 
Tumorläsionen (Uptake: 45.8 ± 8.0% ID/g 168 h p.i.). Während der Tumor Uptake in 
den meisten Organen und Geweben niedrig blieb, verzeichnete der dual-gelabelte 
Antikörper erhöhten Leber Uptake. Dies könnte eine Folge der Lipophilie des 
fluoreszent markierten Antikörpers sein, die zu Akkumulation des Tracers in der Leber 
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führt. Um dies weitestgehend zu vermeiden wird ein niedriges Substitutionsverhältnis 
von ungefähr einem IRDye800CW per Antikörpermolekül empfohlen.
Sowohl die subkutanen als auch die intraperitonealen Xenotransplantate konnten 
in spezifischer Weise mit microSPECT/CT und NIRF Imaging visualisiert werden (2 
d p.i.). Desweiteren wurde die Anwendbarkeit dieses doppelmarkierten Targeting 
Konstrukts für bildgestützte Chirurgie von intraperitonealen Tumoren evaluiert. Aus 
diesen präklinischen Ergebnissen ist zu schließen, dass sich dieser doppelmarkierte 
Antikörper für intraoperative Bildgebung und bildgeleitete Resektion von Prostata 
Karzinomen eignet. 
Abschließend wurde in Kapitel 3.3 ein Ansatz für duale Bildgebung beschrieben, 
für den ein Pretargeting System genutzt wurde. In dieser Studie wurde die Eignung 
der in Kapitel 2.3 beschriebenen Pretargeting Strategie für intraoperatives Imaging 
von Prostata Karzinomen die den anti-TROP-2 x anti-HSG bispezifischen Antikörper 
TF12 nutzt. In diesem Kapitel wurde zusätzlich ein neu entwickeltes dual-label diHSG 
Hapten-Peptid (RDC018) genutzt, welches ein DOTA Chelat zur Radiolabeling und ein 
Fluorophor (IRDye800CW) besitzt für NIRF Imaging. 
Die Bioverteilung des doppelt markierten Peptids 111In-RDC018 und des einfach 
markierten Peptids 111In-IMP288 (Kontrolle) zeigte spezifische Akkumulation in den 
TF12-vorakkumulierten (pretargeted) TROP-2-expressierenden Tumorläsionen (12.4 
± 3.7% ID/g bei 2 h p.i. und 9.1 ± 2.8% ID/g bei 2 h p.i.). Während die Traceraufnahme 
in den meisten Organen niedrig bleib, wurde signifikante Akkumulation in den Nieren 
beobachtet, was wahrscheinlich eine Folge erhöhter tubulärer Reabsorption des 
Peptids ist im Vergleich mit IMP288.
MicroSPECT/CT und NIRF Imaging zeigten spezifische Aufnahme des dual-label 
Peptids 111In-RDC018 in sowohl subkutanen Tumoren als Metastasen der Weichteile 
sowie des Skeletts. Desweiteren wurde der prinzipielle Beweis erbracht für die 
Anwendbarkeit von bildgestützter Resektion von TROP-2 exprimierenden Metastasen 
mithilfe von intraoperativem NIRF Imaging.
Die in dieser Dissertation beschriebenen Studien haben die Kenntnisse über 
Antikörper-basiertes PET und SPECT Imaging von Prostatakarzinomen deutlich 
erweitert. Darüberhinaus wurden zwei duale Radionuklid und NIRF Imaging 
Bildgebungsverfahren entwickelt, welche die bildgestützte Resektion von 
Prostatakarzinom Metastasen ermöglichen. Diese präklinischen Resultate stützen 
und stimulieren die Einleitung klinischer Studien um den Wert von dualen 
Bildgebungsverfahren bei Patienten mit Malignomen der Prostata weiter zu 
evaluieren.
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Toen ik 9 jaar geleden de beslissing nam om een tijdje in Nederland te gaan studeren, 
had ik een aantal dingen volstrekt niet verwacht:
1.   Hoe lang ik zou blijven
2.   Hoe gezellig die Nederlanders toch zijn
3.   Hoeveel kansen ik zou krijgen
4.   Hoe moeilijk het zou zijn, om dit allemaal achter te laten en uit Nederland 
       te vertrekken
Dit boekje is nu een beetje het eindproduct van mijn tijd in Nederland geworden. 
Echter dit proefschrift was nooit tot stand gekomen, als er niet een aantal mensen 
waren geweest die een ontzettend grote bijdrage hieraan hebben geleverd en mij 
in bijzondere mate hebben gesteund. Graag wil ik hen bij deze gelegenheid in het 
bijzonder bedanken.
Prof. Dr. Boerman, beste Otto, je hebt dit al in veel boekjes gelezen, maar ik 
moet dit hier toch nog eens noemen: ook ik had het niet beter kunnen treffen dan 
met jou als mijn eerste promotor. Naast je wetenschappelijke kwaliteiten heb ik veel 
waardering voor je openheid en de oprechte interesse die je hebt voor alle leden van 
je onderzoeksgroep. Ik wil je bedanken voor je onvoorwaardelijke steun tijdens mijn 
promotietijd en je bereidheid om steeds individuele oplossingen mogelijk te maken, 
zoals in begin 2011, toen ik je vroeg om een klein bijbaantje op het lab, wat uiteindelijk 
leidde tot dit promotietraject. Lang niet elke professor is dusdanig open-minded, 
bedankt hiervoor! Bovendien wil ik bij deze gelegenheid nog eens mijn waardering 
uitspreken over hoe snel jij commentaar leverde op diverse manuscripten. Soms 
ontving ik je commentaar op een stuk zelfs twee keer op één dag!
Prof. Dr. Wim Oyen, beste Wim, door jou ben ik bij de afdeling Nucleaire 
Geneeskunde terecht gekomen. Hartelijk dank dat jij mij deze kans gaf. Je 
enthousiasme voor het vak was aanstekelijk! Bedankt ook voor je waardevolle 
inbreng en het richtinggevende commentaar bij het schrijven van artikelen. 
Dr. Rijpkema, beste Mark, je bent een hartstikke goede copromotor. De vele 
besprekingen met jou heb ik als zeer waardevol ervaren. Hoe complex een onderwerp 
ook is, je hebt een talent om het duidelijk en met veel enthusiasme uit te leggen. Heel 
veel dank ook voor je altijd aanhoudende optimisme; vooral als de resultaten weer 
eens niet echt mee zaten hebben jouw optimisme en enthusiame ertoe bijgedragen 
dat wij toch door bleven zoeken. 
Dr. Helfrich, beste Wijnand, bedankt voor het meedenken en al je commentaar 
op onze artikelen. Vanuit een iets andere hoek heb jij altijd nog nieuwe aspecten 
kunnen leveren die onze manuscripten verder verbeterden. Bedankt hiervoor!
Prof. Dr. Gotthardt, lieber Martin, vielen Dank, dass Du mich in Deine Beta-
Projekte hast reinschnuppern lassen, inspirierende Forschung in einer tollen 
Arbeitsgruppe! 
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Besten Dank auch für all Deinen (manchmal mehr, manchmal weniger ernstgemeinten) 
Kommentar zur der deutschen und niederländischen Arbeitsweise in der Klinik. Ich 
bin gespannt, was sich bewahrheitet!
Beste Gerben, heel erg bedankt voor de goede samenwerking de afgelopen 
jaren. Ik heb het als zeer fijn en gezellig ervaren om met jou samen te werken. Vooral 
in het begin hebben we veel samen op het lab gestaan en achter de scanner gezeten 
en heb jij mij de kunst van het labelen (en alle berekeningen :-) ) geleerd. Maar ook 
later stond je mij steeds met raad en daad terzijde. En wilden de labelingen toch een 
keer niet lukken, wist je altijd nog een trucje te bedenken!
Beste Annemarie, ik wil je bedanken voor de goede samenwerking, je hulp met 
het plannen en uitvoeren van experimenten, maar vooral ook je vriendschap en 
gezelligheid. 
Bianca, Kitty, Iris, Henk en Nicole: dankzij jullie verstand en kundigheid in de 
omgang met proefdieren wordt zorgvuldig en verantwoord onderzoek mogelijk. 
Hartelijk dank voor de goede samenwerking, de vele overlegmomenten, jullie 
flexibiliteit in de planning van de experimenten en natuurlijk de gezellige kletspartijen. 
Ik heb het elke keer weer leuk gevonden om weer eens jullie kant op te komen.  
Beste Sandra, je bent altijd een beetje mijn ‘promovendus role model’ 
geweest. Of het nou tips waren met het plannen van experimenten, het maken 
van wetenschappelijke posters/presentaties, of het schrijven/layouten van het 
proefschrift, je was altijd present en bereid om te helpen, ook al had je het druk met 
je eigen werk. Heel erg bedankt voor je hulp!
Beste Katja, bedankt voor het meewerken aan artikelen, posters en presentaties. 
Je wist altijd nog belangrijk commentaar te leveren.
Beste kantoorgenootjes Sam, Floor, Mark en Peter: Ik heb er hartstikke 
van genoten om met jullie een kantoor (en taart/snoep) te delen. Jullie zijn een 
supergezellige club, dit kantoortje zal ik missen!
Cathelijne, Janneke, Maarten, Tessa, Stefanie, Willem, Wietske, Inge, Selen, 
Charlotte, Stijn, Lieke, Desirée, Danny, Jurrian en alle andere medewerkers van de 
afdeling: mede door jullie is mijn tijd bij de Nucleaire Geneeskunde zo leuk geworden. 
Op het lab, of gewoon in de koffiekamer bij een stukje taart, het was altijd gezellig.
Wael: tack så mycket för svenska godis!
Marie-Louise en Jacqueline, ik ben al een redelijk groot aantal secretaresses 
tegengekomen, maar nog nooit heb ik er eentje ontmoet die zo competent en aardig 
was als jullie. Ondanks jullie hoge werkdruk kon ik altijd bij jullie terecht en wisten 
jullie steeds prima oplossingen te vinden, waar ik ook mee kwam. Bedankt hiervoor!
Prof. Dr. Pomper, dear Marty, thank you very much for giving me the opportunity 
to do a research internship in your laboratory. It was an enriching experience! 
Dr. Minn, dear Il, thank you so much for teaching me all kinds of assays in the 
lab and introducing me to intravital fluorescence microscopy. It was inspiring to work 
with you and participate in your projects. I appreciate your enthusiasm. Thank you 
for showing me around in Baltimore and organizing social events.
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Thanks to the members of Karl-Johan Malmbergs research group at the Center for 
Infectious Medicine at Karolinska Institute, especially Kalle, Sandra, Mattias, and 
Monika. The wonderful and inspiring time in such a great research environment 
actually awakened my passion for science.
Lieber Hendrik, vielen Dank für Deine Freundschaft. Seit 2005 haben wir viele 
tolle Dinge zusammen erlebt, sowohl an der Uni als auch privat. Die unzähligen 
geselligen Abende hab ich sehr genossen, Fortsetzung folgt natürlich! 
Lieber Jan, vielen Dank für Deine Unterstützung. Du hattest immer ein offenes 
Ohr, an allen Höhen und Tiefen hast du Anteil genommen und warst einfach immer 
am Start. Danke dafür!
Zu guter Letzt geht mein besonderer Dank an meine Eltern. Ohne Eure 
tatkräftige Unterstützung wäre all das nicht möglich gewesen. Ihr habt mir während 
der langen Jahre des Studiums und der Promotion den Rücken immer frei gehalten 
und mir dadurch die Freiheit gegeben, meine Ambitionen zu verwirklichen, egal 
welche Hürden zu überwinden waren. Vielen Dank für alles!
ABOUT THE COVER
In oncology, the search for tumor lesions in the body of a patient can be compared to 
looking for the proverbial needle in a haystack. With a suitable detection technique, 
the search for this needle could be facilitated. On this cover, the magnet represents 
the detection technique, which in this case would be near-infrared fluorescence 
and radionuclide dual-modality imaging, each being represented by one pole of the 
magnet. With only one pole being active, the needle cannot be detected, however 
when both poles of the magnet are active, the needle, representing a small tumor 
lesion, can be found.


